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Summary.
During the past few decades a new approach has emerged for the treatment of
human disease. In that short period, the concepts and techniques of gene therapy have
progressed from being entirely fanciful to experimental clinical application. A major
stumbling block for gene therapy is the inefficiency of gene transfer and the transient
nature of therapeutic gene expression. Attempts to deliver therapeutic genes using
replication-defective adenoviruses have been hampered by a strong host immune
response to the vector, leading to clearance of transduced cells and loss of transgene
expression. Current adenovirus vectors have an additional disadvantage of being able
to carry only approximately 10 kb of exogenous DNA. The work here describes
attempts to improve upon existing adenoviral vectors by addressing these limitations
In order to reduce the host immune response to the vector, additional deletions
in the residual viral coding regions are required to prevent expression of immunogenic
proteins. Deletion of the major late transcription unit (MLTU), which encodes
virtually all of the viral structural proteins, would achieve this and would also increase
the transgene carrying capacity of the vector. In order to create such a vector, a cell
line would be required to complement the growth of the deleted vector by providing
late gene functions in trans. The work presented here describes the successful cloning
and subsequent analysis of the Ad5 MLTU with expression driven by the major late
promoter (MLP). The expression plasmids constructed express one or more late
proteins from each late gene segment in a transient assay. The plasmids also carry the
EBNA-I and oriP sequences from Epstein-Barr virus which allow the plasmids to be
stably maintained in eukaryotic cells. Stable cell lines were constructed using these
plasmids but no late protein expression from the MLTU could be detected. Attempts
to activate expression from the major late promoter by providing viral transactivating
factors in trans also proved to be ineffective.
To address these problems, an alternative inducible promoter was chosen. The
sheep metallothionein la promoter was cloned upstream of the MLTU and this
construct was then cloned into an episomal expression vector. This plasmid was also
used successfully to regulate the expression of late proteins during transient
transfection studies. However, a stable cell line constructed using the same plasmid
did not show any expression of late proteins.
The reasons for the inability of any cell line constructed to express late proteins
are still undetermined. Possible reasons discussed are plasmid rearrangement,
promoter down-regulation and possible blocks to post-transcriptional processing and
translation of the complex MLTU transcript. Suggested future studies include testing
of these possibilities in order to gain further insight into the regulation of expression
from the MLTU construct, ultimately leading to the construction of a cell line capable
of complementing the growth of adenovirus vectors with late gene deficiencies.
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Chapter 1 : Introduction.
Chapter 1 : Introduction.
1.1. Introduction.
A conceptually new approach to the treatment of human disease has emerged
during the past two decades, termed gene therapy, which promises to revolutionise
modem medicine. Unfortunately gene therapy has an Achilles heel: inefficient gene
delivery.
Viruses have evolved very effective methods of delivering their own nucleic acids
to cells, thereby allowing their own replication and propagation. For this reason
several viruses have been investigated for use as gene delivery vehicles, with mixed
results.
The aim of this introduction is to give a brief overview of the fundamentals of
gene therapy, followed by a detailed review of the gene-delivery vehicle that is the
. subject of the research reported in this thesis, the adenovirus vector.
1.2. Gene therapy - a brief history.
Gene therapy, broadly defined as the treatment or prevention of disease by gene
transfer, is regarded by many as a potential revolution in medicine. This is because
gene therapies aim to treat or eliminate the underlying cause of disease, whereas most
current therapies merely alleviate the symptoms. Although originally intended as a
treatment for inherited disorders (Friedmann and Roblin, 1972), gene therapy is now
being applied to many other fields of medicine, particularly the treatment of cancer
and infectious disease (reviewed by Weatherall, 1995).
Gene therapy is generally considered to be a relatively new form of therapy,
largely because it is only over the past decade that it has been widely recognised as a
valid approach to treating disease (reviewed by Friedmann, 1992). Despite the
apparent infancy of gene therapy, the underlying principals can be traced back to the
classical studies of Avery, McLeod and McCarty (1944) into DNA-mediated genetic
transformation in pneumococcus. Subsequent experiments established that
mammalian cells could be altered by the introduction of exogenous DNA (Kay,
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1961). These findings, in conjunction with the discovery of mammalian cells stably
transformed by DNA introduced by papovaviruses (Sambrook et al., 1968), led to the
proposal that viruses could be used as vectors to deliver therapeutic DNA into cells
(Rogers and Pfuderer, 1968) and mark the birth of gene therapy.
Although the term gene therapy was coined almost thirty years ago, it was not
until the advent of techniques for the efficient isolation and manipulation of DNA in
the 1970s that it began to become a feasible proposition. The subsequent advances in
biotechnological expertise and increased understanding of many disease states at the
molecular level have led to an expansion in gene therapy research. This growing
interest led to the first human gene therapy clinical trial for treatment of adenosine-
deaminase deficiency (ADA), commencing in 1990 (Blaese et al., 1995), and marked
the transformation of gene therapy from a human geneticist's pipedream, to the
focused reality of a whole new industry.
1.2.1. Applications and candidate diseases.
Ideally, gene therapy would emulate transplant surgery, removing a mutant gene
and replacing it with a normal copy. However, this approach has many technical
difficulties and current research in gene therapy is directed towards gene
augmentation. This involves introducing a gene into the target cell in a way that will
allow it to produce sufficient of its product to compensate for lack of expression of its
defective counterpart. Broadly speaking, there are two approaches to gene therapy;
the ex vivo and in vivo approaches. In the ex vivo approach, cells are removed from
the patient, transfected with the therapeutic gene and then reintroduced. This has the
advantage of efficient and controllable gene transfer but has the drawback of being-
patient specific. The in vivo approach involves the direct administration of the gene
transfer vector to the patient. This is therefore not patient-specific but does have the
disadvantage that cells are more difficult to transfect in vivo.
There are a number of diseases, both inherited and acquired, which are candidates
for treatment by gene therapy. Although originally envisioned as a treatment for
monogenic recessive disorders, today gene therapy is being applied to other areas
such as cancer therapy and infectious diseases (reviewed by Verma and Somia, 1997;
Mountain, 2000). Approximately 300 clinical protocols have been approved to date,
with two thirds of them directed at cancer, and most of the remainder at monogenic
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disorders and infectious diseases (Table 1.1). It has been widely publicised that the
outcome of clinical trials in terms of gene expression and clinical benefit has been
disappointing. This is largely due to shortcomings in vector technology, but as vector
technology progresses clinical benefits from gene therapy should become more
apparent. In fact, within the past year, clinical benefit from gene therapy has been
demonstrated for the first time. Patients receiving treatment for critical limb ischaemia
were given naked DNA injections (section 1.2.2.2.1.) of plasmid encoding vascular
endothelial growth factor (VEGF) into skeletal muscle. A dramatic long lasting effect
was observed in many patients, including those who would otherwise have faced
amputation (Baumgartner et al., 1998; 2000). In addition, positive results have been
reported in a trial for the treatment of severe combined immunodeficiency disorder
(SeID) - XI disease (Cavazzana et al., 2000). seID-XI is an X-linked inherited
disorder characterised by a block in T and natural killer (NK) lymphocyte
differentiation. This block is caused by mutations in the gene encoding the common
cytokine receptor gamma chain (gammac). The gene therapy trial involved the ex vivo
delivery of gammac cDNA to eD34+ cells using a Moloney retrovirus derived-vector.
After a 10-month follow-up period, gammac transgene-expressing T and NK cells
were detected in two patients. T, B, and NK cell counts and function, including
antigen-specific responses, were comparable to those of age-matched controls. Thus,
gene therapy was able to provide full correction of a disease phenotype and hence,
clinical benefit.
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Table 1.1: Distribution of gene-transfer clinical trials in
North America and Europe (June 1999).
Disease. Number of protocols.
Cancer. 216
Monogenic diseases. 49
Infectious diseases. 24
Cardiovascular diseases. 8
Rheumatoid arthritis. 2
Cubital tunnel syndrome. 1
Total number of protocols. 300
In vivo gene-transfer. 144
Ex vivo gene-transfer. 156
Adapted from Mountain, 2000.
1.2.2. Gene delivery systems.
Gene delivery vectors fall into three main types: physical, non-viral and viral.
Physical methods include the use of needle-free injectors and electroporators. Non-
viral approaches involve the use of naked DNA or DNA complexed with cationic
lipids (liposomes) or cationic polymers. Many different viruses are being adapted as
vectors, but the most advanced in their development are retrovirus, adenovirus and
adeno-associated virus (AAV) vectors. Each method has its own set of advantages
and disadvantages (Table 1.2)so the choice of vector will often be dictated by the
properties required for a specific application. For example if only short-lived
trans gene expression is required, then the adenoviral vectors are ideal. Whereas if
long term expression is required, an integrating vector such as AAV or a lentivirus
would be more appropriate. All current DNA delivery methods have limitations and
an ideal vector would have to combine properties from both viral and synthetic
systems. The properties of this ideal vector would include production at high
concentration, site-specific integration or episomal maintenance, trans gene expression
regulation, the ability to target specific cell types and low immunogenicity. No single
vector currently fulfills all these requirements, in fact it is largely due to the
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constructs within mouse skeletal muscle cells. The DNA persisted for at least 60 days,
although the mRNA and expressed protein had a half-life of less than 24 hours.
The method of direct DNA injection is a simple, inexpensive and relatively non-
toxic procedure. However, it does have limitations, mainly low transfection
efficiency, transient gene expression that is localised only at the site of injection and
unsuitability for targeting. It may have potential as a vaccination procedure due to the
presence of immunostimulatory sequences in the plasmid DNA (Krieg et al., 1995).
CpG dinucleotide sequences, cytosine followed by guanine elicit immune responses
in animals and are regarded as a very powerful adjuvant, beneficial for any
vaccination procedure.
1.2.2.2.2. Cationic lipids.
Monocationic lipids form liposomes that spontaneously bind polyanionic DNA or
RNA. These can then absorb to the cell membrane and deliver the nucleic acid
directly into the cytoplasm, bypassing the endosomal pathway. Several lipid-DNA
complexes have been shown to give reasonable transfection efficiency ex vivo, and in
vivo after administration to the airway epithelium. Unfortunately transgene expression
is transient and transfection cannot be targeted to a particular cell type (reviewed by
Li and Huang, 2000; Mountain, 2000).
1.2.2.2.3. Condensed DNA particles.
Another class of synthetic vector that has been extensively studied is based on
cationic polymers (reviewed by Li and Huang, 2000; Mountain, 2000). These
polymers, typically polylysine or polyethyleneimine, condense DNA by electrostatic
interaction into small particles, protecting it from degradation and enhancing uptake.
The advantage of this method is that the particles can be retargeted by addition of
ligands for cellular receptors, although transfection efficiency is low.
25
1.2.2.3. Viral delivery systems.
1.2.2.3.1. Retrovirus vectors.
Retrovirus vectors constitute the most widely used vectors to date, having been
shown to be safe and effective at delivering transgenes in ex vivo applications. Over
half of the clinical trials approved in North America and Europe have involved the use
of a retroviral vector (reviewed by Verma and Somia; 1997, Mountain, 2000). The
majority of retroviral vectors are based on murine leukaemia viruses (MLVs); these
are made replication-deficient by replacing the viral genes, gag, pol and env, with a
transgene expression cassette. The lack of these genes is compensated for by growth
in a packaging cell line that expresses the deleted viral genes.
A major advantage of retrovirus vectors is that they integrate a DNA copy of their
RNA genome into the target cell's genome. This leads to constant levels of gene
expression in vitro and all daughter cells inherit a copy of the transgene. However,
when the cells are returned in vivo they often lose expression of the foreign gene
within a few weeks. This silencing phenomenon is not well understood, but is likely
to be the result of methylation in the vicinity of the promoter. Although advantageous
this integration mechanism is random which could lead to a risk of insertional
mutagenesis. This could result in the activation of oncogenes or deactivation of
tumour suppressor genes. Although the theoretical probability of such an event is
quite low, it is still of some concern. Another limitation of retroviral vectors is their
inability to infect non-dividing cells, as they require breakdown of the nuclear
envelope during mitosis before the genome can integrate. However, this is not true for
retroviral vectors based on lentiviruses such as HIV and SIV, which have been shown
to effectively transfect post-mitotic and quiescent cells (reviewed by Trono, 2000).
1.2.2.3.2. Adeno-associated virus (AAV) vectors.
AAV is a member of the Parvoviridae family and normally requires coinfection
with a helper virus (such as adenovirus or herpes simplex virus) for lytic replication in
cell culture (reviewed by Flotte and Carter, 1995). As for retroviruses, AAV is also
capable of integrating into the target cell chromosome, with wild type AAV
specifically integrating into one site on human chromosome 19. It appears however
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that recombinant AAV vectors integrate much less efficiently and in a random manner
(reviewed by Monahan and Samulski, 2000; Mountain, 2000). A major drawback to
using AAV as a gene transfer vector is the limiting size of its genome, which can only
accommodate up to 4.5 kb of foreign DNA. Conversely, its genome is very simple
and easily manipulated in vitro. The difficult manufacturing process imposes other
limitations on the use of AAV vectors. The required use of a helper virus presents
problems of low titre, contamination and costly purification procedures. Only a few
clinical trials involving AAV have been initiated to date, but preliminary results
suggest that long term expression is feasible (Wagner, 1998). With the recent
developments allowing the production of high-titre AAV stocks free of helper virus
contamination (reviewed by Monahan and Samulski, 2000), and AAV's ability to
transduce cells both in vivo and in vitro, more AAV-based therapies are likely to
reach the clinic in the near future.
1.2.2.3.3. Herpesvirus vectors.
Many different herpesviruses may have potential as gene delivery vectors, but
exploitation of this potential has, to date, only been explored using herpes simplex
virus (HSV) (reviewed by Efstathiou and Minson, 1995). HSV is a DNA virus with a
genome of approximately 150 kbp, it is naturally neurotropic and can establish
latency in neurons in a manner which does not depend on viral replication (reviewed
by Roizman and Sears, 1996). This makes it an ideal candidate to deliver genes to the
central nervous system, in order to treat conditions such as Parkinson's disease. HSV
can be rendered replication-defective by deleting essential gene functions; growth of
these vectors in complementing cell lines allows incorporation of about 50 kbp of
foreign DNA. There have been problems associated with inflammatory reactions in
the recipients of these vectors (Wood et al., 1994), although recently derived vectors
have addressed these problems by introduction of further attenuating mutations
(Oligino et al., 1998). HSV can also form the basis of artificial amplicons, plasmids
which contain the viral origin of replication and packaging signal (Frenkel et al.,
1994). These are packaged into virus particles in the presence of a replication-
defective helper virus, thus increasing the insert-size limit to almost 150 kbp. The use
of these amplicons has limitations in that they only grow to low titres and
contamination of the vector stock with helper virus can be a problem.
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1.2.2.3.4. Adenovirus vectors.
Retroviruses aside, vectors based on adenovirus are the most commonly used
gene delivery vehicles in clinical trials today. This is the virus used in the studies
presented here and, as such, warrants a more detailed review. Accordingly, before
reviewing the progress and advances in adapting this virus for use in gene therapy
protocols, an account will be given of this virus, its pathogenesis and replication
cycle.
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1.3. The adenoviruses.
1.3.1. Classification.
Adenoviruses were first isolated in the winter-spring of 1952-53 by two groups of
investigators working independently. In 1953 Rowe and colleagues observed
degeneration of primary cell cultures derived from human adenoids, the agent
responsible being termed the adenoid degenerating (AD) agent (Rowe et al., 1953).
During the same winter another group, studying an epidemic of respiratory illness in
military recruits, isolated an agent able to cause degenerative changes in cultures of
HeLa cells. This was designated the respiratory illness (RI) agent and was soon shown
to be related to the AD agent by complement fixation and neutralisation tests
(Hilleman and Werner, 1954). In 1956 the name "adenovirus" was given to these
agents, after the original source of tissue in which the viral prototype strain was
isolated (Enders et al., 1956).
Since the isolation of the prototype virus, over 50 serotypes of adenoviruses have
been isolated based on their differential resistance to neutralisation by antisera to
other adenoviruses. These constitute the virus family Adenoviridae, which is divided
into two genera, Mastadenoviridae and Aviadenoviridae. The Aviadenoviridae are
viruses of birds while the Mastadenoviridae infect mammals, and includes human,
simian, bovine, porcine, ovine, equine, canine and opossum viruses (reviewed by
Shenk, 1996). The human adenoviruses have been divided into six subgroups, A-F,
based on their ability to agglutinate red blood cells from different sources; thus
haemagglutination is inhibited by antisera specific for viruses of the same subgroup.
The virus used as the basis for the studies presented here was human adenovirus,
subgroup C, serotype 5 (Ad5). Together with serotype 2, these are the two serotypes
that have been studied in most detail. The sequences of the two genomes are 94.7 %
identical and their gene organisation is virtually the same. Because of this similarity,
data derived from studying one of these viruses is generally assumed to apply to both.
1.3.2. Pathogenesis of disease.
Human adenoviruses cause a wide range of diseases in their hosts, most
commonly infections of the upper respiratory tract (Adl,2,3,5 and 6). These infections
are usually self-limiting, but can lead to pneumonia and some epidemics of Ad7 have
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led to considerable mortality. Adenoviruses can also infect and replicate at other sites,
leading to acute follicular conjunctivitis (Ad3 and 7), acute haemorrhagic cystitis
(Adll and 21), gastroenteritis (Ad40 and 41) and occasionally meningoencephalitis.
Many adenovirus infections are subclinical and result in antibody formation that is
probably protective against exogenous reintroduction of the same serotype.
Adenoviruses can achieve persistence in some tissues (tonsils, adenoids and intestine)
of an infected host, although the mechanism of persistence for adenoviruses is poorly
understood. All human adenoviruses tested are capable of transforming rodent cells in
vitro and some are highly oncogenic in rodents (Ad12, 18 and 31). However, neither
Ad5 nor any other group C adenovirus is known to be tumourigenic in humans
(reviewed by Shenk, 1996).
1.3.3. Virion structure.
Adenoviruses are nonenveloped DNA-protein complexes of icosahedral symmetry
(20 triangular faces and 12 vertices) with a diameter of 70-100 nm. The double
stranded (ds) DNA genome (35938 bp for Ad5; Chroboczek et al., 1992) constitutes
13 % of the mass of the virion, the remaining 87 % being protein with trace amounts
of carbohydrate due to glycosylation of the fibre protein (reviewed by Shenk, 1996).
The protein shell (capsid) comprises 252 subunits (capsomeres), of which 240 are
hexons (so called because they are each surrounded by six neighbouring capsomeres)
forming the faces and edges of triangular facets. The remaining 12 subunits are
pentons (having five neighbouring capsomeres) which form the vertex capsomeres.
Each penton contains a base unit within the body of the capsid and a projecting fibre,
which terminates in a knob (reviewed by Stewart et al., 1993). The structure and
polypeptide components of the adenovirus capsid are depicted in figure 1.1a.
The protein capsid is composed of at least 11 polypeptides (figure 1.1b) as
determined by SOS-PAGE and open reading frame (ORF) analysis, many of which
are encoded by the major late transcription unit (MLTU). The capsid of the virion is
composed of seven known polypeptides. Three tightly associated molecules of
polypeptide II, the most abundant virion constituent, form each hexon capsomere.
Associated with these hexons are polypeptides VI, VIII and IX, which serve to
stabilise the capsomere framework, with polypeptides VI and VIII probably bridging
between the capsid and core components. The penton base protein is composed of five
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Figure 1.1. Models of the adenovirus virion. A: A three-dimensional representation
of the adenovirus particle. Indicated are hexons (H), peripentonal hexons (PE)
pentons (P), and fibre (F). B: A stylised cross-section of the adenovirus particle based
on current understanding of its polypeptide components. Virion constituents are
designated by their polypeptide number, as noted in the text, with the exception of
terminal protein (TP). From Stewart et al. (1991).
molecules of polypeptide III and has the fibre protein (a trimer of polypeptide IV)
projecting from within it. The core of the virion contains four polypeptides, V, VII, J.l
and terminal protein (TP), associated with the viral genome. Polypeptide V binds to
pentons and may bridge between the core and capsid. Polypeptide VII is the major
core constituent and may act as a histone-like centre around which the viral DNA is
wrapped and may also form links with polypeptide IlIa in the capsid. The function of
the J.l protein is unknown whilst the remaining protein, TP, is covalently attached to
the S' ends of the genome and serves in the initiation of viral DNA replication and in
the attachment of viral DNA to the nuclear matrix.
1.3.4. Genome organisation.
The adenovirus genome is a linear double stranded DNA molecule, with short
inverted terminal repeats (ITRs) which range in size from 100-140 bp, depending on
serotype. These repeat sequences have a role in DNA replication and are discussed in
more detail in section 1.3.5.3. The genome also contains a cis-acting sequence
necessary for packaging of viral DNA into capsids, which is located approximately
260 bp from the left end of the viral genome.
Transcription of the viral genome is split into two phases, with the early (E) phase
occurring before the onset of viral DNA replication, and the late (L) phase beginning
at the onset of viral DNA replication. However, this distinction is not absolute as
some late genes are expressed at low levels during the early phase and transcription of
early genes continues in the late phase. There are also two genes (IVa2 and IX) that
are transcribed at an intermediate stage and are termed delayed early (reviewed by
Shenk, 1996). The transcription map of AdS is shown in figure 1.2. The program of
gene expression starts from both strands of the viral genome, the rightward (r) strand
encodes El, E3, IX, viral associated (VA) RNA and MLTU, whilst the leftward (I)
strand encodes E2, E4 and IVa2. All genes are transcribed by cellular RNA
polymerase II with the exception of VA RNA genes that are transcribed by RNA
polymerase III. Transcription starts from both ends of the genome; thus the first genes
expressed are EIA and E4. Each gene transcribed gives rise to multiple RNA species
that are differentiated by alternative RNA splicing and in some cases by the use of
different poly (A) sites. An example of this is the MLTU that produces at least 18
distinct mRNAs grouped into five families, termed Ll - LS. Indeed it was the analysis
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Figure 1.2.Human adenovirus type 5 transcription map.
Adapted from Leppard (1998).
The virus genome is represented in the centre by parallel lines, with numbering
indicating the distance from the conventional left end in kb. Genes or gene regions are
shown in boldface. mRNAs are shown as solid lines, with gaps to indicate introns;
RNA polymerase II promoters are shown as solid vertical lines, with polyadenylation
sites designated by broken vertical lines. RNA polymerase III transcripts are shown as
paired vertical lines. mRNAs transcribed from the r-strand are shown above the
genome, those transcribed from the I-strand are shown below. Proteins translated from
mRNAs are indicated adjacent to the mRNA; conventions for naming proteins are
given in section 1.3.4. Abbreviations: PT, virion protease; DBP, DNA binding
protein; pTP, terminal protein precursor; Pol, DNA polymerase.
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of adenovirus mRNA which led to the discovery of RNA splicing (Berget et al., 1977;
Chow et al., 1977). Proteins produced by each transcription unit are shown in figure
1.2. These are named either by sedimentation coefficients of the encoding mRNA
(e.g. EIA-13S), molecular weight (e.g. EIB-55K), the open reading frame from
which they are expressed (e.g. E4-0rf6) or function (e.g. DNA binding protein). Late
structural proteins are numbered II - IX in order of decreasing size (reviewed by
Shenk, 1996).
1.3.5. Replicative cycle.
A simplified adenovirus replication cycle is presented diagrammatically in figure
1.3.
1.3.5.1. Adsorption and entry.
The first step in human adenovirus infection consists of virus-cell recognition and
attachment involving the carboxy-terminal region of the viral fibre protein (which
forms the terminal knob of the fibre trimer) and host cell surface receptors. Two fibre
receptors have been described to date, a 46 kDa glycoprotein termed the
coxsackievirus - adenovirus receptor (CAR) (Bergelson et al., 1997; Tomko et al.,
1997) and the major histocompatibility complex class I (MHC-I) a2 domain (Hong et
al., 1997). CAR protein can function as a cellular attachment protein for serotypes
from subgroups A, C, D, E and F (Roelvink et al., 1998) and recent findings suggest
CAR is the primary receptor, with MHC-I a2 domain only being used in the absence
of CAR (Davison et al., 1999). Detailed analysis of the CAR protein has revealed that
the fibre binding activity is located in the amino-terminal IgV-related extracellular
domain and only this domain is required for virus attachment and entry (Bewley et al.,
1999; Freimuth et al., 1999; Roelvink et al., 1999; Wang and Bergelson, 1999; Kirby
et al., 2000). Subsequent efficient internalisation of adenovirus into cells requires a
second interaction, mediated by the viral penton base and another cell surface protein.
These cellular proteins are members of the integrin family, primarily av~3 and av~5
vitronectin-binding integrins, although other members of the family may be involved
(reviewed by Shenk, 1996; Davison et al., 1997). This interaction occurs between the
integrin and an arg-gly-asp (ROD) motif present on each molecule of polypeptide III
of the penton base.
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The penton-integrin interaction triggers a series of events which see adenovirus-
receptor complexes diffuse into clathrin-coated pits, where they are internalised by
receptor-mediated endocytosis. This is a highly efficient process, with half of the
adsorbed virus being internalised within ten minutes (reviewed by Shenk, 1996;
Nemerow and Stewart, 1999). The internalised virus then escapes into the cytosol,
with disruption of the early endosome triggered by a drop in pH and possibly
involving the penton base protein (reviewed by Shenk, 1996). Prior to escape,
sequential disassembly of the virion begins by selective dissociation and proteolytic
degradation of specific proteins. Fibre, penton base, lIla and VIII are removed prior to
movement of the virus into the cytosol. Once in the cytosol, polypeptide VI is
degraded, possibly by the virus-coded protease. Polypeptide IX is also lost and the
DNA-containing core is freed from the remaining hexon shell (Greber et al., 1993;
reviewed by Shenk, 1996). During the disassembly process the virus moves towards
the nuclear envelope by a process involving microtubules, possibly mediated via an
interaction with the hexon protein (Suomakinen et al., 1999). Upon reaching the
nucleus the viral genome enters via nuclear pores, the genome which is still associated
with polypeptide VII then associates with the nuclear matrix via its terminal protein
(Schaack et al., 1990; Fredman and Engler, 1993; Greber et al., 1997).
1.3.5.2. Early gene expression.
Transcription of early genes begins 1-2 hours after the virus comes into contact
with the cell. Both transcription and replication of the viral genome occur within
discrete regions of the nucleus, termed inclusion bodies, or replication centres (Pombo
et al., 1994), with transcription shifting to the periphery of these bodies as DNA
replication proceeds. As a rule, early gene products are involved in preparing the host
cell for adenovirus replication. They mediate viral gene expression and DNA
synthesis, induce cell cycle progression, block apoptosis, and antagonise a variety of
host cell antiviral measures, as discussed below.
1.3.5.2.1. The El region.
The products of the adenovirus El A gene are the first polypeptides to be
synthesised during viral infection. This gene produces five mRNAs through
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differential splicing with the two most abundant and important being the 12S and 13S
mRNAs, which encode 243- and 289-amino acid proteins, respectively (termed 243R
and 289R). Both proteins have identical amino and carboxy-terminal ends; they differ
from each other in that the 243R protein lacks an internal stretch of 46 amino acids,
designated conserved region 3 (CR3). The EIA proteins are constructed of three of
these highly conserved regions (CRI, CR2 and CR3) separated by less highly
conserved domains. The major function of these proteins is in activation of viral and
cellular genes, either through direct interaction with the basal transcription machinery,
or through interaction with upstream acting transcription factors. The EIA-13S
protein can activate transcription through the TATA motif, resulting from binding of
the CR3 region directly to the TAT A binding protein (TBP), which is the DNA
binding subunit of cellular transcription factor lID (TFlID). One method of
transcriptional activation involves the tumour suppressor protein p53, which is known
to repress transcription by binding to TBP; EIA-13S binding to TBP displaces p53
and relieves p53-mediated repression (Horikoshi et al., 1995). Both El A-12S and
EIA-13S are capable of activating transcription by interacting with upstream
transcription factors, one such example being the cellular factor E2F. E2F forms a
complex with the cellular retinoblastoma tumour suppressor protein (pRb) which
serves to repress transcription. EIA proteins can bind to pRb, mediated by the CRI
and CR2 domains and so displace E2F. This release of active E2F causes expression
of cellular genes necessary to allow the cell to progress into S phase, which is the
optimal environment conducive to viral replication. In addition EIA proteins can bind
to the cellular transcriptional activator p300, this renders p300 incapable of binding to
the transcription initiation complex and transcription is repressed. Genes regulated by
p300 might encode proteins involved in cell cycle regulation. Therefore EIA
inactivation of p300 could deregulate the cell cycle and induce cells to enter S phase
(reviewed by Akusjarvi, 1993; Jones, 1995; Nevins, 1995; Shenk, 1996).
The deregulation of cell cycle control by El A results in the accumulation of high
levels of p53 in the nucleus. Normally p53 accumulation is associated with either
growth arrest or apoptosis, in the presence of EIA apoptosis results. The EIB gene
encodes proteins whose functions allow adenovirus to replicate successfully through
blocking EIA-induced apoptosis (reviewed by Chinnadurai, 1998; White, 1998).
Inhibition of apoptosis is largely achieved by the El B-19K protein, which is a
homologue of the cellular antiapoptotic protein Bcl-2. El B-19K acts downstream in
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the apoptosis pathway by an as yet unidentified mechanism, and is capable of
blocking p53-mediated apoptosis and also apoptosis triggered by tumour necrosis
factor (TNF)-a and anti-Fas antibodies. The EIB-55K protein also plays a role in
inhibition of apoptosis by binding directly to the amino terminus of p53, which
inhibits p53 function. Another important function of EIB-55K protein is its
involvement in the differential control of viral gene expression, which it affects in
conjunction with the E4-0rf6 protein, as will be discussed in section 1.3.5.2.4.
1.3.5.2.2. The E2 Region.
The E2 transcription unit encodes three proteins, all of which are vital for viral
DNA replication. These are the 72-kDa single stranded (ss) DNA binding protein
(DBP, encoded by E2A), the 80-kDa precursor terminal protein (pTP, encoded by
E2B) and the 140-kDa DNA polymerase (Adpol, encoded by E2B). The exact roles of
these proteins in viral DNA replication will be discussed in section 1.3.5.3. Besides its
role in DNA replication, DBP is also involved in repression of E2 transcription,
mRNA stability, virus assembly and host range function.
Activation of the E2 promoter is regulated by the EIA-13S protein. In the absence
of EIA expression, constitutive expression from the E2 promoter is low. Upon
expression of EIA, transcription from the E2 promoter increases, mediated through
the dissociation ofE2F and pRb (see section 1.3.5.2.1), allowing E2F to bind to and
activate the E2 promoter (reviewed by Swaminathan and Thimmapaya, 1996).
1.3.5.2.3. The E3 Region.
The E3 region of Ad5 gives rise to nine overlapping mRNAs that are alternatively
processed from a common pre-mRNA that initiates from the E3 promoter. Of these
nine predicted proteins, six have been identified in infected cells. These include the
gpl9K, 10.4K, 14.5K and 14.7K proteins, so called because of their molecular
weights, which are involved in helping the virus evade the host immune responses
directed against it. The E3 region is only required for viral replication in vivo and can
be deleted without affecting growth in cell culture (reviewed by Wold and Gooding,
1991; Wold and Tollefson, 1998).
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The E3-gp 19K protein binds to and retains newly synthesised major
histocompatibility complex (MHC) class I molecules in the endoplasmic reticulum.
This class of MHC molecule is involved in presenting endogenous peptides to CD8+
cytotoxic T-Iymphocytes (CTLs), normally resulting in lysis of the presenting cell.
Thus gp19K expression results in down-regulation of CTL-mediated lysis of
adenovirus infected cells (reviewed by Blair and Hall, 1998).
E3-14.7K protein inhibits TNF-induced apoptosis, possibly by interfering with the
signalling pathway by which TNF exerts its effects after binding to the cellular
receptor TNFRI (reviewed by Wold and Tollefson, 1998). Recently, a cellular protein
named FIP-3, a member of the GTPase superfamily of signal transducers, was
discovered due to its interaction with E3-14.7K. This raises the possibility that FIP-3
is the protein through which 14.7Kmediates its anti-apoptotic effects (Li et al., 1999).
The E3-10AK and 14.SK proteins associate to form a complex termed RID, an
acronym for receptor internalisation and degradation. Both 10AK and 14.SK are
integral membrane proteins and localise to the plasma membrane and intracellular
vesicles (reviewed by Wold and Tollefson, 1998). RID prevents TNF-induced
apoptosis by inhibiting translocation of cytosolic phospholipase A2 (cPLA2) to
membranes (Dimitrov et al., 1997). Cleavage of arachidonic acid from membrane
glycolipids, mediated by cPLA2, is an important signal in TNF-induced apoptosis.
This action of RID could explain how it blocks TNF-induced apoptosis and
contributes to the survival of the infected cell. In addition, the RID complex also
stimulates internalisation of the cell surface receptor Fas (Shisler et al., 1997). These
receptors function by inducing apoptosis when engaged by Fas ligand (FasL)
expressed on the surface of CTLs. Thus RID expression is another way in which
adenovirus can down-regulate CTL-mediated cell lysis.
In addition to proteins involved in regulation of the host immune response, the E3
region also encodes an 11.6 kDa membrane glycoprotein, termed the adenovirus death
protein (ADP). ADP ultimately localises to the nuclear membrane and facilitates the
release of progeny virions by triggering cell lysis. The mechanism by which ADP
achieves this is poorly understood (Tollefson et al., 1996a, 1996b).
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1.3.5.2.4. The E4 Region.
The E4 region encodes one or more functions that are required for lytic growth in
cell culture. These include DNA replication, mRNA stability and host cell shutoff
(reviewed by Leppard, 1997). Primary transcripts from the E4 promoter are
alternatively spliced to produce at least 18 distinct mRNAs. These are predicted to
encode for seven polypeptides termed Orfl - Orf4, Orf6, OrfJ/4 and Orf617. All these
have been demonstrated to exist in infected cells with the exception of the Orf3/4
protein.
The Orf6 protein functions as a complex with the EIB-55K protein and facilitates
the export of viral mRNAs from the nucleus and also inhibits the export of most
cellular mRNAs (reviewed by Imperiale et al., 1995). It can also bind to p53 and
block p53-induced apoptosis (Dobner et al., 1996), a process that is independent of
the presence of El B-55K, which separately plays a role in disrupting p53 function.
The Orf3 protein can initiate the reorganisation of specialised structures in the nucleus
known as promyelocyte oncogenic domains (PODS; Carvalho et al., 1995, Doucas et
al., 1996), although the reason for this in the context of viral infection is unclear.
Additionally, both OrfJ and Orf6 can independently improve the stability of late RNA
in the nucleus (Ohman et ai, 1993; Nordqvist et al., 1994) and they play an as yet
undefined role in regulation of Ad DNA replication (reviewed by Leppard, 1997). The
activities of these two proteins are apparently redundant in lytic infection, either one
is sufficient for efficient virus production (Bridge and Ketner, 1989; Huang and
Hearing, 1989a).
Of the remaining proteins, Orf617 regulates the Ad E2 promoter, an effect
mediated through its ability to bind to and stabilise E2F dimers bound at the promoter
(Huang and Hearing, 1989b). The Orf4 protein is important in down-regulating the
expression of El A and E4 genes, an effect mediated through its interaction with
protein phosphatase 2A (PP2A; Bondesson et al., 1996). Orf2 is a soluble cytoplasmic
\
protein with no known function (Dix and Leppard, 1995) and OrfJ/4 has yet to be
detected in infected cells but is predicted to exist based on Ad2 mRNA analysis
(Virtanen et al., 1984).
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1.3.5.2.5. The delayed early genes.
The genes encoding polypeptides IX and IVa2 are designated delayed early due to
the time in the infectious cycle at which they are expressed, around the time of the
onset of viral DNA replication. They are not regarded as true late genes as their
expression does not absolutely depend on viral DNA replication. IX has been reported
to be incorporated into the mature viral capsid, where it strengthens hexon-hexon
interactions (Boulanger et al., 1979). pIX has also been shown to act as a
transcriptional activator of TATA-containing promoters (Lutz et al., 1997). The IVa2
protein may have a role in viral DNA encapsidation (Zhang and Imperiale, 2000) in
addition to its function as a transcriptional activator of the major late promoter (MLP),
which is discussed in detail in section 3.4.
1.3.5.3. DNA replication.
DNA replication begins about 5 hours after infection in HeLa cells and continues
until the host cell dies (reviewed by Shenk, 1996). The E2 gene encodes the three
viral replication proteins (section 1.3.5.2.2.) which are capable of initiating DNA
replication, although this is inefficient and chain elongation is limited. Efficient DNA
replication requires three additional cellular proteins, nuclear factors (NF) I, II and III
(reviewed by De long and Van der Vliet, 1999). The sequences needed in cis for
replication are located within the terminal 51 bp at either end of the genome. Within
this origin of replication (ori) are three regions, an essential core region and two
auxiliary regions that enhance the efficiency of DNA replication. The auxillary
regions bind NFl and NFII, which enhances recruitment of p'I'P-Adpol by the core
region. Binding of NFl seems to be enhanced by the presence of DBP which forms a
regular multimeric protein-DNA complex with the ds DNA (Stuiver and Van der
Vliet, 1990).
Replication of the genome begins with the preterminal protein (pTP) acting as a
primer to initiate replication exactly at the genome termini, so preserving the integrity
of the ITRs during multiple rounds of DNA replication. An ester bond is formed
between the P-OH group of a serine residue in pTP and the a-phosphoryl group of
dCMP, the first residue at the 5' end of the DNA chain. This reaction requires the
presence of the viral polymerase (Adpol) and occurs after the pTP-Adpol complex is
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correctly positioned on the template. The resulting 3' -OH group of the pTP-dCMP
complex then serves to prime DNA synthesis (reviewed by Shenk, 1996).
Chain elongation requires the other E2 proteins, Adpol and DBP, and a cellular
protein NFII. DBP facilitates chain elongation by unwinding the dsDNA molecule
and is displaced by Adpol as the nascent chain of DNA is synthesised. NFII has
topioisomerase activity and is required for chain elongation to proceed beyond 9 kbp
of the genome (Nagata et al., 1982). The ssDNA chain produced is stabilised by
binding ofDBP, which protects it from nucleases and self-hybridisation.
Synthesis of a complete genome occurs by one of two mechanisms; termed Type I
and Type II replication. In Type I replication Adpol synthesises DNA from one
terminus of the linear DNA molecule to the other, resulting in the production of a new
viral genome with a displaced single strand. In Type II replication the complementary
ends of the displaced strand anneal to form a panhandle structure, with the duplex
region forming a complete ITR element. This ITR allows DNA replication to proceed
in the same manner as for the ds genome (reviewed by Van der Vliet, 1995).
1.3.5.4. Late gene expression.
Late genes begin to be expressed efficiently at the onset of viral DNA replication.
All late proteins are encoded by the major late transcription unit (MLTU) which is
under the control of the major late promoter (MLP). The MLP is active at basal levels
during the early phase, with its activity increasing to high levels after the onset of
viral DNA replication (Shaw and Ziff, 1980). The MLTU encodes the structural
proteins necessary for the construction of the viral capsid and also the scaffold
proteins necessary for its correct assembly. The regulation of the MLP is of particular
relevance to this thesis and is discussed in detail in section 3.4.
1.3.5.4.1. Splicing and polyadenylation of late pre-mRNA.
The adenovirus MLTU generates a primary transcript of approximately 28,000
nucleotides that can be processed into a minimum of 20 cytoplasmic mRNAs (figure
1.4). These mRNAs are grouped into five families (LI to L5), each consisting of
multiple species which have their poly (A) tails in the same position. All MLTU
mRNAs have a common 5' leader sequence, the so-called tripartite leader, which is
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spliced to the body of the mRNA sequence. Therefore, the MLTU is an example of an
alternatively spliced gene in which one 5' splice site (leader 3) can be spliced to more
than 15 different 3' splice sites. The 5' tripartite leader (TPL) is a 201 nt sequence
consisting of three short exons 1,2 and 3 (Berget et al., 1977; Chow et al., 1977). An
additional exon, the 440 nt i leader, may be included between exons 2 and 3. Inclusion
of the i leader is temporally regulated by two Ad proteins, E4-0rf3 and E4-0rf6
(Ohman, 1993; Nordqvist et al., 1994), such that it is included in mRNAs produced
from the MLTU at early times, but is usually excluded at late times. The function of
the i leader sequence and the 16.5 kDa protein it encodes are unclear (Symington et
al., 1996). The role of the TPL sequence in translation of late mRNAs is discussed in
section 1.3.5.4.2.
Transcription of the MLTU occurs during both early and late phases. The
transcription start site is the same both early and late (Shaw and Ziff, 1980) but the
length of the primary transcript and the structure of the resulting mRNAs differ
considerably (Chow et al., 1979). At early times, transcription from the MLP is
subjected to a control at the level of transcription termination. At this stage the
transcriptional activity decreases gradually over a large region beginning around map
unit 40, with no polymerases extending beyond map unit 75 (Iwamoto et al., 1986).
At late times, the transcription termination block is alleviated and transcripts initiated
at the same promoter continue to the right hand end of the genome. During the early
phase of infection, only the Ll poly (A) site is utilised, despite the fact that
transcription proceeds across the L2 and L3 poly (A) sites (Akusjarvi and Persson,
1981; Nevins and Wilson, 1981; Iwamoto et al., 1986). The presence of a cis-acting
selector element upstream from the Ll poly (A) site is thought to be responsible for
the preferential L1 production at this stage (De Zazzo and Imperiale, 1989). Late after
infection the situation is reversed and the L2 and L3 poly (A) sites are used more
efficiently than the L1 site (Nevins and Wilson, 1981).
Alternative splicing within the L1 gene family has been widely studied and
involves a choice between two alternative 3' splice sites. The L1 region encodes two
major mRNAs, the so-called 52/55K (proximal 3' splice site) and IlIa (distaI3' splice
site) mRNAs. 52/55K mRNA is the only mRNA expressed at early times of infection,
while IlIa mRNA splicing is confined to the late phase (Shaw and Ziff, 1980;
Akusjarvi and Persson, 1981; Nevins and Wilson, 1981). Studies have shown that the
shift from only 52/55K to both 52/55K and IlIa mRNA splicing results from a
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reduction in 52/55K 3' splice site usage, combined with an enhanced recognition of
the IlIa 3' splice site (Kreivi and Akusjarvi, 1994).
1.3.5.4.2. Nuclear export and translation of late mRNAs.
During the late phase of infection, cellular protein synthesis is shut off, due to a
translational block of host cell mRNAs (reviewed by Zhang and Schneider, 1993). In
addition, most cellular mRNAs fail to accumulate in the cytoplasm despite continued
nuclear synthesis and processing (Beltz and Flint, 1979). In contrast, late viral
mRNAs are selectively exported to the cytoplasm and are efficiently translated late
after infection (Babich et ai, 1983; Binger and Flint, 1984).
The selective accumulation of viral mRNAs during the late phase of infection is
mediated by the Ad encoded EIB-55K and E4-0rf6 proteins, which form a specific
complex within infected and transiently transfected cells (Sarnow et al., 1984;
Goodrum et al., 1996). The EIB-E4 protein complex appears to modulate viral and
cellular mRNA transport after transcription and processing but before translocation of
mRNAs through the nuclear pores (Leppard and Shenk, 1989). Studies have shown
that both proteins are localised within and about the periphery of viral nuclear
inclusion bodies (Ornelles and Shenk, 1991) which are believed to be the sites of viral
replication (Puvion-Dutilleul and Puvion, 1991). This observation is consistent with
the idea that the EIB-E4 complex regulates RNA metabolism at an intranuclear step,
possibly by facilitating the movement of mature viral mRNA to the nuclear pore
complex (Dix and Leppard, 1993; Leppard, 1993; Nordqvist et al., 1994). The
mechanism by which the EIB-E4 complex regulates mRNA transport may be more
complicated than originally envisioned. The complex has been shown to continuously
shuttle between the nucleus and cytoplasm (Dobbelstein et al., 1997), suggesting an
alternative theory for how it regulates mRNA export.
In addition to their facilitated transport from the nucleus, viral mRNAs are
preferentially translated when they reach the cytoplasm. Three virus-encoded
functions, VAl RNA, the tripartite leader sequence (TPL) and the L4-100K protein
have been shown to increase translational efficiency during the late phase of infection.
Following infection by a number of viruses, EIF-2a kinase inhibits translation by
phosphorylating the a subunit of the initiation factor EIF-2 (Reichel et al., 1985). It
has been proposed that VAl RNA functions by binding to EIF-2a kinase, thus
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blocking its activation and preserving the function of ElF-2 (Katze et al., 1987). VAl
RNA has been shown to co-purify with viral mRNAs (Mathews, 1980) and, as a
result, they might protect viral but not cellular protein synthesis, providing a
functional compartmentalisation.
The TPL sequence increases translation of heterologous mRNAs during the late,
but not the early phase of infection and does not increase translational efficiency
when placed at the 3' end of mRNA, suggesting a role in initiation (Logan and Shenk,
1986). The TPL sequence lacks secondary structure and it has been proposed that
TPL-containing viral mRNAs can continue to be translated late after infection
because the 40S ribosome can scan from the cap to AUG codon without the need for a
helicase as eIF-4F activity becomes limiting due to inactivation late during adenovirus
infection (Huang and Schneider, 1991). In contrast, most cellular mRNAs are no
longer translated in the absence of eIF-4F because they require the helicase to permit
scanning through the more extensive secondary structure at their 5' ends.
Finally, there is a selective activation of viral late protein synthesis by the L4-
lOOKprotein (Hayes et al., 1990) by an as yet unknown mechanism. The L4-100K
protein has been shown to bind to mRNA (Adam and Dreyfus, 1987; Riley and Flint,
1993), suggesting it may function at the polysome to facilitate viral translation.
1.3.5.5. Virus assembly and release.
Structural proteins along with scaffolding proteins are transported to the nucleus,
the site of virus assembly (reviewed by D'Halluin, 1995; Shenk, 1996). Capsids are
formed through a number of stages; firstly trimeric hexon capsomeres are rapidly
assembled, a process which requires the scaffolding protein L4-100K. Penton
capsomeres, consisting of the penton base and trimeric fibre protein, assemble more
slowly. After their production, hexon and penton capsomeres accumulate in the
nucl~us where they associate to form light intermediates. Into these are inserted the
viral DNA; the cis-acting sequences necessary for encapsidation of the genome reside
between bp 194 and 358 in Ad5 (reviewed by Schmid and Hearing, 1995). Cellular
factors that bind to these sequences may playa role in DNA encapsidation (Schmid
and Hearing, 1998). Also the Ll 52/55K protein, in addition to its role as a
scaffolding protein (Hasson et ai, 1992), may also be involved in DNA encapsidation
(Gustin and Imperiale, 1998). Packaging of the genome leads to the formation of
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heavy intermediates, which are converted to mature virions through the proteolytic
cleavage of the precursor forms of several virion polypeptides such as pTP, pVI, pVII
and pVIII. These cleavage events are mediated by the encapsidated viral protease and
function to stabilise the structure and render it infectious.
Release of the mature virions from the infected cell is facilitated by disruption of
the cytoskeleton in response to the EI B-19K protein and the viral protease. These
proteins weaken the integrity of the cell and leave it susceptible to lysis by mechanical
stress (Chen et al., 1993). An additional protein required for efficient cell lysis is the
adenovirus death protein (ADP), an 11.6kDa protein encoded by the E3 region
(Tollefson et al., 1996a, 1996b).
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1.4. Adenovirus vectors.
Adenoviral vectors represent an important class of gene delivery vehicle for in
vivo gene therapy. There are several major advantages of adenoviral vectors that make
them ideally suited to gene therapy applications. Their structure, genome organisation
and replication cycle are all well characterised, as are the functions of individual
proteins and their interactions with cellular factors. The safety profile of adenovirus is
well established; live, encapsulated strains of serotypes 4 and 7 have been used as an
oral vaccine to vaccinate military personnel against acute respiratory infections for a
number of years (Top et al., 1971). Also, the serotypes used most commonly as gene
therapy vectors (2 and 5) do not generally cause serious disease, being associated with
mild self-limiting infections of the upper respiratory tract. Adenoviral vectors can be
grown to high titres (in excess of 1011 plaque forming units (pfu) per ml) and easily
purified making them suitable for in vivo applications. In contrast to retroviruses that
can only infect actively dividing cells, adevoviruses can infect and deliver their DNA
directly to the nucleus, without the need for cell division, enabling them to transduce
both dividing and non-dividing cell types. Additionally, they are able to infect a wide
variety of cell types due to the ubiquitous nature of the CAR receptor.
1.4.1. Construction of adenovirus vectors.
Gene delivery using adenovirus faces two initial problems, a wild type virus can
only efficiently package approximately 2 kbp of exogenous DNA (Ghosh-Choudhury
et al., 1987) and such vectors would be replication-competent in vivo, leading to
infection and spread of the virus. To address these problems the viral genome is
engineered to remove essential gene functions and create extra capacity for insertion
of heterologous sequences. The E3 region is non- essential for growth in tissue culture
and can be deleted without having any adverse effects on virus growth in vitro. The
El region is essential for viral growth, and represents an ideal region for deletion in
order to render the virus replication-defective. To allow the virus to grow in tissue
culture (essential for production of vector stocks) the missing El functions must be
provided in trans. The existence of a human embryonic kidney cell line (293 cells;
Graham et al., 1977) has allowed the isolation and propagation of a number of viruses
with mutations and deletions in the El region (reviewed by Shenk and Williams,
1984). A combination of deletions in the El and E3 regions allows the insertion of
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approximately 8 kbp of foreign DNA. Vectors engineered in this way were the first to
be developed and used in pre-clinical and clinical trials, and are discussed in section
1.4.2.
A scheme for constructing a recombinant adenovirus is depicted in figure 1.5.
Because of the size of the genome (and the resulting high frequency of restriction
enzyme sites), it is difficult to directly clone any heterologous DNA into the genome.
Instead, homologous recombination is used. The heterologous sequence is cloned into
a plasmid that contains the left end of the viral genome, such that the inserted gene is
flanked on one side by the ITR (0 - 1 map units) and on the other by approximately 2
kb of Ad sequence (9 - 16 map units), so that it replaces the El region. This plasmid
is linearised and transfected into 293 cells, along with linear viral DNA backbone that
has been digested to remove the left end. Homologous recombination then occurs
between the plasmid and viral DNA and recombinant virus that contains the inserted
transgene is produced. The recombinant virus is only infectious in 293 cells, which
provide El functions in trans. For reviews of the construction and use of adenovirus
vectors for gene therapy, see Kozarsky and Wilson, 1993; Trapnell and Gorziglia,
1994; Bramson et al., 1995 and Benihoud et al., 1999.
1.4.2. First generation adenovirus vectors.
The so-called first generation vectors, those deleted for Eland E3, are the largest
group of adenovirus vectors so far studied for the purpose of gene therapy. The range
of applications for which they have been investigated is beyond the scope of this
section (reviewed by Kozarsky and Wilson, 1993; Trapnell and Gorziglia, 1994),
instead this section will concentrate on those studies which first revealed the
limitations of these vectors and prompted their further development.
Due to their natural tropism for the respiratory tract, adenoviruses have been
investigated as candidates for gene therapy of the two most common inherited gene
defects which generate pathology in the lung, cystic fibrosis (CF) and ai-antitrypsin
(cq-A'I) deficiency. Studies by Rosenfeld et al. (1991) showed that ai-AT delivered
by tracheal instillation to cotton rats using an EIlE3-deleted Ad5 vector, could be
expressed and detected in epithelial lining fluid for at least one week. Further studies
by the same group (Rosenfeld et al., 1992) showed that the chloride ion secretory
defect of CF could be corrected in an in vitro model and was also expressed in cotton
45
Figure 1.5. Generation of recombinant adenoviruses by homologous
recombination.
(a) A plasmid containing the left-most 15 map units (5800 bp) of Ad DNA, with a
transgene (e.g. CMV-driven p-galactosidase) replacing Ad El sequences, is
constructed. The plasmid sequences indicated (red) contain the ampicillin
resistance gene and bacterial origin of replication.
(b) Plasmid is linearised (with NheI in this example) and transfected into 293 cells
along with ClaI-digested non-infectious viral DNA lacking the left end.
(c) Recombination occurs between the homologous Ad sequences (9 - 16 map units),
and recombinant adenovirus containing the lacZ reporter gene but deleted for El
is produced.
Numbers indicate map units of the Ad genome and the diagonal lines represent a
length of DNA not shown.
(a). NheI
lacZ
(b).
NheI digest.
Linearised plasmid.
0-lPS!Y11111111111.9 1•6., p.l.as.m.id .
"), 100 !
CZaI-digested Ad DNA
(c).
Co-transfection into 293 cells
followed by homologous
recombination.
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rats. They used an EllE3-deleted Ad5 vector to deliver the cDNA encoding the
normal human cystic fibrosis transmembrane conductance regulator (CFTR) to the
lungs of cotton rats. CFTR RNA transcripts could be detected for up to 6 weeks, with
protein detected up to 14 days post-infection. In another report Englehardt et al.
(1993b), using a human bronchial xenograft model in nude mice, demonstrated that an
El-deleted Ad5 vector could transduce 5-20 % of human lung surface epithelial cells
with the human CFTR. This expression was detectable up to 5 weeks post-infection,
with the protein correctly localised to the apical membrane.
The study of Englehardt et al. (1993b) was among the first to address what has
become one of the major disadvantages of first generation vectors; residual viral gene
expression. It revealed that the EI-deleted vector used, when administered at high
multiplicity of infection, expressed high levels of the E2A-encoded early protein DBP
in a small subset of cells. However, no expression of the late proteins hexon or fibre
and no replication-competent virus was detected. These results suggested that the
vector was prevented from entering the late phase of the replication cycle in the
absence of E1A and E1B, but the E2A promoter was activated in a subset of cells,
possibly via the action ofE1-like cellular proteins, or pre-existing El sequences. This
hypothesis is supported by the previously reported finding that cellular transcription
factors, such as NF-IL6, can compensate for a lack of E1A (Spergel et al., 1992).
Indeed, E I-deleted virus has long been known to be replication-competent at high
multiplicities of infection (Nevins, 1981).
The first clinical trial for gene therapy of CF was that of Crystal et al. (1994).
Using the vector of Rosenfeld et al. (1992) they showed that the normal CFTR cDNA
could be expressed in the respiratory epithelium, with no adverse effects evident at
doses up to 2 X 107pfu. However, a transient systemic and pulmonary syndrome was
observed in one patient who received a dose of 2 x 109 pfu. This was most likely
caused by vector-induced inflammation of the lower respiratory tract, a hypothesis
supported by the patient having high serum levels of interleukin (Il.) 6. Despite this,
no virus was shed, ruling out the possibility that IL-6 had induced vector replication
by inducing the EIA-like transcription factor NF-IL6. Although the trial showed
CFTR expression, it failed to show the correction of any of the clinical defects of CF.
Another trial by Zabner et al. (1993) showed that the chloride ion transport
defect in patients with CF could be corrected in nasal epithelium using CFTR cDNA
delivered by an El-deleted Ad2 vector. However, the correction was only evident for
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three weeks post-therapy and as with the study by Crystal et al. (1994), significant
inflammatory reactions were observed in patients receiving the highest vector doses.
Subsequent studies by Knowles et al. (1995) failed to show any correction of the CF
defect using an EIIE3 deleted AdS vector, although this could be due to differences in
their protocol, including the use of a different vector construct and an alternative
method of measuring the potential difference across the nasal epithelium.
In addition to CF gene therapy, first generation vectors were also being used in
other applications. The feasibility of intramuscular injection of adenovirus vectors
was demonstrated by several groups (Quantin et al., 1992, Stratford-Perricaudet et
al., 1992, Ragot et al., 1993). The study by Ragot et al. (1993) showed that the
minidystrophin cDNA could be delivered and expressed in muscle fibres of
dystrophin-deficient mdx mice, raising the possibility for gene therapy of Duchenne
muscular dystrophy. Expression of the minidystrophin cDNA could be detected in 5 -
50 % of the injected muscle fibres; this expression declined to 20 % over 13weeks.
Other studies using first generation vectors reported similar results; efficient gene
transfer accompanied by an immune response and transient transgene expression
(reviewed by Kozarsky and Wilson, 1993; Trapnell and Gorziglia, 1994; Bramson et
al., 1995). Despite the mixed results of these first trials, they did show the limitations
of the vectors used, mainly the fact that they were capable of expressing viral genes
and were not completely replication-deficient. The immune response to the vectors
was also a potential problem, ruling out the possibility of using repeat doses to
compensate for the transient transgene expression (Yei et al., 1994). In addition to
this, vector stocks could be contaminated by replication-competent virus produced by
homologous recombination between the vector and El sequence present in 293 cells.
The most tragic and unexpected outcome of a clinical trial occurred in 1999 at the
University of Pennsylvania's Institute of Human Gene Therapy (IHGT). Jesse
Gelsinger, an 18-year-old volunteer in a Phase I clinical trial, died on September 17,
1999 after complications arose following treatment with an adenovirus vector.
Gelsinger was one of 18 participants in the trial to develop a treatment of ornithine
transcarbamylase (OTC) deficiency, which is an inherited enzyme deficiency
resulting in a block to ammonia metabolism in the liver. Gelsinger received 3.8 x 1013
particles, the highest dose of vector in the trial, delivered directly into the hepatic
artery. However, post-mortem examination detected vector and OTC transgene
sequences in other organs in addition to those in the target organ, the liver. The
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autopsy also revealed that the major factor in Gelsinger's death was oxygen
deprivation brought on by Adult Respiratory Distress Syndrome (ARDS), a severe
lung dysfunction. Immediately following vector administration there was an innate
immune response, followed by injury to the liver and inappropriate blood coagulation.
His underlying genetic defect made it difficult for him to handle the stress of the
immune activation, resulting in an accumulation of ammonia in the blood, and then
coma. The onset of ARDS occurred three days later, which could not be reversed in
the time leading to his death. It was also discovered that complications might have
arisen due to Gelsinger's bone marrow being depleted of erythroid precursor cells,
suggesting an undetected genetic condition or a pre-existing parvovirus infection.
Following this event the Food and Drug Administration (FDA) stopped all eight trials
run by the IHGT after finding "serious deficiencies" in the monitoring of clinical
trials. A full report can be found on the University of Pennsylvania's Institute of
Human Gene Therapy homepage (http://www.med.upenn.edu/ihgt/jesse.html). The
results of this trial highlight that it is not only vector design that has to be improved,
but also the quality control and monitoring of clinical trials.
1.4.3. The immune response to adenovirus vectors.
After administration, first generation vectors elicit an immune response which is
both cellular and humoral in nature. This response is similar to that seen in a wt virus
infection (Prince et al., 1993), with an initial influx of inflammatory cells and the
release of TNFa and interleukins (IL-l p, IL-6 and IL-8). This initial inflammatory
response does not appear to require expression of adenovirus or transgene encoded
proteins and may even be triggered by the infection process itself (Bruder and
Kovesdi, 1997). Immunoc1earance of infected cells then occurs, mediated by MHC
class I-restricted CTLs directed towards viral antigens andlor the transgene product.
During AdS infection, the major epitopes for CTLs are generated by the products of
the El A region (Routes et al., 1991). Thus the strength of the immune response
against EIA-deleted vectors was unexpected. In order to improve the effectiveness of
adenovirus vectors, studies were initiated to define the nature of the immune response
responsible for the elimination of transgene expression and development of pathology
in transfected tissues.
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Studies by Yang et al. (1994a) investigated adenovirus-mediated gene transfer to
the livers of immunocompetent (CBA) and genetically athymic (nu/nu) mice. An
EIlE3-deleted vector, expressing a lacZ reporter gene, was infused into the biliary
tract of female mice and longevity of transgene expression monitored. Over the
duration of the study (60 days), no reduction in expression of lacZ was observed in
nu/nu mice, whereas in CBA mice lacZ expression was undetectable by day 21.
Persistence of viral DNA in nu/nu but not in CBA mice was also apparent after
Southern blot analysis. Analysis of splenocytes harvested from mice after 14 days
showed that CBA mice had MHC-restricted CTL activity, indicating the involvement
of these cells in the immune response against adenovirus vectors. The detection of
low levels of E2A-DBP and hexon protein suggested that the cellular immune
response was directed against de novo synthesised viral antigens.
Further studies in mice by Yang et al. (1995) determined that MHC class 1-
restricted CDS+CTLs were activated in response to newly synthesised viral antigens,
leading to destruction of transduced cells and loss of transgene expression. MHC class
II-restricted CD4+ T helper cells, activated by exogenous viral antigens, were
insufficient to completely eliminate transgene-containing cells in the absence of CDS+
T cells. However, they did contribute to the formation of neutralising antibodies in the
airway that would block any subsequent adenovirus-mediated gene transfer.
Subsequent work showed that a response by CD4+ cells alone was sufficient to
destroy transduced hepatocytes, although the possibility of contaminating CDS+cells
was not excluded (Yang and Wilson, 1995). These results supported a then recent
finding of Bendelac et al. (1994) that a subset of CD4+ T cells could be selected by
MHC class Imolecules and contribute to the clearance of viral infection.
Even though the nature of the immune response to AdS vectors was becoming
clearer, it was still undetermined as to whether it was the expression of transgene or
viral proteins that was responsible for the response. Studies by Yang et al. (1996b)
showed that transfer of the lacZ gene to the lungs of mice transgenic for (and
therefore tolerant of) lacZ resulted in a CTL response and loss of transgene
expression. Similar results were found when using the gene for ornithine
transcarbamylase (OTC), an endogenous protein found in the liver. These results
indicated that CTLs specific for viral antigens were responsible for transgene
instability and that CTLs specific for the transgene product alone could not account
for the observed problems. In contrast to these findings, Tripathy et al. (1996) showed
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definite involvement of an immune response directed at the transgene-encoded
protein. In their study immunocompetent mice were injected intramuscularly with
identical Ad vectors encoding either self (murine) or foreign (human) erythropoietin
(AdmEpo and AdhEpo respectively). Mice injected with AdmEpo had an increase in
haematocrit when compared to mice that received a control virus lacking a transgene.
In contrast, mice injected with AdhEpo showed significantly lower haematocrits than
the control, indicating that expression of hEpo had reduced the number of red blood
cells. When the AdhEpo virus was administered to CD8+ T cell-deficient mice,
haematocrit levels were similar to those seen in immunocompetent mice receiving
AdmEpo. These results suggested that the CD8+ T cell response directed against
transduced cells was directed at the transgene-expressed protein. Studies by
Wadsworth et al. (1997) also showed that there was a T cell response against foreign
transgenes, but it was ineffective at eliminating transduced cells. To add further
confusion, studies by Sparer et al. (1997) and Jooss et al. (1998a) showed that the
recognition of Ad epitopes by CTLs was dependent on the MHC haplotype of the
mouse strain used. In C57BLl6 mice the viral hexon protein contained the
immunodominant epitope, whereas in C3H mice it was the alkaline phosphatase
transgene protein. As the human population has diverse HLA haplotypes, this would
present another problem to be overcome when designing vectors for human gene
transfer applications.
In summary, administration of first generation vectors elicits a bi-phasic immune
response. Firstly an inflammatory response results in clearance of the majority of the
vector. This is followed by a CTL response (mostly CD8+but also CD4+)against viral
or transgene encoded proteins, which leads to the destruction of the transduced cells.
The epitope(s) recognised by the CTL are dependent on transgene origin, viral
attenuation and the recipient's haplotype.
1.4.4. Second generation adenovirus vectors.
The limitations of first generation vectors prompted a major re-evaluation of
adenovirus vector design. The problems of leaky viral DNA replication and
accumulation of late gene products had to be addressed. To prevent these events it
was necessary to further engineer the viral genome to remove essential gene
functions. Adenovirus vector development has focused on crippling the virus by
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deleting essential genes and complementing the missing function(s) in trans using
engineered cell lines or viral helper systems. This multi-deficient vector approach has
several advantages: increased capacity for transgene DNA; decreased incidence of
replication-competent virus in vector stocks by requiring two or more independent
recombination events to occur to generate such virus; addition of extra blocks to viral
replication and protein expression, leading to a lower expressed viral antigen burden.
1.4.4.1. Modifications to the E2 region.
Adenovirus DNA replication, required for expression of late gene products, is
regulated by many viral proteins encoded by the El, E2 and E4 regions (reviewed by
Shenk, 1996). Early attempts to improve first generation vectors focused on the
introduction of mutations into the E2A-encoded DBP. Engelhardt et al. (1994) used
the Ad5 temperature sensitive (ts) mutant H5ts 125 (Klessig and Grodzicker, 1979) to
generate a second generation vector. This EIlE3 deleted vector contains a ts mutation
in the DBP that allows the virus to grow at the permissive temperature of 32°C, but
not at 39 CC.Studies using this vector in vivo showed prolonged expression of a lacZ
reporter gene in mouse liver compared to that of a first generation vector (70 days, as
opposed to 14 days). It was also observed that the immune response against the two
vectors differed. The initial innate phase was the same against the two vectors, but in
the second phase a marked reduction in infiltration of CDS+T cells, together with a
delayed and blunted inflammatory response was observed, adding weight to the
previous suggestion that earlier vectors were not completely-replication deficient.
Another study by Yang et al. (I994b) using the same vector, but this time
administered to mouse lung, again showed improved persistence of lacZ expression
and a reduced inflammatory response. Additional experiments using a similar vector
containing CFTR also showed increased persistence when compared to an El-deleted
vector containing the same transgene. This increased persistence was attributed to the
E2A ts mutation although it could have been due to the difference in E3 status as the
second generation vector retained the majority of the E3 region. Pre-clinical trials in
baboons gave similar results (Goldman et ai, 1995), although transgene expression
from the E2A ts vector was not as prolonged as expression from an EI-deleted vector
in immunodeficient mice. These results suggested that an immune response against
second generation vectors was still responsible for clearance of transduced cells, an
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effect Goldman et al. (1995) attributed to leaky expression of the E2A ts mutant at the
intermediate temperature of 37 °C. This observation tied in with the results of the in
vitro experiments of Engelhardt et al. (1994) that showed low but detectable levels of
viral growth at 37 °C. These results suggested that a more complete block to viral
DNA replication and late gene expression, possibly by deletion of the E2A gene,
would be more effective.
In order to construct a vector containing a deletion in the E2A gene a
complementing cell line was needed to provide the missing gene function in trans.
Several publications describe the construction of cell lines expressing DBP (Brough et
al., 1992; Gorziglia et al., 1996; Zhou et al., 1996). The cell lines of Gorziglia et al.
(1996) and Zhou et al. (1996) were used to grow vectors with partial deletions in the
E2A gene, increasing the capacity for insertion of exogenous DNA to about 9 kbp.
Evaluation of these vectors suggested that a partial deletion of E2A had no effect on
the efficiency of transduction, while the persistence of transgene expression has yet to
be evaluated in vivo. One potential problem is that E2A-deleted vectors are hindered
by a 10-30 fold reduction in growth in vitro, even in complementing cell lines.
Reduced viral replication and late gene expression is accomplished with these vectors;
however, it is possible that deleting E2A also triggers enhanced expression from other
viral genes such as E4 (Rice and Klessig, 1985). This could lead to other problems
unless the E4 region is also deleted, an approach that is discussed in section 1.4.4.2..
Complementing cell lines expressing other E2 proteins have been described
(Schaack et al., 1995; Langer and Schaack, 1996; Amalfitano and Chamberlain, 1997;
Amalfitano et al., 1998). Moorhead et al. (1999) reported the construction of a vector
with a deletion in the preterminal protein (pTP). This vector was shown to elicit a
reduced immune response when injected intradermally into mouse ears. Duration of
transgene expression was also increased when compared with a first generation
vector. Results from this and the study by Amalfitano et al. (1998) suggested that
deletion of additional early gene functions would result in reduced expression of late
genes and increased transgene persistence. However, the eventual loss of transgene
expression and the observed immune response showed that these second generation
vectors still had limitations and required further modification.
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1.4.4.2. Modifications to the E4 region.
Investigations of E4 gene product functions identified the OrD and Orf6 proteins
as being essential, with either sufficient to provide an E4 function necessary for the
normal viral lytic cycle (Bridge and Ketner, 1989; Huang and Hearing 1989a).
Complementing cell lines have been developed which express E4-0rf6 (Brough et al.,
1996, Gao et al., 1996) and these are capable of supporting the growth of vectors with
the E4 region deleted. Studies by Gao et al. (1996) showed that deletion of the E4
region resulted in reduced liver toxicity and increased persistence of transgene
expression when compared to first generation vectors in mouse models. An additional
advantage of this EIlE4-deleted vector was the reduced risk of contamination by
replication-competent virus, since there were no overlapping sequences between the
cell's E4 gene and the vector E4 region to facilitate recombination. Lusky et al.,
(1998) conducted an in vivo comparison of second generation vectors expressing lacZ
or CFTR transgenes, that were isogeneic for deletions in El and E3, with additional
deletions in either the E2A or E4 genes. It was found that the E2A deletion had the
most profound effect on late gene expression, however, no differences could be
detected in the persistence of viral DNA in the liver and lungs of treated mice. These
results led to the suggestion that viral antigens played a minor role in immune
clearance of vector transduced cells.
Despite these findings recent publications present apparently conflicting data
concerning the effect of E4 deletion on transgene persistence in vivo. Annentano et al.
(1997) showed that retaining an entire E4 region could prolong transgene expression.
They also showed that E4 gene products acted in trans to overcome down-regulation
of expression of the transgene from the cytomegalovirus (CMV) intermediate-early
promoter. E4-0rf6 alone was insufficient to overcome this effect but recent studies
show that E4-0rf3 alone can achieve long-term transgene expression from the CMV
promoter (Annentano et al. 1999), possibly by relieving its repression, as truncation
of the CMV promoter abolishes the need for E4-0rD. The earlier studies by
Annentano et al (1997) highlighted the importance of considering the vector
background when choosing promoters to drive transgene expression. Although E4
was shown to have an effect on expression from the CMV promoter, no effect was
seen on the persistence of transgene expression from similar vectors using the El A
promoter. These considerations were further emphasised by the studies of Dedieu et
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al. (1997), who showed that E4 status had no effect on transgene persistence when
using the Rous sarcoma virus LTR promoter.
Despite these apparent contradictions, EIlE4-deleted vectors have been shown to
invoke reduced pathological responses in transduced mouse liver and therefore appear
to be advantageous (Gao et al., 1996, Dedieu et al., 1997). Deletion of the E4 region
also increases the transgene carrying capacity to about 11 kbp when engineered into a
vector containing Eland E3 deletions. There is also increasing evidence that E4
deletion may be necessary for safety reasons, namely the observations that E4-0rfl
can have transforming activity (Javier, 1994), that E4-0rf6 can block p53 activation
(Dobner et al., 1996) and cooperate with EIA to transform cells in vitro (Moore et al.,
1996).
1.4.4.3. Modifications to other regions.
Polypeptide IX is a minor capsid component involved in stabilising hexon
interactions and is required for packaging of full-length genomes (Ghosh-Choudhury
et al., 1987). The polypeptide IX gene is within the EIB region and its previous
deletion from vectors had placed a restriction on the size of transgene that could be
inserted. Caravokyri and Leppard (1995) described the construction of a 293-based
cell line expressing polypeptide IX. Use of this cell line allowed the construction of
vectors with deletions in the IX gene that showed packaging capacity similar to that of
IX+vectors. Deletion of IX also allows insertion of up to 9.2 kbp of exogenous DNA
into an EllE3-deleted vector. Krougliak and Graham (1995) also used IX expressing
cells to produce a vector deleted in El. E3. E4 and pIX. resulting in a transgene
carrying capacity of approximately 11 kbp.
Von Seggem et al. (1998) described the construction of a 293-based cell line
expressing polypeptide IV. the constituent of the trimeric fibre protein. This cell line
was capable of supporting the growth of a virus containing a ts mutation in the fibre
protein and was subsequently used to produce fibre-less particles (Von Seggem et al.
(1999).
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1.4.5. Improving adenovirus vectors for gene therapy.
1.4.5.1. Regulation of the immune response.
Some of the major limitations to the use of adenovirus vectors in gene therapy are
the vector-induced inflammation, the transient expression of transgenes, and the
development of adenovirus-specific neutralising antibodies, which hinder repeat
administration of the vector. Attempts to overcome these problems have manifested
themselves in numerous approaches.
Reduction in both the humoral and cellular immune response has been achieved
through the use of immunosuppressive reagents at the time of vector administration.
Yang et al. (1996a) and Scaria et al. (1997) administered antibodies directed against
molecules involved in the host immune response (CD4 and CD40 respectively),
followed by administration of the vector. They showed that transgene expression was
partially stabilised and that neutralising anti-Ad antibodies did not form, allowing
repeat administration in both studies. Other studies have investigated blocking
immune cell activation by blocking a co-stimulatory molecule necessary for the
efficient stimulation of T cells, CTLA4. Kay et al. (1997) co-administered soluble
CTLA4Ig, which is known to block co-stimulatory signals between T cells and
antigen presenting cells, along with anti-CD40 antibody. These studies showed that
use of both antibodies together, but neither one alone, led to maintenance of
expression of human aI-AT in the livers of mice for over a year, and allowed
effective repeat administration in 50% of animals. Similar studies by Jooss et al.
(1998b) also demonstrated improved transgene persistence. While these results may
be encouraging, systemic immune suppression may be unacceptable in the clinical
setting. An alternative approach of expressing immunomodulatory proteins from the
adenovirus vector alongside the principal transgene, may achieve targeted immune
suppression and have fewer safety risks (Schowalter et al., 1997a).
Adenovirus encodes its own immunomodulatory proteins, the products of the E3
transcription unit. Han et al. (1997) have demonstrated that expression of the E3
region from a CMV promoter reduces the anti-adenovirus humoral immune response.
Intravenous administration of this vector to rats also resulted in a decrease in
neutralising antibody formation, allowing repeat administration. The E3-encoded
gp19K protein has been shown to block the ability of adenovirus-specific CTLs to
recognise virus-infected cells in vitro, an effect it achieves by down-regulating the
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expression ofMHC class I molecules (Burgert and Kvist, 1987). Studies by Bruder et
al. (1997) have shown that expression of gp 19K from a vector leads to improved
trans gene expression in mouse liver and lungs. However a similar study by
Schowalter et al. (1997b) failed to show any effect of gp 19K expression on trans gene
persistence, although this could have been due to the use of a different promoter and
mouse strain. Other studies have concentrated on blocking TNFa signalling, which is
involved in triggering cytolysis and inflammation. Peng et al. (1999) showed that
blocking TNFa activity in mouse liver and lung leads to prolonged transgene
expression.
Another approach is to transiently deplete the numbers of macrophages before
vector administration, as macrophages are responsible for removal of 90 % of
transduced cells immediately after infection (Worgall et al., 1997). The consequences
of depletion of this cell type have been studied, using dichloromethane-
bisphosphonate (ChMBP), which is an immunosuppressant that depletes the numbers
of liver macrophages. Studies by Wolff et al. (1997) showed a ten-fold increase in
reporter gene levels after such treatment, plus the rate of removal of transduced cells
was decreased.
As neutralising antibodies directed against one adenovirus serotype do not block
infection by another serotype (Wolfhart, 1988; reviewed by Horwitz, 1996), one
possible approach to achieving successful readministration is to alternate the serotype
of the vector used. Mastrangeli et al. (1996) successfully administered an AdS vector
to the lung, following prior immunisation with Ad4 or Ad30 virus. Similarly,
successful transgene expression was achieved from an AdS vector following prior
immunisation with Ad4 and Ad7 (Kass-Eisler et al., 1996). Using a different
approach, Roy et al. (1998) overcame the immunity to AdS by using a chimeric AdS
vector containing the hexon protein from Ad12. This vector was successfully used to
transduce the livers of mice previously immunised with AdS.
1.4.5.2. Targeting adenovirus vectors to specific cell types.
Adenovirus vectors lack tissue-specificity due to the broad expression of the
primary receptor, CAR. In contrast, transduction of some cell types is limited because
of low expression of the CAR molecule. Therefore, the inability of adenovirus to
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efficiently transduce certain tissues, coupled with its lack of tissue-specificity, has led
to efforts to redirect adenovirus tropism.
Initial attempts at modifying tropism involved replacing the AdS fibre knob with
the fibre knob from another adenovirus serotype. For example, switching the AdS
fibre knob for the Ad3 fibre knob, which recognises a different cellular receptor
(Stevenson et al., 1995), allows the modified vector to transduce some cell types more
efficiently (Stevenson et al., 1997). Peptide ligands may also be inserted into the fibre
protein to broaden the cell types that can be transduced by adenovirus. Wickham et al.
(1996a) constructed a vector that contained a heparin-binding domain incorporated
into the fibre protein, which targeted the virus to broadly expressed, heparin-
containing cellular receptors.
Adenovirus tropism has also been modified by non-covalently attaching
bispecific molecules to the virus. The bispecific molecule contains a first specificity
for the virus and a second specificity for the cellular receptor. Wickham et al. (1996b)
demonstrated that an adenovirus vector could be retargeted using a bispecific
antibody recognising a FLAG (phenylalanine-Ieucine-alanine-glycine) peptide
inserted into the Ad penton and the av integrin cellular receptor. This retargeting
increased transduction of endothelial and smooth muscle cells that express av
integrins. A drawback to this approach is that the adenovirus retains its native
receptor-binding activity and is not truly retargeted. Douglas et al. (1996) overcame
this problem and created a truly targeted adenovirus system. They achieved this by
chemically conjugating folate to an anti-fibre antibody. This blocked native receptor
binding and retargeted the vector to cells expressing the folate receptor. Similarly,
when the antibody was conjugated to fibroblast growth factor 2 the vector was
redirected to Kaposi's sarcoma cells expressing fibroblast growth factor receptors
(Goldman et al., 1997).
An alternative to modifying the tropism of the virus is to use a tissue-specific
promoter. Larochelle et al. (1997) constructed vectors expressing a reporter gene
under the control of a truncated creatine-kinase promoter/enhancer (MCK) which is
specific for differentiated skeletal and cardiac muscle tissue. After injection of the
vector to skeletal muscle, heart, lung, brain, kidney and liver of mice, reporter gene
expression was only evident in the heart and skeletal muscle when compared to a
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much broader spectrum of expression achieved by a similar vector containing the
RSV-LTR promoter.
1.4.5.3. Increasing the transgene carrying capacity of adenovirus vectors.
The limited space available for insertion of heterologous sequences limits the use
of adenoviral vectors for gene therapy. Complete deletion of the El, E3 and E4
regions allows the insertion of approximately 11 kbp of exogenous DNA, which is not
enough for some transgenes, e.g. the 14 kbp full-length dystrophin cDNA (Koenig et
al., 1987). Also the potential use of tissue specific promoter/enhancer sequences and
the need to include immunomodulatory sequences, such as those from E3, further
reduces capacity and indicates that current vector capacity will be insufficient. To
solve these problems attempts have been made to generate adenovirus vectors with a
large, often complete, deletion of viral coding sequences. These highly deleted viruses
are often referred to as "gutless" or "gutted" vectors.
The only viral sequences required for efficient replication and packaging of viral
genomes are the origins of replication (present in each ITR) and the packaging signal
(bp 194 to 358 in Ad5). The remainder of the genome can be deleted and replaced
with heterologous sequences, with the proteins necessary for virus growth being
provided in trans either by a complementing cell line or a helper virus. Removal of all
viral coding sequences clearly eliminates all expression of viral antigens in transduced
cells and so would be expected to make the vector less immunogenic.
The first approaches toward creating vectors devoid of all viral coding sequences
used replication-deficient helper viruses to provide the trans-complementation
functions, with the helper virus being removed from the vector preparation
subsequently by equilibrium density centrifugation. In a preliminary study by Mitani
et al. (1995) it was shown that a vector deleted in Ll , L2, VAl, VAIl and pTP could
be constructed using wt adenovirus as the helper virus. Subsequent work by the same
researchers demonstrated the construction of a vector devoid of all viral coding
sequence, which was capable of expressing both p-galactosidase and full-length
dystrophin in vitro (Kochanek et al., (1996). The helper virus used in this study was
rendered replication-defective by an El-deletion and a partial deletion of the
packaging sequence. This helper virus was removed from the vector preparation by
caesium chloride density gradient centrifugation, resulting in vector preparations with
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approximately 1 % contamination by helper virus. This vector was shown to be
capable of p-galactosidase and dystrophin expression in muscle cells of mdx mice
(Clemens et al., 1996). However, dystrophin expression declined over 6 weeks post-
vector administration, possibly due to an immune response directed against the
reporter gene or to proteins expressed from the contaminating helper virus. Further
studies by Chen et al. (1997) showed that stable expression of dystrophin in mouse
muscle was possible if mice transgenic for lacZ were used, suggesting that an immune
response directed at this reporter gene was responsible for loss of transgene
expression. A similar vector was constructed by Fisher et al. (1996), encoding the
human CFTR and grown using an EI-deleted helper virus. This group also suggested
that more efficient ways of producing and purifying these vectors would be required
before their use in gene therapy was feasible.
An alternative approach to provide helper functions without helper VIruS
contamination of vector preparations involved the use of the Cre-loxP system from
bacteriophage PI (Parks et al. 1996; Hardy et al. 1997). loxP recombination sites
were introduced on either side of the helper virus packaging signal. Upon infection of
cells expressing the Cre recombinase enzyme the packaging signal is excised,
rendering the helper virus incapable of packaging its genome. Thus the proteins
encoded by the helper virus should be used exclusively to package coinfecting vector.
Using a vector produced using this method, Schiedner et al. (1998) showed
persistence of human o.l-AT expression in mouse liver when compared to that from a
first generation vector. This expression was sustained for 40 weeks, at over lOO-fold
higher levels than was achieved from the first generation vector.
Despite these encouraging results, the production of "gutless" vectors is very
inefficient, with only low titre obtained, which limits their potential use for in vivo
human gene therapy applications. Studies by Hartigan-O'Connor et al. (1999) have
shown "gutless" virions can be produced up to 50 times more efficiently if grown in
cell lines coexpressing the adenovirus preterminal protein and DNA polymerase. Also
the packaging efficiency of the genome is dependent on its size, with genomes 75 -
105 % of wild type length being packaged more efficiently (Parks and Graham,
1997). However, care must be taken when increasing the length of a vector genome to
fall within these optimum limits. Sandig et al. (2000) showed that the nature of the so-
called "stuffer DNA" used to increase genome size had an effect on the growth
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1.4.6. Conclusions.
Progress in recombinant adenovirus technology has made this vector more and
more attractive for in vivo gene transfer to many tissues. Highly deleted vectors can
accommodate large transgenes associated with specific regulatory sequences that
provide suitable regulation of transgene expression. The development of retargeting
strategies has allowed adenovirus-mediated gene transfer to many new cell types.
However, there are still major hurdles to be overcome before adenovirus vectors will
achieve positive results in the clinic. The expression of residual viral late proteins and
the potency of the immune response directed against them is one such problem.
characteristics of the vector and studies by Parks et al. (1999) demonstrated the
possibility of CTL responses being directed against some "stuffer' sequences used.
1.5. Aims.
Second generation adenovirus vectors and highly-deleted vectors have their own
advantages and disadvantages. Second generation vectors are easy to grow at high
titres but are hampered by residual viral gene expression and low transgene carrying
capacity. Highly deleted vectors have a large insert capacity and no residual viral gene
expression. However, they are difficult to grow to high titres and purification away
from the helper virus can be a problem. The work presented in this thesis was
designed to address some of the limitations of current vector systems in order to build
upon, and further develop past techniques for adenovirus vector production. The
major aims were:
1. To create a plasmid construct containing the MLTU from human adenovirus type 5.
The MLTU would be flanked by engineered Pad restriction sites, enabling it to be
removed from the plasmid as a single fragment. This strategy would simplify any
future manipulations of the MLTU and enable it to be cloned into alternative plasmid
backbones. The first such manipulation would involve cloning the MLTU into an
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episomal expression plasmid, which would be used subsequently to attempt to create
a stable cell line.
2. To determine the scope of late protein expression from the cloned MLTU. This
would be achieved by Western blotting using antibodies specific for AdS late
proteins. Currently available antibodies were used, in addition to generating a new
polyclonal antiserum with reactivity against virion proteins. Attempts were made to
show the expression of at least one protein from each late gene.
3 . To use the cloned MLTU construct to develop expression systems for adenovirus
late proteins. Initially this would involve production of a stable cell line, with
expression of the AdS late genes controlled by the major late promoter, which would
cloned as part of the MLTU. Other possibilities would then be explored such as the
use of a regulated heterologous promoter to control late gene expression.
The overall aim of this work was to move towards the creation of a cell line
capable of complementing the growth of an adenovirus vector with late gene
deficiencies.
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Chapter 2 : Materials and Methods.
Chapter 2 : Materials and Methods.
2.1. Materials.
2.1.1. Common buffers and solutions.
5 X SDS-PAGE loading buffer: 2 % (w/v) SDS, 5 % (v/v) p-mercaptoethanol, 10 %
(v/v) glycerol, 0.01 % (v/v) bromophenol blue.
chloroform/iso-amyl alcohol: 96 % (v/v) chloroform, 4 % (v/v) iso-amyl alcohol
50 X Denhardt's solution: 1 % (w/v) Ficoll, 1 % (w/v) polyvinylpyrrolidone, 1 %
(w/v) BSA.
LB: 1 % (w/v) bactotryptone, 1 % (w/v) NaCI, 0.5% (w/v) yeast extract
LB agar: LB containing 1.5 % (w/v) bacto-agar
Phosphate buffered saline (PBS): 137 mM NaCI, 2.7 mM Na2HP04, 1.4 mM
KH2P04
PBS/glycerol: 40 % (v/v) PBS, 60 % (v/v) glycerol
Phenol/chloroform: 50 % (v/v) Tris buffered phenol, 48 % (v/v) chloroform, 2 %
(v/v) iso-amyl alcohol
TBE: 89 mM Tris. base, 89 mM boric acid, 1 mM ethylenediaminetetra-acetic acid
(EDTA) pH 8.0
TD: 25 mM Tris.HCI pH 7.5,137 mM NaCI, 5 mM KCI, 0.7 mM Na2HP04
TE: 10 mM Tris.HCl pH 8.0, 1 mM EDTA
TFB I: 100 mM RbCl, 50 mM MnCh, 10 mM CaCh, 30 mM potassium acetate, 19 %
(w/v) glycerol, pH 5.8
TFB II: 10 mM 3-[N-Morpholino ]propanesulphonic acid (MOPS), 10 mM RbCI,
75 mM CaCh, 19 % (w/v) glycerol, pH 7.0
TNE: 10 mM Tris.HCI pH 8.0, 100 mM NaCI, 1 mM EDT A pH 8.0
TS: 25 mM Tris.HCl pH 7.5,137 mM NaCl, 5 mM KCI, 0.7 mM Na2HP04, 0.9 mM
CaCh, 1 mM MgCh
10 X SSC: 87.65 gil NaCl, 44.1 gil sodium citrate, pH 7.0
62
2.1.2. Bacterial strains.
E. coli strain Phenotype
XL-l Blue recAi endAi gyrA96 thi-I hsdRi7 supE44 relAi lac [F'
proAB lacflZt1Mi5 TniO (Te{)]. (Used for all cloning steps).
2.1.3. Adenovirus strains.
wt300 Wild type (Jones and Shenk, 1979).
Virus strain Phenotype
2.1.4. Cell lines.
Cell line Origin
293 Adenovirus-transformed human embryonic kidney
(Graham et al, 1977)
Hela Human cervical epitheloid carcinoma (Scherer et ai, 1953).
A549 Human lung carcinoma (Giard et ai, 1973).
2.1.5. Antibodies and conjugates.
Primary antibody Dilution used
Name I protein(s) Type I origin Western I.F
recognised
AbBFI Mouse polyc1onal (from B. 11500
Il,IlI Flanagan, University of Warwick).
AbRl/89 Rabbit polyc1onal (from V. Mautner, 111000
III, IV, L4 lOOk University of Birmingham).
Anti-DBP Rabbit polyclonal (from E. Harfst, 111000
72KDBP University of Warwick).
Anti-lOOK Mouse monoclonal (from w.e. 111000 111000
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L4 lOOK Russell, University ofSt Andrews}.
Anti-IVa2 Rabbit polyclonal (from S. Brey, 111000
IVa2 PhD thesis, University of Warwick,
1999).
Anti -pIX Rabbit polyc1onal (Caravokyri and 111000
pIX Leppard, 1995).
Anti-Ll 52/55K Rabbit polyclonal (from A. 111000
L152/55K Arslanoglu, PhD thesis, University
of Warwick, 1999).
Secondary antibody
Rabbit Ig Biotinylated 1goat 1/1000
Mouse Ig Biotinylated 1goat 1/1000
Rabbit Ig HRP conjugated 1donkey 111000
Mouse Ig HRP conjugate 1 sheep 1/1000
Rabbit Ig Rhodamine conjugate 1goat 11200
Rabbit Ig Fluorescein conjugate 1goat 1/200
Mouse Ig Fluorescein conjugate 1goat 11200
Conjugate
Streptavidin-biotinylated 11500
HRP complex
2.1.6. Oligonucleotides.
All oligonucleotides were obtained from Gibco BRL and are shown 5' to 3'.
Annealing sites for primers are given in the text when they arise.
2.1.6.1. PCR primers.
Primer #1: TCCTCCTGTTCCTGTCCATC
Primer #2: ATCATCGCTGAGGAGACCAC
Primer #3: GATCTGTT AATTAAGCTATGTGGTGGTGGGGCTATAC
Primer #4: CATAGCTT AATT AACAGATCACCGTACCTT AATC
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2.1.6.2. Sequencing primers.
SEQ-D:CTGTGTACTCTGTGTGTTGG
2.1.6.3. Adaptors.
NdeI-PacI adaptor: TATTAATTAA
BamHI-PacI adaptor: GATCTTAATTAA
EcoRI-PmeI adaptor: AATTGTTTAAAC
2.2. Suppliers.
All chemicals of analytical or molecular biology grade were supplied by Sigma
(Poole, Dorset, UK) or BDH Laboratory supplies (Merck Ltd, Poole, Dorset, UK)
unless otherwise stated below.
Amersham Pharmacia Biotech (Bucks., UK).
Biotinylated goat a-mouse IgG, Biotinylated goat a-rabbit IgG, streptavidin-
biotinylated horseradish peroxidase complex, a_32P-dCTP,Hybond N and Hybond C
membranes, SDS-PAGE molecular weight markers, Sephadexf G50 medium,
Hypcrfilm'" ECL, ECLTMWestern blotting detection reagents, dATP, dCTP, dTTP,
dGTP.
Becton-Dickinson (Cockeysville, USA).
Yeast extract.
Biorad (Hemel Hempstead, Herts., UK).
Acrylamide, N.N'-methylene-bis-acrylamide, ammomum persulphate, 4-
chloronapthol, electrophoresis grade sodium dodecyl sulphate (SDS), Biorad protein
assay reagent.
BOC (Surrey, UK).
C02, dry ice.
Boehringer Mannheim UK (East Sussex, UK).
Hygromycin B.
Calbiochem (Nottingham, UK).
6S
Goat a-mouse IgG fluorescein isothiocyanate (FITC)-conjugate, goat a-rabbit IgG
rhodamine conjugate, goat a-rabbit IgG fluorescein isothiocyanate (FITC)-conjugate.
Difco Laboratories (Hants., UK).
Bacto-agar, bactotryptone, Noble agar.
Fisher Scientific (Loughborough, UK).
Caesium chloride, sodium dodecyl sulphate (SDS).
Fuji Photo Film Co. Ltd. (Dusseldorf, Germany).
Super RX x-ray film.
Gibco BRL Life Technologies Ltd. (Renfrewshire, Scotland).
Restriction enzymes, lkb DNA ladder, calf intestinal alkaline phosphatase (ClAP),
Taq DNA polymerase, DNA polymerase I large (Klenow) fragment, T4 DNA ligase,
T4 RNA ligase, T4 DNA polymerase, Dulbecco's modified Eagles medium (DMEM),
newborn calf serum (NCS), foetal calf serum (FCS), trypsin, versene.
Kodak (London, UK).
X-ray developing fluid, X-ray fixative.
New England Biolabs (Hearts., UK).
Restriction enzymes, Vent®DNApolymerase.
Premiere Beverages (Stafford, UK).
Dried milk powder (Marvel).
Promega UK (Southampton, UK).
Wizard®PureFection plasmid purification kit.
Qiagen (Hilden, Germany).
Qiaprep miniprep reagents.
University of Warwick media preparation service.
Sterile PBS, distilled H20.
Vector Laboratories (Burlingame, CA).
Vectashield" mounting medium.
Whatman International (Maidstone Kent).
3MM chromatography paper.
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2.3. Methods.
2.3.1. DNA manipulations.
2.3.1.1. Restriction enzyme digestion.
All DNA was digested in the buffers supplied by the manufacturer at the
recommended temperature, typically in a volume of 20 - 100 ,.il. Digestion of DNA
with multiple enzymes was performed in the buffer which gave optimum activity of
all enzymes. Reactions were stopped by the addition of EDT A to 25 mM or heat
inactivation where appropriate.
2.3.1.2. Dephosphorylation of DNA.
Dephosphorylation reactions were performed in REact3™ (50 mM Tris.HCI pH 8.0,
10 mM MgCh, 100 mM NaCl), using calf intestinal alkaline phosphatase (ClAP).
DNA fragments with protruding 5' termini were incubated at 37°C for 30 min with 1
unit of ClAP, followed by a repeat incubation with a further aliquot of ClAP. DNA
fragments with recessed 5' termini or non-cohesive ends were incubated at 37°C for
15 min, 55°C for 15 min with 1 unit of ClAP, followed by repeat incubations with a
further aliquot of ClAP. All reactions were stopped by heat inactivation (75°C, 15
min) in the presence of 25 mM EDT A. Electrophoresis and electroelution was used to
purify the dephosphorylated DNA prior to its use in any cloning steps.
2.3.1.3. End filling of 5' overhangs (Klenow filling).
DNA fragments with extended 5' termini were converted to non-cohesive ends using
the Klenow fragment of E. coli DNA ploymerase I.DNA was incubated with 2 units
of enzyme at 22°C for 20 min in 50 mM Tris.HCI pH 8.0, 10 mM MgCh, 50 mM
NaCl. The reaction was stopped by heat inactivation (70°C, 5 min).
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2.3.1.4. Removal of 3' overhangs.
DNA fragments with extended 3' termini were converted to non-cohesive ends using
T4 DNA ploymerase. DNA was incubated with 2 units of enzyme at 37 °C for 5 min
in 33 mM Tris-HCI pH 7.9, 66 mM potassium acetate, 10 mM magnesium acetate, 0.5
mM DTT, 100 JlM dATP, 100 JlM dTTP, 100 JlM dCTP, 100 JlM dGTP. The
reaction was stopped by heat inactivation (75 °C, 10 min).
2.3.1.5. Ligation of DNA molecules.
DNA fragments with cohesive ends were ligated for 16 hrs at 15 °C, using 2 units of
T4 DNA ligase in the supplied buffer (50 mM Tris.HCI pH 7.6, 10 mM MgCh. 1 mM
ATP, 1 mM dithiothreitol (DTT), 5 % (w/v) polyethylene glycol (PEG) 8000). DNA
fragments with non-cohesive ends were ligated for 16 hrs at 22 °C, using 10 units of
enzyme in the buffer described above. Typically a 5 fold molar excess of insert over
vector DNA fragments was used.
2.3.1.6. Gel electrophoresis of DNA molecules.
DNA fragments were separated on type I agarose (0.6 - 1.4 % w/v), TBE gels,
containing 0.5 mg/ml ethidium bromide. Samples were loaded in 30 % glycerol, 0.04
% bromophenol blue. Electrophoresis was performed in TBE at 70 mA until the
required degree of separation was achieved. Bands were then visualised by
transillumination with UV light and photographed using computerised gel imaging
equipment (Prior Laboratory supplies, UK). DNA fragment sizes were estimated by
comparison to a DNA ladder of known fragment size (1 kb ladder, GibcoBRL).
2.3.1.7. Electroelution of DNA molecules from agarose gels.
The DNA to be purified was excised from the gel and eluted into sealed dialysis
tubing (molecular weight cut-off, 16,000) containing 500 JlI TBE by electrophoresis
in 0.5 X TBE at 100 V for 1 hr. The eluate was then phenol/chloroform extracted
twice, followed by ethanol precipitation.
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2.3.1.8. Phenol/chloroform extraction.
An equal volume of phenol/chloroform was added to the DNA solution and mixed
by repeated inversion. Phase separation was achieved by centrifugation at 10,000 x
gravity (g) for 2 min; the lighter aqueous phase was removed to a clean tube.
2.3.1.9. Ethanol precipitation.
DNA was precipitated from aqueous solution by addition of sodium acetate to 300
mM, plus 2 volumes of ethanol. This was placed at -20 °C for 1 hr, after which the
DNA was pelleted by centrifugation at 18,000 x g for 15min, washed with 70 % (v/v)
ethanol and re-centrifuged for 5 min. The pellet was dried briefly in a vacuum
dessicator and resuspended in 10mM Tris.HCI pH 7.5.
2.3.1.10. Spectrophotometric quantification of DNA.
The concentration and purity of DNA in aqueous solution was determined by
absorbancies at 260 run and 280 run. An absorbance of 1.0 at 260 run is equal to 50
ug/ml for double stranded DNA. Purity was assessed by the ratio of absorbance at 260
run to that at 280 run, a ratio of 1.7 - 1.8 indicating high purity.
2.3.1.11. Automated DNA sequencing.
Automated DNA sequencing was performed by Mrs L. Ward, Department of
Biological Sciences, University of Warwick, using an Applied Biosystems sequencer
(model 373a).
2.3.1.12. Polymerase chain reaction (peR) (after Mullis et al. 1986).
Target DNA was amplified by PCR; all reactions were optimised but a typical 50 J.lI
reaction mix would consist of 100 ng target DNA, 1mM each ofdATP, dCTP, dGTP,
dTTP, required concentration of MgS04, 1 unit of Vent®DNA polymerase, in the
buffer supplied by the manufacturer. Reaction conditions were:
94°C, 1minute; 60 °C, 1minute; 74 °C, 3 min (19 cycles), and then
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94 "C, 1 minute, 60 °C; 1 minute, 74 °C; 7 min (l cycle), followed by a 4 °c soak
until the sample could be removed for processing.
2.3.2. Bacteriological techniques.
2.3.2.1. Culture and storage of bacteria.
E.coli XLI-Blue were cultured in LB containing 15 ug/rnl tetracycline at 37 "C with
shaking. Transformed bacteria were grown on LB agar plates or as liquid cultures,
both containing 100 ug/ml ampicillin (LBamp) and incubated at 37 °C with shaking.
Bacteria containing larger plasmids (20-40 kb) were cultured at 30 °c to allow
efficient plasmid replication.
Cultures were maintained in long-term storage as a 50 % (v/v) mix of glycerol and
exponential phase liquid culture, at -80 °C.
2.3.2.2. Preparation and transformation of competent bacteria.
5 ml of LB was inoculated with a single colony of E. coli strain XLI-Blue and
cultured to stationary phase at 37 °C. 50 JlI of this was used to inoculate 25 ml of LB
which was cultured to ODs5o 0.3 - 0.4. This was split equally between two flasks,
each containing 250 ml of LB, and cultured to ODs so 0.4 - 0.5. The cultures were
cooled on ice for 15 min then the cells were harvested by centrifugation (1,300 x g, 10
min, at 4 °C). Pellets were resuspended gently in 100 ml of ice-cold TFB I and re-
centrifuged. The supernatant was discarded and the pellet resuspended in 10 ml of ice-
cold TFB II. 0.5 ml aliquots were rapidly frozen in a dry ice/ethanol bath and stored at
-70°C.
To transform competent bacteria, DNA (10 ng control plasmid or 15 JlI ligation
reaction) was diluted in 100 JlI of sterile distilled water and placed on ice. Competent
bacteria were thawed rapidly and 150 JlI added to the DNA solution, which was left
on ice for 1 hr, subjected to heat-shock (42 "C, 2 min) then placed on ice for 5 min.
300 JlI of LB was then added and the cells incubated at 37 °C for 30 min prior to
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plating on LB agar plates containing 100 ug/ml ampicillin, which were then incubated
for 16 hrs at 37°C.
2.3.2.3. Small scale preparation of plasmid DNA.
Plasmid DNA was isolated from 1.5 ml of bacterial culture using a Qiagen Miniprep
plasmid purification kit, following the manufacturer's instructions. This DNA was
suitable for restriction enzyme analysis and cloning.
2.3.2.4. Large scale preparation of plasmid DNA.
A single bacterial colony containing the plasmid of interest was used to inoculate 1.5
ml of LBamp and cultured to stationary phase. 50 JlI of this was used to inoculate 25
ml of LBamp, which was cultured to OD6ooof 0.6. This culture was then used to
inoculate 500 ml of LBamp and cultured to OD6ooof 0.4. Chloramphenicol at 100
ug/ml was then added to amplify the plasmid, and the culture was incubated for a
further 16 hrs. All incubations were carried out at 37°C unless stated otherwise in the
relevant results chapter.
Cells were collected by centrifugation (1,600 x g, 30 min, 4°C) and resuspended in
10ml of cold 25 % sucrose, 50 mM Tris.HCl pH 8.0. 4 ml of cold 0.25 M EDTA was
added, mixed gently and placed on ice for 5 min. 20 mg of lysozyme dissolved in 2
ml of TNE was then added, mixed gently and placed on ice for 15 min. Following
this, 16 ml of cold Triton Lysis mixture (0.1 % (v/v) Triton X-lOO, 62.5 mM EDTA,
50 mM Tris.HCl pH 8.0) was added, mixed gently and placed on ice for a further 5
min. Cellular debris was then removed by centrifugation (35,000 x g, 40 min, 4°C).
The supernatant was then extracted by mixing vigorously with 7 ml Tris-buffered
phenol and 1 ml chloroform/iso-amyl alcohol, allowed to stand for 10 min and then
centrifuged (18,000 x g, 10 min, 4°C). The aqueous phase was removed and further
extracted by the addition of 20 ml chloroform/iso-amyl alcohol, vigorous mixing and
centrifugation as before. The aqueous phase was removed and DNA precipitated by
the addition of 2 volumes of 95 % (v/v) ethanol at -70°C for 1 hr. The DNA was
pelleted by centrifugation (18,000 x g, 20 min, 4°C) and dried in a vacuum dessicator
for 15 min. The pellet was resuspended in 4.5 ml TNE , to which was added 4.72 g
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CsCI and 320 JlI ethidium bromide (10 mg/ml). Plasmid DNA was purified by
equilibrium density gradient centrifugation in a Beckman Vti65 rotor (200,000 x g, 16
hrs, 20°C). Ethidium bromide was removed from the DNA by repeated extraction
with an equal volume of NaCl-saturated isopropanol. 3 volumes of TNE were then
added and the DNA precipitated at -70°C using 95 % (v/v) ethanol. Plasmid DNA
was recovered by centrifugation (15,900 x g, 30 min, 4°C), washed in 70 % (v/v)
ethanol, then dried and resuspended in 0.5 milO mM Tris.HCI pH 8.5, containing 10
pg RNaseA.
Alternatively, plasmids were purified usmg the Purefection®Plasmid DNA
Purification kit (Promega), following manufacturer's instructions.
2.3.3. Tissue culture techniques.
2.3.3.1 Maintenance of cell lines.
All cell lines were cultured in 90 mm )I-irradiated tissue culture dishes at 37°C in a 5
% C02 atmosphere and passaged when confluent. 293 cells (and derivatives) were
maintained in DMEM / 10 % NCS (v/v), HeLa and A549 cells were maintained in
DMEM / 10 % FCS. Cells were passaged as follows: monolayers were washed with
0.02 % (v/v) versene, then cells detached by adding 2.5 ml of 0.02 % (v/v) versene
containing 1.25 mg trypsin, for 3-5 min. Cells were removed into 0.5 ml NCS and
centrifuged at 600 x g for 4 min. The pellet was resuspended in the appropriate
medium and cells seeded at the required density.
2.3.3.2. Long term storage of mammalian cells in liquid nitrogen.
Sub-confluent 90 mm dishes of cells were trypsinised for passage and the cell pellet
resuspended in 1 ml of 92 % (v/v) NCS, 8 % (v/v) dimethyl sulphoxide (DMSO).
The cell suspension was frozen in 0.5 ml aliquots by cooling slowly to -70°C
overnight. Frozen vials were subsequently transferred to liquid nitrogen.
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2.3.3.3. Recovery of frozen cell stocks from liquid nitrogen storage.
Cells were thawed rapidly at 37°C then transferred to 10 ml of pre-warmed growth
medium in a 90 mm dish. The medium was replaced the following day to remove
residual DMSO.
2.3.3.4. Transfection of mammalian cells with dsDNA.
2.3.3.4.1 Calcium phosphate transfection.
Cells to be transfected were grown to the required density (usually 70 % confluency)
in 60 mm tissue culture dishes. The calcium phosphate / DNA precipitate was
prepared as follows : 0.5 ml of mix A (250 mM CaCh) containing the DNA to be
precipitated was added dropwise to 0.5 ml of mix B (0.06 mM Na2HP04, 10 mM
KCI, 270 mM NaCI, 0.2 % (w/v) glucose, 1% (w/v) N-2-hydroxyethylpiperazine-N'-
2-ethanesulphonic acid (Hepes), pH 7.08 - 7.12) whilst bubbling air through mix B.
This was left at room temperature for 30 min then added dropwise to the cell cultures,
0.5 ml per 60 mm dish containing 5 ml growth medium. Cells were incubated at 37°C
for 4 hrs and the medium replaced. Cells were subsequently incubated at 37°C / 5 %
CO2 for the desired period.
2.3.3.4.2. Liposome mediated transfection.
Cells were transfected with LIPOFECTAMINETM, LIPOFECTINTM and LIPOFECTACETM
(Gibco BRL, Renfrewshire, Scotland) according to manufacturer's instructions.
2.3.4. Virological techniques.
2.3.4.1. Virus infection of mammalian cells.
Infections were initiated by removing the growth medium and adding an amount of
virus calculated to give the desired multiplicity of infection, diluted in DMEM
without serum. Cells were incubated at 37°C and rocked every 15 min. After 1 hr,
full growth medium containing serum was added and the cells incubated at 37°C for
the time appropriate to the experiment.
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2.3.4.2. Large scale preparation of virus stocks and DNA.
90 % confluent dishes of cells were infected with virus (m.o.i, of 2 pfu/cell) and
harvested at full cytopathic effect. Cells were collected by centrifugation (500 x g, 5
min) and resuspended in cold 0.1 M Tris.HCI pH 8.0, to a final volume of 5 ml for up
to 4 dishes. This suspension was sonicated on ice using a Jencons sonicator with a 3
mm tip, using two sets often, one second, pulses separated by 30 seconds. Cell debris
was removed by centrifugation (5,600 x g, 10 min, 4°C) and the supernatant layered
over a two-step CsCI gradient (2 ml 1.4 g/ml CsCI, 3 ml 1.25 g/ml CsCI, both in TD).
Gradients were centrifuged (150,000 x g, 1 hr, 15°C) in a Beckman SW 41 rotor and
the virus band collected by puncturing the tube and collecting the relevant part of the
flow-through. This was then diluted with 1.35 g/ml CsCI I TD and centrifuged to
equilibrium (150,000 x g, 16 hrs, 15°C) in a Beckman SW 50.1 rotor. The virus band
was collected as before and either used to prepare a purified virus stock or viral DNA:
(i), Purified virus stock.
A small sample of the collected virus was diluted 1 in 500 with TE / 0.1 % (w/v) SDS
and the optical density measured. Virion concentration was determined using the
formula, A260of 1.0 = 1012 virions/ml. The remaining virion stock was then diluted
five fold with stabilising buffer (0.1 % (w/v) BSA, 50 % (v/v) glycerol, 10 mM
Tris.HCL pH 8.0, 100 mM NaCI, 2 mM MgCh) and stored at -20°C.
(ii).Viral DNA.
Collected virus was diluted with two volumes of H20 and precipitated with 2 volumes
of ethanol at -70°C for 30 min. Virions were pelleted by centrifugation (7,600 x g, 20
min,4 °C), dried briefly and resuspended in 2 ml TNE containing 120 ~110 % (w/v)
SDS, 40 ul 250 mM EDTA and 200 ug proteinase K. This was incubated at 37°C for
1 hr, then extracted twice with an equal volume of phenol/chloroform. The aqueous
phase was collected and NaCl added to a final concentration of 0.1 M. Viral DNA
was precipitated by addition of2 volumes of ethanol at -70°C for 30 min. DNA was
pelleted by centrifugation (15,900 x g, 30 min, 4°C), washed in 70 % ethanol, dried
and resuspended in 0.5 ml TE pH 8.0.
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2.3.5. Analysis of protein expression.
2.3.5.1. Extraction of total cellular protein from mammalian cells.
Cells and medium from 60 mm dishes were collected and the cells harvested by
centrifugation (500 x g, 5 min). Pellets were resuspended in a small volume (100 -
200 J.1I)of 1 X SDS-PAGE loading buffer containing 1 mM phenylmethylsulphonyl
fluoride, vortexed and placed on ice for 15 min. Cell debris was removed by
centrifugation (18,000 X g, 30 min) and samples stored at -20°C.
2.3.5.2. SDS polyacrylamide gel electrophoresis (SDS-PAGE).
Protein samples were denatured and reduced by boiling in SDS-P AGE loading buffer
for 5 min. Proteins were separated by electrophoresis in discontinuous SDS-
polyacrylamide gels according to the method of Laemmli (1970). Gels consisted of a
5 % stacking gel (120 mM Tris.HCI pH 6.8, 4.57 % (w/v) acrylamide, 0.12 % (w/w)
N.N' -methylene-bis-acrylamide, 0.1 % (w/v) SDS, 0.1 % (w/v) ammonium
persulphate and 0.3 ul/ml TEMED) and a 10 % resolving gel (430 mM Tris.HCI pH
8.8, 10 % (w/v) acrylamide, 0.27 % (w/v) N.N'-methylene-bis-acrylamide, 0.1 %
(w/v) SDS, 0.07 % (w/v) ammonium persulphate and 0.2 ul/ml TEMED).
Electrophoresis was performed for 2-3 hrs at 240 V in running buffer (50 mM Tris
base, 380 mM glycine, 0.1 % (w/v) SDS) using the Gibco BRL vertical gel
electrophoresis system. Alternatively the Bio-Rad mini-PROTEAN II electrophoresis
system was used according to the manufacturer's instructions.
2.3.5.3. Western blotting.
Proteins were separated by SDS-PAGE and transferred to nitrocellulose membrane
according to the method of Towbin et al. (1979). The gel and membrane were
equilibrated in transfer buffer (25 mM Tris.HCI, 192 mM glycine, 20 % methanol) for
30 min. Proteins were transferred to the membrane by electroblotting using a Bio-Rad
Trans-Blot™ apparatus at 70 V for 3 hrs. Alternatively, electroblotting of mini gels
was performed in the Bio-Rad Mini Trans-Blot® Electrophoretic Transfer Cell, at 100
V for 1 hr. The membrane was blocked in PBS / 5 % (w/v) milk powder for 1 hr at
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room temperature or overnight at 4°C, then probed with antibodies (see 2.1.5 for
dilutions used). The membrane was incubated with primary antibody for 2 hrs,
followed by a I hr incubation with secondary antibody and a 1 hr incubation with
enzyme conjugate (if required). All antibodies were diluted in PBS and incubations
performed at room temperature with vigorous shaking. Between each incubation
membranes were washed four times (5 min per wash) in PBS / 0.1 % (v/v) Tween 20.
Following the final wash membranes were washed in PBS (2 x 5 minute washes) prior
to developing. Membranes were developed by addition of a freshly made mixture of
20 ml of methanol containing 60 mg 4-chloro-napthol (4CN) and 100 ml PBS
containing 60 III H202 (100 vol). Membranes were washed in distilled water after
bands reached the desired intensity. Alternatively, ECUMWestern blotting detection
reagents (Amersham) were used according to the manufacturer's instructions.
2.3.5.4. Fluorescence microscopy of cell monolayers.
Expression of GFP in eukaryotic cell cultures was observed by growing cells on glass
coverslips in 6 well tissue culture dishes. Coverslips were washed twice in PBS,
mounted in Vectashield" mounting medium, then viewed and photographed using a
Nikon epifluorescence microscope, using a UV filter (B2-H, Nikon) with an
excitation filter from 450-490 nm.
2.3.5.5. Immunofluorescence microscopy.
Cells grown on coverslips were washed twice in PBS, fixed for 15 min in methanol
(at -20°C), washed again and then stored immersed in PBS at 4°C). Before analysis
coverslips were incubated in PBS / 1 % BSA for 1 hr and all reagents used
subsequently were diluted in this solution. To detect specific antigens, coverslips were
incubated with the relevant primary antibody for 1 hr, followed by three washes in
PBS. Bound primary antibody was then detected by incubating coverslips for 1 hr
with species-specific secondary antibody conjugates (see section 2.1.5 for details and
dilutions used), and then washed as before. If staining of nuclei was required, 4,6-
diamidino-2-phenylindole (DAPI) was added to the final PBS wash at 1 ug/ml.
Coverslips were mounted in Vectashield® mounting medium, then viewed and
photographed using a Nikon epifluorescence microscope.
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2.3.5.6. Protein assay.
.
The Bio-Rad protein assayTMwas used according to the manufacturer's instructions
using BSA as a standard for determination of protein concentrations.
2.3.5.7. Detection of (3-galactosidase activity in mammalian cells.
Cell monolayers grown on coverslips were washed twice in PBS and fixed (100 mM
Na2HP04, 100 mM NaH2P04, 0.1 mM MgCh, 0.225 % (v/v) glutaraldehyde) for 15
min. Cells were washed twice before the addition of X-gal staining solution (PBS
containing 10 mg/ml (w/v) X-gal, 4 mM K3Fe(CN)6, 4 mM ~Fe(CN)6, 2 mM
MgCh) and left overnight at 37°C. Staining solution was then removed, followed by
one wash in PBS and coverslips mounted in PBS/glycerol. Cells were photographed
using a Nikon phase-contrast microscope.
2.3.6. DNA extraction from mammalian cells.
2.3.6.1. Extraction of total cellular DNA.
Cells grown as monolayers in 90 mm dishes were washed from the dish in PBS and
harvested by centrifugation (500 x g, 5 min). Pellets were resuspended in 2 ml RIPA
buffer (10 mM Tris.HCI pH 7.5, 150mM NaCI, 1% (w/v) sodium deoxycholate, 1%
(v/v) Triton-XIOO, 0.1 % (w/v) SDS), left on ice for 30 min and vortexed at five
minute intervals. This was then extracted twice with an equal volume of
phenol/chloroform and once with chloroformliso-amly alcohol alone. The aqueous
phase was removed, sodium acetate added to 0.3 M and DNA precipitated by adding
2 volumes of 95 % (v/v) ethanol at -70°C for 1 hr. DNA was pelleted by
centrifugation (15,900 x g, 30 min, 4°C), washed in 70 % (v/v) ethanol, dried briefly
and resuspended in 200 ul TE, containing 2 Ilg RNaseA.
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2.3.7. Detection of specific DNA by Southern blotting.
2.3.7.1. Generating a radioactive probe by nick translation.
Probes for use in Southern Blotting were generated by nick translation. The reaction
consisted of 30 IlCi a-32P-dCTP (specific activity 3000 Ci/mmol), 200ng target
DNA, 0.1 mg/ml DNase I, 1 unit DNA polymerase I, 20 mM each of dATP, dGTP
and dTTP, 14 mM Tris.HCI pH 7.4, 7 mM MgCh, 50 mM NaCI and 2 mM DTT. The
reaction was incubated at 16°C for 3 hrs and the probe separated from unincorporated
nucleotides. This was achieved using a Sephadex® G50 column of 10 ml bed volume
in TNE/0.1 % (w/v) SDS. The sample was loaded in an equal volume of 30 % (v/v)
glycerol, 1 % (w/v) SDS, 50 mM Tris.HCI pH 8.0, 0.01 % (w/v) bromophenol blue,
and 0.3 ml flow-through fractions collected. The fractions containing probe were
pooled and denatured by boiling for 10 min then placed immediately on ice, prior to
use.
2.3.7.2. Southern transfer of DNA to nitrocellulose (after Southern, 1975).
DNA was separated on agarose gels and exposed to short wave UV light for 5 min.
Gels were then soaked in 1.5 M NaCI, 0.5 M NaOH for 30 min, 2 M NaCl, 1 M
Tris.HCI pH 5.5 for 30 min, then placed in 2 X SSC. DNA was transferred to nylon
membrane overnight in lOX SSC by capillary action.
DNA was fixed onto the membrane using a Stratalinker®UV Crosslinker (Stratagene,
CA). The membrane was then soaked in prehybridisation fluid (50 mM Tris.HCI 7.5,
0.5 % (w/v) SDS, 1 mM EDTA, 3 X SSC, 100 ug/ml denatured salmon sperm DNA,
I X Denhardt's solution) for 4 hrs at 64°C then soaked for 16 hrs at 64°C in
prehybridisation fluid containing radioactive DNA probe.
The membrane was then washed in 2 X SSC, 0.5 % (w/v) SDS for 5 min at room
temperature, 2 X SSC, 0.1 % (w/v) SDS for 15 min at room temperature, 0.1 X SSC,
0.5 % (w/v) SDS for 2 hrs at 64°C and 0.1 X SSC, 0.5 % (w/v) SDS for 30 min at 64
cC. The membrane was then blotted dry, wrapped in cling-film and exposed to x-ray
film at -70 "C. Intensifying screens were used to enhance band intensity.
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Chapter 3 : Construction of an episomal expression plasmid
containing the Major Late Transcription Unit (MLTU) of AdS.
3.1. Introduction.
Conventional adenovirus gene delivery vectors are based on replacement of early
regions of the viral genome with an expression cassette coding for a gene of interest
(discussed in detail in section 1.4). These vectors have two major drawbacks which
limit their effectiveness. First, they have a capacity for insertion of foreign sequences
which is limited to around 8 -10 kb. Second, despite deletion of the El region these
vectors still express low levels of immunogenic late proteins. This leads to an immune
response and elimination of transduced cells when used in vivo. Gutted adenovirus
vectors overcome these drawbacks but introduce another problem, namely that the
helper virus used in the preparation of vector can contaminate the stock. The ideal
solution to these problems would be a vector with properties between these two
extremes, having a high insert capacity and reduced expression of immunogenic
proteins but not requiring helper virus for growth. Developing such vectors forms the
basis for the research presented in this thesis.
3.2. Aims.
The aim of this work was to construct a plasmid containing the major late
transcription unit (MLTU) of AdS, with expression driven by the major late promoter
(MLP). This construct would be flanked by PacI sites to make any further
manipulations more straightforward. Ultimately an expression plasmid based upon an
Epstein-Barr virus (EBV) replicon would be constructed which would be capable of
episomal maintenance in eukaryotic cells.
3.3. Episomal maintenance ofEBV-derived expression vectors.
The first step towards constructing an adenovirus deleted in one or more essential
functions is to create a complementing cell line capable of expressing the genes
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intended for deletion. An expression plasmid containing an Epstein-Barr virus
replicon was chosen to be used to create a complementing cell line expressing the
Ad5 MLTU. This approach has been used previously to construct a cell line capable
of complementing a pIX-deleted virus (Caravokyri and Leppard, 1995).
Epstein-Barr virus (EBV) is a gammaherpesvirus that establishes a latent infection
in B-Iymphocytes. EBV is widespread in all human populations, with the great
majority having antibodies to the virus (reviewed by Rickinson and Kieff, 1996).
Infection may contribute to the initiation and progression of several human neoplasias
including Burkitt's lymphoma and nasopharyngeal carcinoma (reviewed by Zur
Hausen, 1981; Kieff, 1996). During latency the -170 kb double stranded DNA
genome replicates as a circular episome that divides synchronously with the cellular
genome (Adams, 1987; Yates and Guan, 1991). The replication and stable
maintenance of latent genomes requires only two viral elements: the protein, Epstein-
Barr virus nuclear antigen 1 (EBNA-l, Hearing et al., 1984) and the latent replication
origin, oriP (Yates et ai, 1984, 1985).
EBNA-l binds to clusters of sites in two regions of oriP which are both essential
and together sufficient for viral DNA replication (Rawlins et al., 1985). One region,
termed the dyad symmetry region, spans -120 bp and contains four EBNA-l binding
sites. The other known functional element of oriP is a 20-member family of 30 bp
tandem repeats, with each repeat containing an EBNA-l binding site. In addition to its
well known function in DNA replication, other studies have suggested that EBNA-l
might also facilitate the retention of viral genomes (Krysan and Calos, 1993;
Middleton and Sugden, 1992,1994). EBNA-l has also been shown to bind to
metaphase chromosomes (Marechal et al,. 1999), suggesting it may play a role in
anchoring viral genomes to cellular chromosomes, thus ensuring proper partition and
retention during cell division. A further role for EBNA-l could be to prevent loss of
newly synthesised plasmids as plasmids containing oriP are efficiently replicated in
human cells, but are rapidly destroyed in the absence of EBNA-l (Aiyar et al,. 1998).
Comprehensive understanding of the interactions between EBNA-l and oriP has
allowed the development of expression vectors capable of stable expression of
heterologous sequences in mammalian cells. Consequently, vectors based on EBV are
now used routinely to generate cell lines expressing novel proteins (reviewed by
Margolskee, 1992). The EBV vector is a convenient gene expression system as, after
transfection, a much higher number of cells will retain and express an EBV vector
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than will stably integrate a non-replicating vector (Sclimenti and Calos, 1998).
Multiple copies of the EBV vector may be present per cell, leading to higher
expression levels of heterologous sequences. This, together with predictable gene
expression that is free from position effect suppression that often affects randomly
integrated DNA, makes establishing stable cell lines a more straightforward task.
3.4. The adenovirus major late promoter (MLP).
The adenovirus major late promoter (MLP) controls expression of the major late
transcription unit (MLTU) that encodes most of the structural proteins and several
non-structural proteins. The MLTU extends from the promoter at 16.8 map units to a
termination signal close to the right hand end of the genome at 91.3 map units.
mRNAs originating from the MLTU are grouped into five families (designated Ll to
L5), where each family consists of mRNAs that have co-terminal 3' ends. These are
produced by alternative poly (A) site utilisation and splicing (discussed in section
1.3.5.4.1).
The MLP of subgroup C adenoviruses is one of the most intensively studied
examples of a eukaryotic RNA polymerase II promoter. Early studies, using in vitro
transcription and plasmid-borne transfection assays, defined the requirements for cis-
acting sequences for quantitative and accurate transcription initiation (reviewed by
Berk, 1986). These early studies identified several transcriptional elements and two
cellular transcriptional activating factors. More recently, genetic systems were
developed to examine the function of the MLP in the context of the viral genome
(Logan and Shenk, 1986; Brunet et al., 1987; Reach et al.; 1990). Together, these
results strongly support the promoter structure shown in figure 3.1. The MLP contains
two basal elements, a TATA box that is the binding site for the cellular transcription
factor TFIID (Sawadogo and Roeder, 1985, Nakajima et al., 1988) and an initiator
element (INR) centred on the start site (Concino et al., 1984). The MLP also contains
two upstream activating elements, the upstream promoter element (UPE) that binds
the cellular upstream stimulatory factor (USF) (Sawadogo and Roeder, 1985; Gregor
et al., 1990) and an inverted CAAT box that binds the cellular transcription factor
CP1 (Chodosh et al., 1988, Maity et al., 1988). Two further activating elements are
located downstream of the transcription start site and are termed DEI and DE2, which
bind DEF-A and DEF-B, respectively (Jansen-Durr et al., 1989; Mondesert et al.,
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1992). Recently, DEF-A and DEF-B have been shown to consist of a heterodimer of
the virus-encoded IVa2 protein and an unidentified protein, and a homodimer of IVa2,
respectively (Tribouley et al., 1994; Lutz and Kedinger, 1996).
The MLP exhibits a low level of activity early after infection, and it becomes
several hundredfold more active on a per molecule basis during the late phase (Shaw
and Ziff, 1980). Analysis of the upstream and downstream activating elements has
attempted to determine the mechanisms responsible for activation of the MLP.
Sequences implicated in the basal activity of the MLP are the TATA box, INR, UPE
and CAAT box (Hen et al., 1982, Logan and Shenk, 1986). The TATA box and UPE
have been reported to be functionally redundant with respect to the INR and CAAT
box, respectively (Reach et al., 1991). Binding ofTFIID to the TATA box appears to
be the prerequisite for assembly of the initiation complex, which is further stabilised
by interactions between TFIID and USF bound to the nearby UPE site (Sawadogo and
Roeder, 1985). TFIID also represents, in this promoter, the main target for direct
activation by the EIA-13S protein. EIA-13S protein is able to bind to TFIID
(Horikoshi et al., 1991) and stimulate transcription from the MLP (Lewis and Manley,
1985; Leong et al., 1988). In addition, the adenovirus DNA binding protein (DBP)
has been shown to stimulate MLP activity in vitro (Chang and Shenk, 1990), possibly
by a mechanism that involves subtle changes in viral DNA structure that enhance
USF binding to the UPE sequence (Toth et al., 1992; Zijderveld et al., 1994).
The late-phase-dependent activation of the MLP is specified by sequence
elements that have been located downstream from the transcription start site (Mansour
et al., 1986; Alonso-Caplen et al., 1988). DNA-binding and transcriptional studies
have allowed the delineation of these downstream elements (DE) within the first
intron of the MLTU. DEI is located between +85 and + 98; DE2, between +100 and
+120. DEI binds a factor, DEF-A, which also interacts with the distal part of the DE2
site (DE2a), whereas a second factor DEF-B, interacts with the proximal portion of
DE2 (DE2b). The binding of these proteins correlates with transcriptional activation
of the MLP (Jansen-Durr et al., 1988, 1989; Leong et al., 1990; Mondesert et al.,
1992). Purification of DEF-B allowed identification of the protein as the product of
the adenovirus IVa2 gene. DNA-binding and transcriptional experiments have
confirmed that the IVa2 protein contributes to late phase specific activation of the
MLP by binding to DE2 as a dimer (Tribouley et al., 1994). The IVa2 protein has also
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been shown to be part of the DEF-A complex (Lutz and Kedinger, 1996), although the
identity of the other protein that constitutes the DEF-A heterodimer is still unknown.
In addition to these trans-acting factors, a cis-acting change in the viral
chromosome is also required for activation of the MLP. MLP expression is strongly
stimulated after the onset of DNA replication (Shaw and Ziff, 1980; Grass et al.,
1987), however, the molecular basis of this replication dependence of the MLP
activity is unclear. Using superinfection experiments, Thomas and Mathews (1980)
demonstrated that the early-to-Iate transition is a function of the particular state of the
viral DNA template, as induced by its own replication. One possible explanation for
this observation is that the DNA replication process allows transcription factors to
gain access to the promoter. Non-replicated, input viral DNA molecules do not appear
to be associated with the same set of proteins as replicated viral DNA molecules
(Dery et al., 1985; Chatterjee et al., 1986a; 1986b). Therefore, the structure of viral
chromatin in the early phase of infection might prevent transcription factors from
binding to the MLP, an idea supported by the studies of Toth et al. (1992) which
showed that DNA replication facilitates the binding of USF to the UPE sequence.
Alternatively, transcription factors may not bind to pre-formed viral chromatin,
instead they might gain access to the viral template during the process of DNA
replication as nucleosomes are disassembled and reassembled. This idea is consistent
with earlier work showing that USF cannot activate a promoter that has been pre-
assembled in chromatin while it can compete for template binding during the
assembly process and subsequently activate transcription (Workman et al., 1990).
3.5.0.(Supplemental). Strategy for the construction of an episomal expression
plasmid containing the Ad5 ML TU.
The aims of the strategy were to clone the MLTU into a pBR322-derived
plasmid, with Paci sites flanking the construct, to enable more straightforward
manipulations of the MLTU to be performed during any further studies. This MLTU
sequence would then be excised via its Paci sites and cloned into an episomal
expression plasmid derived from pMEP4 (Invitrogen). This plasmid would be
modified prior to use by removal of the human metallothionein promoter (phMTIIa)
and the introduction of a unique PacI site, into which the MLTU construct would be
inserted. Thus the MLTU would remain under the control of its own promoter, rather
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than any exogenous vector-derived promoter. The overall cloning strategy is outlined
in figures 3.2.supp.A and 3.2.supp.B.
3.5. Construction of plasmid pAdJPacI.
Plasmid pFGdXI (figure A.1, kindly donated by Prof. F.L. Graham, McMaster
University, Canada), a plasmid containing AdS bp 21S62 - 3S938, with a deletion in
the E3 region, was digested with BamHI and Spel. The resulting 6978 bp fragment
was cloned into BamHI / Spel cut pBR322Spel (figure A.2) to generate plasmid
pAdJYI. Plasmid pAdJYI contains AdS bp 27082 - 3S938, with a 1878 bp deletion
between the two Xbal sites at 28S92 and 30470. Plasmids bearing the correct insert
were determined by restriction enzyme analysis using EcoRV (figure 3.2), the bands
of2696 and 2374 bp show that the insert is present and in the correct orientation.
3.5.1. Insertion of unique PacI restriction site.
The target position for insertion of the Pad restriction site relative to the viral
transcription unit is shown in figure 3.3.
Two pairs of primers were used to amplify two overlapping regions of the AdS
genome, using plasmid pAdJYI as the template. Primer sequences are given in section
2.1.6. PCR reactions were performed as described in section 2.3.1.12. using
Vent®DNApolymerase. Primer #1 (anneals to AdS bp 30994 - 31013) and Primer #3
(anneals to AdS bp 32862 - 32884 and has a S' extension GATCTGTTAATTAA,
which contains a PacI restriction site) were used to amplify a 1903 bp product (figure
3.4A). Primer #2 (anneals to AdS bp 3330S - 33324) and Primer #4 (anneals to AdS
bp 32890 - 32909 and has a 5' extension CATAGCTTAATTAA containing a Pad
restriction site) were used to amplify a 448 bp product (figure 3.4A). Generation of
these two products was monitored by agarose gel electrophoresis (figure 3.4B).
Optimum amplification of Products A and B was achieved with an MgS04
concentration of2 mM (figure 3.4B, lanes 2 and S).
PCR product of 2338 bp (spanning AdS·bp 30994 - 33324, with a Pad site at
32884) was produced by combining products A and B at a 1:1 molar ratio and heat
denaturing them at 90 "C for 1 minute. They were then cooled slowly to 2S "C to
84
Figure 3.2.supp.A. Overall cloning strategy. Part A.
Step 1: In order to insert a unique Pad site at the right-end of the MLTU, the right-end
of the AdS genome (6978 bp Spe1-BamH1 [linkered right-end] fragment) was sub-
cloned from pFGdXl into pBR322SpeI (section 3.S).
Step 2:The above cloning step resulted in the construction of plasmid pAdJY1, a
plasmid containing AdS sequence from bp 27082- 3S938 (figure 3.2).
Step 3: Plasmid pAdJY1 was constructed so that a unique BssHII fragment could be
removed, engineered by PCR, and then re-introduced. Site-directed mutagenesis was
used to insert a unique PacI site at bp pos. 32884 (section 3.5.1). This is downstream of
the MLTU sequence in a non-coding region. This plasmid was termed pAdJPacI
(figure 3.6).
Step 4: Cloning of the full length MLTU was achieved by constructing a plasmid
containing the left-end of the MLTU which overlapped with the MLTU sequence in
pAdJPacI. Firstly, a Pad site was engineered in pBR322 at the Ndei site (position
2297). Subsequently, the Bstll071 fragment from AdS genomic DNA (bp 5764-29010)
was ligated into the unique Bstl1071 site (position 2245) in pBR322PacI (section 3.6).
Step 5: The above cloning step resulted in the construction of plasmid pBRZ 171,
which contains the left-end of the MLTU with a unique PacI site upstream of the
MLTU (figure 3.9).
Step 6: The Clai-Spei fragment from pAdJPacI was cloned into Clai-Spei digested
pBRZI7I (section 3.7).
Step 7: The above cloning step resulted in the construction of plasmid pAdMLTU
which contains AdS sequences from bp 5764-35938. Within this sequence is the
MLTU flanked by Pad sites (figure 3.10).
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Figure 3.2.supp.B. Overall cloning strategy. Part B.
Step 1: Expression of the MLTU is driven by the endogenous MLP. The hMTIIa
promoter present on plasmid pMEP4 would not be required and was therefore removed
by digestion withXbaI and NheI, followed by religation of the linear molecule (section
3.8). This plasmid was termed pMEP4~P (figure 3.11).
Step 2: An oligonucleotide adaptor was ligated into the unique BamHI site of
pMEP4~P (section 3.8), thus creating a unique Pad site to facilitate cloning of the
Pad-flanked MLTU construct. This plasmid was termed pgERI (figure 3.12).
Step 3: The PacI fragment containing the MLTU was excised from plasmid
pAdMLTU and cloned into the unique Pad site present in plasmid pgERI. Clones
containing the insert in either orientation were isolated (section 3.8).
Step 4: The above cloning step resulted in the construction of episomal expression
plasmids pEPI and pEPII (figure 3.13), which contain the full length Ad5 MLTU and
sequences from EBV required for episomal maintenance of the plasmid in eukaryotic
cells.
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Figure 3.2 : pAdJYI. Plasmid
bearing Ad5 sequence from 27082-
35938 bp.
A: Plasmid map showing unique sites
and sites of interest. Numbering in
brackets refers to the original
numbering in the Ad5 sequence
(Chroboczek et al., 1992). Amp,
ampicillin resistance gene. Ad5,
adenovirus sequence.
B: 1.0 % agarose gel visualised by
ethidium bromide staining, Lane 1, 1
kb DNA ladder. Lane 2, EcoRV
digest of pAdJYI. The arrows
indicate diagnostic bands used to
determine insert orientation.
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Figure 3.3 : Insertion of a unique PacI restriction site by site directed mutagenesis.
Part I.
Simplified transcription map of Ad5 showing the region to be targeted by peR for
insertion of unique Paci restriction site.
Figure 3.4 : Insertion of a unique Pad restriction site by site directed mutagenesis.
Part II.
A. Two peR reactions were performed, one using primers #1 and #3 to generate a 1903
bp product (Product A), the other using primers #2 and #4 to generate a 448 bp product
(Product B).
B. 1.2 % agarose gel visualised by ethidium bromide staining.
Lane 1, 1 kb ladder.
Lanes 2 and 3, Product A from peR reactions containing 2mM and 4mM MgS04
respectively.
Lanes 4 and 5, Product B from Pf'R reactions containing 2mM and 4mM MgS04
respectively.
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allow their complementary 3' ends to anneal. Full length template was made by
allowing the peR reaction to proceed for one cycle without primers, followed by
addition of Primers #1 and #2 to amplify the full length product (figure 3.SA).
Generation of full length product was monitored by agarose gel electrophoresis
(figure 3.SB). Production of the full length peR product was optimum at 4 mM
MgS04 using a molar ratio of 1:1 (Product A to Product B). These reaction conditions
also produced less significant amounts of smaller products when compared to other
reaction conditions used.
The full length product was purified by gel electrophoresis / electroelution and cut
with BssHII. Plasmid pAdJYI was also cut with BssHII and the peR product cloned
into the dephosphorylated vector, replacing the original AdS sequence and creating
plasmid pAdJPacI (figure 3.6A). Restriction enzyme digestion with BgnI generated
bands of 1672 and 1628 bp (not resolved on gel but diagnosed as a doublet based on
intensity) confirming the presence of the peR insert (figure 3.6B). Digestion with
EcoRV and Pad (figure 3.6e, lane 4) gave bands of 3714 and 872 bp, showing that
the 4586 bp band produced by EcoRV digestion alone (figure 3.6e, lane2) had been
cut by PacI. This analysis confirmed that the PacI site was present and the insert was
in the correct orientation. Automated sequencing (figure 3.7), using primer SEQ-D
which anneals to AdS bp 32950 - 32969 (section 2.1.6.2), confirmed the presence of
the PacI site. This sequence analysis also revealed that a G to e substitution had
occurred immediately adjacent to the PacI site. This should not have any effect on
expression ofLS reading frames as it is in a non-coding region of the AdS genome.
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Figure 3.5 : Insertion of a unique Pad restriction site by site directed mutagenesis.
Part III.
A. Full length peR product was produced by heat denaturing Product A and B, then
allowing them to re-anneal by their complementary 3' termini. The peR reaction was
allowed to proceed for one cycle before the addition of primers # 1 and #2, followed by
19 cycles to generate the 2338 bp product.
B. 1.2 % agarose gel showing production of full length peR product at varying MgS04
concentration and molar ration of Product A : Product B.
Lane 1, 1 kb ladder.
Lane 2, 2mM MgS04, A:B ratio of 1:4.
Lane 3, 2mM MgS04, A:B ratio of 1:1.
Lane 4, 4mM MgS04, A:B ratio of 1:4.
Lane 5, 4mM MgS04, A:B ratio of 1:1.
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Figure 3.6. Plasmid pAdJPacI.
A. Plasmid map showing unique restriction sites and sites of interest. Numbering in
brackets refers to the original numbering in the AdS sequence (Chroboczek et al., 1992).
Amp; ampicillin resistance gene. AdS; adenovirus sequence.
B. 1.4 % agarose gel visualised by ethidium bromide staining.
Lane 1, 1 kb DNA ladder.
Lane 2, BglII digest of pAdJPacl.
c. 1 % agarose gels visualised by ethidium bromide staining.
Lane 1, 1 kb DNA ladder.
Lane 2, EcoRV digest of pAdJPacl.
Lane 4, 1 kb DNA ladder.
Lane 4, EcoRV and Pacl double digest of pAdJPacl.
Arrows indicate bands discussed in the main body of text.
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3.6. Construction of plasmid pBRZ17I.
An oligonucleotide adaptor was used to insert a Pad site in pBR322 which would
ultimately be the Pad site at the left end of the MLTV. Ndel / Pad adaptor (section
2.1.6.3) was heated to 75°C for 5 minutes and allowed to cool slowly to room
temperature, allowing the oligonucleotide to anneal and form a double stranded
molecule. Plasmid pBR322 (figure A.3.) was digested with Ndel (position 2297) and
the adaptor ligated into it to generate plasmid pBR322Pacl. A positive clone was
isolated and presence of the Pad site was confirmed by restriction enzyme analysis
(figure 3.8). HindIII, Pstl, Pad digestion produced bands of 2282 and 1318 bp
showing that the Pad site was present. Absence of these same bands after digestion
with HindIII, Pstl and Ndel showed that the Ndel site had been removed leaving the
3600 bp fragment uncut.
Genomic DNA isolated from Ad5 was digested with Bstll 071 and the resulting
23246 bp fragment containing the Ad5 MLP and MLTV segments L 1 - L4 was
cloned into pBR322PacI linearised with Bst11071, creating plasmid pBRZI71.
Plasmids containing the insert in the correct orientation were identified by EcoRV
digestion (figure 3.9). Diagnostic junction fragments of 5743 and 3784 bp showed
that the insert was present and in the correct orientation. Insert in the alternative
orientation would show bands at 5498 and 4029 bp. Other EcoRV fragments resulting
from digestion at sites within the insert (7639, 4546, 2623,2052, 1238 bp) were all
present as expected.
3.7. Construction of plasmid pAdMLTU.
A plasmid containing the full length MLTV was constructed from pBRZ 171 and
pAdJPacl. pAdJPacI was digested with C/al and Spel and the resulting 7332 bp
fragment was cloned into C/al / Spel cut pBRZ17I, creating plasmid pAdMLTV. This
plasmid contains the complete Ad5 MLTV flanked by two Pad restriction sites.
Positive clones were identified by EcoRV digestion (figure 3.10, lane 2), bands of
5743 and 2623 bp showed that the insert was present and in the correct orientation.
Other fragments of 7639, 4586, 4546, 2623, 2052 and 1238 bp were also present as
expected. Digestion with Pad (figure 3.10, lane 3) showed the presence of the two
Pad sites.
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Figure 3.8. Plasmid
pBR322PacI.
A. Map showing unique
restriction sites. Amp,
ampicillin resistance gene; tet,
tetracycline resistance gene.
B. 1.2 % agarose gels
visualised by ethidium
bromide staining. Lanes 1+3,
1kb ladder. Lane 2, HindIII,
Pacl, Pstl digest. Lane 4,
HindIII, Pac!, NdeI digest.
The arrows indicate bands
discussed in the text.
A. (5764)27623,Bst 11071;Pac 1,53
24!92,Eco RV.
.Clal,2!48
:... EcoRV,23!0
amp
22954,EcoRV.
.SpeI,4!94
.....Bst!! 071,4377
. (29010)
27625 bps
..Srj1,5858
·...EcoRV,6094
...Spel,6305
pBRZ171
20!30,Pmei
EcoRV,87!7
!3839,NdeI
1 2
Figure 3.9 : pBRZ17I. Plasmid
bearing Ad5 sequence from
5764 - 29010 bp.
A: Plasmid map showing unique
sites and sites of interest.
Numbering in brackets refers to
the original numbering in the
5743 bp Ad5 sequence (Chroboczek et
3784 bp al., 1992). Amp; ampicillin
resistance gene. Ad5; adenovirus
sequence.
B: 1.0 % agarose gel visualised
by ethidium bromide staining.
Lane 1, 1 kb ladder. Lane 2,
EcoRV digest ofpBRZ17I. The
arrows indicate diagnostic bands
used to determine insert
orientation.
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Figure 3.10. pAdMLTU. Plasmid
bearing Ad5 sequence from 5764-
35938 bp.
A: Plasmid map showing unique sites
and sites of interest. Numbering in
brackets refers to the original
numbering in the Ad5 sequence
(Chroboczek et al., 1992). Amp;
ampicillin resistance gene. Ad5;
adenovirus sequence.
B: 0.8 % agarose gel visualised by
ethidium bromide staining .. Lane 1, 1
kb ladder. Lane 2, EcoRV digest of
pAdMLTU. Lane 3, Paci digest of
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3.8. Construction of episomal expression plasmid pEPII.
Plasmid pMEP4 (figure AA) is an episomal expression vector (previously
marketed by Invitrogen) and can be used for transient or stable expression. It contains
the EBV sequences oriP and EBNA-l (discussed in section 3.3) as well as the
hygromycin B resistance gene for use as a selectable marker in mammalian cells.
Plasmid pMEP4 was digested with NheI and XbaI to remove the human
metallothionine I1a promoter, which would not be required for expression of the
MLTV. The plasmid was then circularised by ligation of the compatible cohesive
ends to create plasmid pMEP4~P. Plasmids lacking the promoter were identified by
restriction enzyme analysis (figure 3.11). Removal of the promoter resulted in a band
of 5246 bp being produced upon digestion with EcoRV and Clai, this band would
have been 6159 bp after digestion of the parental plasmid pMEP4.
In order to clone the MLTV from pAdMLTV into pMEP4~P an oligonucleotide
adaptor (BamHI-Pad adaptor, section 2.1.6.3) was used to insert a unique Pad site
into the polylinker ofpMEP4~P. The adaptor was inserted into the unique BamHI site
ofpMEP4~P using the method described in section 3.6. The presence of the Pad site
was confirmed by restriction enzyme analysis and plasmid pgERI isolated (figure
3.12). A ClaI and Pad digest produced bands of 4931 and 4608 bp showing that the
plasmid was cut by both enzymes and the Pad site was present.
The MLTV sequence from pAdMLTV was excised by digestion with Pad and
cloned into Pad cut pgERI. An EcoRV digest (diagnostic bands of 12377 and 4364;
alternative orientation 12605, 4136 bp) and an XhoI digest ( diagnostic bands of 9595
and 6236; alternative orientation 15727, 104 bp) were used to identify clones with the
insert in the desired orientation (figure 3.13). Plasmid pEPII was used for the majority
of subsequent expression analysis. However plasmid pEPI (with the insert in the
alternative orientation, figure A.5) was used in the initial expression studies.
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Figure 3.11 : pMEP4M. Derivative of plasmid
pMEP4 which does not contain the human
metallothionine Ha promoter (phMTHa).
A.Plasmid map of pMEP4.0.P showing unique sites.
Abbreviations: pTK, thymidine kinase promoter;
Hygromycin, hygromycin-B resistance gene.
TKpA, thymidine kinase polyadenylation signal;
SV40 pA, simian virus 40 polyadenylation signal;
OriP, EBV latent origin of replication; EBNA-I.
Epstein-Barr virus nuclear antigen 1; amp/ori,
ampicillin resistance gene/bacterial origin of
replication.
B. 0.8 % agarose gel visualised by ethidium
bromide staining. Lane 1, 1 kb ladder. Lane 2,
EcoRV/ClaI digest ofpMEP4.0.P. The arrow
indicates the band discussed in the text.
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Figure 3.12 : pgERI. Derivative ofpMEP4~P
containing a Pact site in the poly-linker.
A. Plasmid map showing unique sites.
Abbreviations: pTK, thymidine kinase promoter;
Hygromycin, hygromycin-B resistance gene.
TKpA, thymidine kinase polyadenylation signal;
SV40 pA, simian virus 40 polyadenylation signal;
OriP, EBV latent origin of replication; EBNA-l.
Epstein- Barr virus nuclear antigen 1; amp
ampicillin resistance genelbacterial origin of
replication.
B. 0.8 % agarose gel visualised by ethidium
bromide staining. Lane 1, 1 kb ladder.
Lane 2, ClaI / Pac! digest of pgERI.
Figure 3.13 : Plasmid pEPIl.
A. Plasmid map showing unique restriction sites and sites of interest. Numbering in
brackets refers to the original numbering in the Ad5 sequence (Chroboczek et al. 1992).
Abbreviations: Hygromycin, hygromycin resistance gene; SV40 pA, simian virus 40
polyadenylation signal; OriP, EBV latent origin of replication; EBNA-l. Epstein-Barr
virus nuclear antigen 1; amp, ampicillin resistance gene, Ad5, adenovirus sequence.
B. 0.8 % agarose gels, visualised by ethidium bromide staining, showing restriction
enzyme digests of pEPII.
Lanes 1,1 kb ladder.
Lane 2, EeaRV digest of pEP II.
Lane 3, 1 kb ladder.
Lane 4, Xhal digest of pEPIl.
The arrows indicate diagnostic bands used to determine insert orientation.
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3.9. Discussion.
The cloning strategy employed was successful in constructing an episomal
expression plasmid containing the Ad5 MLTU. Despite the complexity of the cloning
procedure it was decided not to completely sequence the insert. This was due to the
fact that there was over 25 kb of Ad5 DNA and sequencing would have been very
time consuming. Instead it was considered better to validate the integrity of the
individual reading frames through expression analysis. Having achieved expression of
specific proteins, any attempt to complement gene deficiencies should be
accompanied by sequencing of the relevant region of the plasmid.
The primary intended use of this plasmid was to create stable cell lines expressing
Ad5 late proteins in order to grow deleted adenovirus vectors. This application is
considered further in subsequent chapters of this thesis. Other possible applications
are discussed in chapter 7.
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Chapter 4 : Characterisation of late protein
expression from plasmid pEPII.
Chapter 4 : Characterisation of late protein expression from plasmid
pEPII.
4.1. Introduction.
4.1.1. Proteins encoded by the major late transcription unit (MLTU).
The adenovirus MLTU encodes the capsid and core proteins that are eventually
assembled into virions, in addition to several non-structural proteins. A summary of
the properties of these proteins is presented in table 4.1. More detailed discussions of
their functions can be found in section 1.3.3. (polypeptides II - IX); section 1.3.5.5.
(LI 52/55K, L4 lOOK, viral protease) and section 1.3.5.4.2. (L4 lOOK).
4.2. Aims.
As already discussed in sections 1.3.5.4, expression of late proteins is regulated at
many different levels. One such regulatory role is performed by the major late
promoter (MLP), as discussed in detail in section 3.4. Briefly, the promoter shows
basal activity in the absence of the viral IVa2 protein, which is a component of MLP-
transactivating factors DEF-A and DEF-B. Cellular transcription factor TFIill is
involved in basal transcription of the MLP, a process that has been shown to be
stimulated by the adenovirus EIA-13S protein. As 293 cells express the El proteins,
it is conceivable that basal expression from the MLP would occur if the expression
plasmid were transfected into 293 cells. Ideally, the MLP would be inactive in 293
cells until stimulated by expressing the IVa2 protein in the same cell. Constitutively
high levels of late proteins could cause toxicity problems if a stable cell line were to
be isolated which contained the MLTU.
The aim of this work was to determine if any expression of late proteins from
plasmid pEPII occurred in 293 cells. If so, what was the extent of this expression.
Levels of late protein expression would be determined by Western blot analysis of
protein extracts taken from 293 cells transiently transfected with plasmids pEP! or
pEPII.
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4.3. Preliminary evaluation of expression from plasmids pEPI and pEPII.
A transient transfection assay was used to determine if late proteins were
expressed from the plasmids in the absence of any exogenous viral proteins. 10 f,lgof
either pEPI or pEPII (chapter 3) was used to transfect 4 x 106 293 cells in a 60 mm
dish using calcium phosphate precipitation. Cells were left for 48 hours before protein
extracts were made as described in section 2.3.5.1. For Ad5-infected cell extracts, 4 x
106 293 cells were infected at an m.o.i. of 10 pfu/cell and proteins extracted 24 hours
later. Proteins were separated by SDS-PAGE with the protein from I x 106 cells
loaded per lane for transfections, and from 5 x 104 cells/lane for virus-infected cells.
Proteins were then transferred to nitrocellulose membranes and probed with anti-Ll
52/55K antibody or a mouse polyc1onal antiserum raised against intact wt Ad5 virions
(AbBFl) (figure 4.1). The anti-Ll antibody was chosen because LI 52/55K represents
an early MLP product (section 1.3.5.4) which might be expected to be expressed even
if full transcription of the MLTU and differential splicing of the RNA were not
occurring. The anti-Ll 52/55K antibody detected a band of the expected size for Ad5
LI 52/55K in extracts from cells transfected with pEPI and pEPII. The band was also
present in Ad5 infected cell extracts but not in the mock-transfected cells, thus
confirming that the protein expressed from the plasmids was Ll 52/55K. Antiserum
AbBFI detected a band of approximately 66 kDa in transfected and infected cell
extracts, but which was absent from the mock extracts. Antiserum AbBFI was raised
against intact Ad5 virions and would therefore be expected to have reactivity against
the hex on, penton or fibre polypeptides. Based on this and the size of the band, the
protein detected was predicted to be the penton polypeptide. The two plasmids
expressed approximately equivalent levels of penton polypeptide, with pEPn
appearing to express LI 52/55K at a higher level. However, this could be due to
variations in gel loading or transfection efficiency. For the remainder of studies only
plasmid pEPII was used.
These initial results suggested that at least some expression from the plasmid was
possible in the absence of the proposed late promoter activator, the IVa2 protein.
However, the plasmids failed to express detectable levels of late proteins when
transfected into HeLa cells (data not shown) suggesting that the EIA-13S protein
present in 293 cells could be responsible for the observed activation of the MLP. The
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Figure 4.1. Expression of late proteins from plasmids pEPI and
pEPIl.
Protein extracts from transfected 293 cells, analysed on a lO % (w/v)
polyacrylamide-SDS gel followed by Western blotting with anti-Ll
52/55K monospecific antiserum (A) and polyclonal antiserum AbBFl
(B). The plasmid transfected is indicated above the relevant lane with
Ad5 infected-cell extract used as a positive control. Positions of
molecular weight markers are indicated on the left, with arrows on the
right indicating positions of viral proteins.
antibodies used show expression of proteins from the Ll and L2 genes, with further
analysis now required to show expression from other late genes and thus prove that
the MLTU primary transcript is being processed correctly to give a full range of
mRNAs.
4.3. Production of a polyclonal antiserum against late proteins.
4.3.1. Rabbit inoculation procedure.
In order to raise antibodies against a range of late proteins, an inoculation
procedure using denatured adenovirus virions was devised. A preparation of wild type
Ad5 virions was produced using the method described in section 2.3.4.2, but omitting
the dilution in stabilising buffer. This was then dialysed against PBS for 16 hours at 4
"C, using dialysis tubing with a molecular weight cut-off of 16,000. Virions were then
dialysed against 8 M urea for 4 hours at 4°C, followed by dialysis against PBS for 16
hours at 4 °C to remove the urea. Protein concentration was determined by the Biorad
protein assay (Bradford, 1976) and the sample stored at -70°C.
For the primary immunisation, 100 ug of protein (in 330 J,llPBS) was mixed with
50 J,ll of Bacillus Calmette-Guerin (BCG) suspension, an attenuated strain of
Mycobacterium bovis, which acts as an adjuvant and enhances the immune response
to antigens. An emulsion was formed by the addition of 720 J,ll of non-ulcerative
Freund's adjuvant (Guildhay Ltd., Guildford, Surrey) followed by gentle vortexing
for 30 minutes. This was then used to inoculate a rabbit subcutaneously. A booster
immunisation followed after 4 weeks, when 100 J,lg of protein (in 380 J,ll PBS) was
again emulsified with 670 J,llof non-ulcerative Freund's adjuvant, omitting the BCG.
Blood was taken 16 weeks post-immunisation and incubated at 4 °C for 16 hours to
allow a clot to form. The clot was removed by centrifugation at 1,300 x g for 10
minutes and the serum frozen at -70°C.
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4.3.2. Analysis of antiserum reactivity.
The antiserum produced from the method described in section 4.3.1, termed
AbJLB1, was tested for its ability to react with adenovirus late proteins. Ad5 virions
were denatured in 0.1 % SDS and proteins separated by SDS-PAGE and analysed by
Western blotting with antiserum AbJLBl (figure 4.2). The antiserum reacted with
several proteins present in Ad5 virions which were also present in Ad5-infected cells,
but which were absent from mock-infected cells. An intense band migrating at
approximately 120 kDa was predicted to be the hexon polypeptide as this is the major
virion constituent and has a molecular weight of 120 kDa in Ad2 virions. Two other
proteins of approximately 72 and 60 kDa were predicted to be the penton polypeptide
and IlIa respectively, with a further band at approximately 48 kDa most likely to be
protein V. A band of approximately 24 kDa present in virion protein samples but not
present in infected cells was assumed to be protein VI. This protein is produced by
processing of a larger 27 kDa precursor polypeptide (pVI) which can be seen in
samples from Ad5-infected cells.
This preliminary evaluation of antiserum reactivity was confirmed by comparison
with antiserum AbR1I89 (kindly donated by Dr. V. Mautner, University of
Birmingham) that is known to have reactivity against the penton and fibre
polypeptides. Comparison of reactivity of AbR1I89 and AbJLB 1 with virion proteins
(figure 4.3) shows that they both react with the penton polypeptide and that AbJLB 1
may also react with L4-100K, which was not previously observed. This data, in
conjunction with later expression studies (figure 4.6) shows that AbR1I89 also has
reactivity against L4-100K. This is an unexpected observation as both antisera were
raised against purified virions and the L4-100K protein has never been detected in
mature virions. L4-100K has been shown to act as a scaffolding protein and facilitates
the assembly of hexon capsomeres during virus assembly by binding to hexon
monomers (Oosterom-Dragon and Ginsberg, 1981; Cepko and Sharp, 1982).
Therefore, one possible explanation for the observed L4-100K reactivity is that the
virion preparation used for immunisation contained immature virions and therefore
also contained L4-100K still associated with the hexon capsomere.
The protein migrating at approximately 60 kDa (figure 4.3, lane 2) has a higher
molecular weight than the fibre polypeptide detected by AbR1I89 (figure 4.3, lane 1)
and therefore must be IlIa, as this is the only other viral protein in this size range.
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Figure 4.2. Detection of late proteins by polyclonal antiserum.
10 - 0.1 Ilg samples of denatured Ad5 virions analysed on a 10 % (w/v)
polyacrylamide-SDS gel followed by Western blotting with AbJLB 1.
Also shown are samples from Ad5-infected and mock-infected 293 cells.
Positions of molecular weight markers are indicated on the left, with
arrows on the right indicating positions of viral proteins.
M 1 M 2
25kDa -
VI
Figure 4.3. Detection of late proteins in adenovirus type 5 virions.
10 ug samples of denatured virions analysed on a 10 % (w/v)
polyacrylamide-SDS gel followed by Western blotting. Samples were run
in duplicate on the same gel, with the nitrocellulose filter subsequently
divided and probed with AbR1/89 (Lane 1) or AbJLB1 (Lane 2). Positions
of molecular weight markers (M) are indicated on the left, with arrows on
the right indicating positions of viral proteins.
Comparison of reactivity of AbR1I89 and AbJLB 1 on AdS-infected cell extracts
further supports these observations (figure 4.4). Once again, AbJLBl reacts with a
protein equivalent in molecular weight to the penton polypeptide, and the putative Ilia
protein migrates with a higher molecular weight than the fibre polypeptide. Taken as a
whole these results suggest that antiserum AbJLBl has reactivity against a range of
late proteins including hexon, penton, Ilia, V and VI.
4.4. Further evaluation of late protein expression from pEPII.
To determine the extent of late protein expression from plasmid pEPII, the two
available antisera, AbJLB 1 and AbR1I89, together with an anti-L4 lOOK antibody
(kindly donated by Prof. W.e. Russell, University of St. Andrews), were used to
detect late proteins in a transient transfection assay. In addition to pEPII, the
expression of late proteins from modified forms of pEPII was also analysed. pEPM
and pEP~I1 are deleted variants of pEPII (figure 4.5) and pEP~2A has an intact
MLTU but contains a point mutation in the E2A-DBP coding region. Details of the
construction of these plasmids is given in section 5.4.
10 ug of each plasmid was transfected into 4 x 106 293 cells in a 60 mm dish
using calcium phosphate precipitation. Cells were left for 48 hours before protein
extracts were made as described in section 2.3.S.l. Proteins were separated by SDS-
PAGE with the equivalent of protein from 1x 106 cells loaded per lane. Proteins were
then transferred to nitrocellulose membranes and probed for late protein expression.
Analysis with AbR1I89 reveals the expression of the three proteins known to be
detected by the antiserum; penton, fibre and L4-100K (figure 4.6). pEPIl expresses all
three proteins as does pEP~E2A. pEP~I expresses fibre and L4-100K, but not penton
as the reading frame has been deleted from the plasmid. There is a feint band
migrating at the position predicted for the penton polypeptide, which is also present in
pEP~I samples. This is most likely to be a protein reacting non-specifically with the
antiserum, as the band is not as sharp or intense as the band from pEPII and
pEP~2A samples. pEP~I1 expresses the fibre polypeptide, but does not express
either penton or L4-100K. A protein of higher molecular weight than lOOK is visible
(indicated by broken arrow in figure 4.6), which is most likely to be the product of the
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Figure 4.5. Modified expression plasmids used in transient
transfection assays.
A. Diagrammatic representation of modifications to the ML TU of
plasmids pEPL'lI And pEPL'lII. Restriction enzyme sites used to create
the deletions and their positions in the viral genome are indicated.
B. Proteins predicted to be expressed from plasmids pEP LlI and
pEPL'lII.
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in-frame fusion of the penton and L4-100K reading frames created when the deletion
was made in plasmid pEPI!. This fusion protein is predicted to have a molecular
weight of approximately 100 kDa based on amino acid composition. The deleted
plasmids pEPLlI and pEPLlII express higher levels of fibre and L4-100K, which is
possibly due to there being fewer splicing alternatives available during primary
transcript processing. However, this could also be due to variations in transfection
efficiency between the plasmid preparations used.
Antiserum AbJLBl reacts with three proteins in cells transfected with pEPII
(figure 4.7 A). From the known reactivity already determined for this antiserum,
expression of hexon, penton and IlIa from plasmid pEPII is confirmed. The identity of
the protein with a molecular weight of 66 kDa is confirmed as being IlIa and not the
fibre polypeptide due to the fact that it is expressed in pEPLlII transfected cells, but
not in pEPLlI transfected cells. Both plasmids would be expected to express fibre but
only pEP~I1 will express IlIa as it is deleted from plasmid pEPM. The antiserum also
reacts with a protein in pEP~I1 transfected cells that appears to co-migrate with the
hexon polypeptide. The modification to pEPLlIl removes the hexon reading frame so
this protein must be the penton / L4-100K fusion protein. Analysis with anti L4-100K
antibody (figure 4.7B) shows expression of L4-100K from plasmid pEPII and pEPM,
confirming the observed expression pattern in figure 4.6. This result also shows that it
is the penton polypeptide component of the fusion protein that is recognised by
AbJLB 1 and AbR1I89 as there is no band present in pEP~n samples probed with anti
L4-100K antibody.
4.5. Discussion.
These results show that the expression plasmid pEPII is capable of expressing a
range of late proteins in transiently transfected cells. The expression of at least one
protein from each region of the MLTU has been demonstrated, showing that the full
range of poly (A) sites is being used, with a variety of splice sites being selected. This
therefore appears to mimic the expression of the MLTU in the context of the viral
genome, although it is not possible to say whether the relative levels of expression are
identical to those in the late phase of infection.
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Figure 4.7. Further analysis of late proteins expressed in transfected
293 cells.
Protein extracts from transfected 293 cells, analysed on a 10 % (w/v)
polyacrylamide-SDS gel follwed by Western blotting with polycIonal
antiserum AbJLBl (A) or anti-L4 lOOK antiserum (B). The plasmid
transfected is indicated above the relevant lane with AdS infected-cell
extract used as a positive control. Positions of molecular weight markers
are indicated on the left, with arrows on the right indicating positions of
viral proteins.
A major problem became apparent in trying to use a transient transfection assay
to detect late protein expression. This was that the levels of expression were low and
variable. Some transfections failed to show any late protein expression and
experiments had to be repeated several times in order to confirm the observed patterns
of expression presented in this chapter. One possible explanation for this variability is
variation in transfection efficiency. Preliminary control transfections using a lacZ
reporter plasmid (figure A.6) suggested that only approximately 10 % of cells in a
transfection received the plasmid. As plasmid pEPII is considerably larger than the
lacZ plasmid, it was assumed that the transfection efficiency would be similar, if not
lower. To investigate this, two plasmids expressing GFP were constructed, 4 and 30
kbp in size. These plasmids were transfected into 293 cells, with the 30 kb plasmid
showing a marked reduction in transfection efficiency (data not shown). To try to
compensate for the fact that very few cells would receive the expression plasmid,
attempts were made to load more cell equivalents of protein per gel. This in itself
caused additional problems as cells had to be lysed in smaller volumes of lysis buffer,
leading to more contaminating DNA being loaded onto the gel. This ultimately
resulted in poor quality, smeared Western blots. The possibility that the plasmid was
expressing toxic proteins and killing the transfected cells, leading to them being lost
from the pool of cells before harvesting was also investigated. Plasmid pEPll was
cotransfected into 293 cells with the lacZ control plasmid and the number of lacZ
expressing cells was determined. Cotransfection of pEPII had no effect on the number
of lacZ expressing cells (data not shown), showing that pEPII was not killing the cells
before they could be harvested and protein extracts made.
As the expression plasmid pEP II is 37 kbp in size it will be more prone to
damage by shearing forces during isolation and subsequent handling. Reducing the
number of closed-circular molecules in the plasmid preparation will result in a
reduction in transfection efficiency. Steps were taken to minimise damage to the
larger expression plasmids, including using the Promega Wizard® PureFection
plasmid purification kit, which avoids the use of narrow gauge needles during
purification, unlike the CsCl-gradient method. Also, plasmid preparations were stored
at 4 °C and not frozen at -20°C to avoid damage by freeze-thawing.
The levels of expression from pEPII are ultimately difficult to quantify and
comparisons with late protein expression in a viral infection are not possible due to
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the low number of cells recei ving the plasmid. A fair comparison would require stable
expression of the late genes from pEP II in a cell line, with the use of viral
transactivators to achieve maximum levels of expression from the MLP.
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Chapter 5 : Construction of stable cell lines
containing adenovirus type 5 late protein
expression vectors.
Chapter 5 : Construction of stable cell lines containing adenovirus
type 5 late protein expression vectors.
5.1. Introduction.
Adenovirus vectors offer a wide range of advantages over other viral vectors and
therefore represent attractive gene delivery vehicles for gene therapy applications.
These advantages include ease of genome manipulation, efficient gene transfer into
dividing and non-dividing cells and ease of production of high titre vector stocks.
However, the adenovirus vectors currently used in clinical trials have two major
disadvantages; the immune response observed upon vector administration and the
limited capacity for insertion of heterologous sequences.
Strategies to overcome these obstacles have focussed on the deletion of additional
viral coding sequences, in order to reduce the expression of viral antigens and also to
increase the trans gene carrying capacity of the vector. This approach has been taken
to its limit by the production of "gutless" vectors. These vectors are deleted for all
viral coding sequences, but retain the ITRs and packaging signal required for
replication and packaging of the genome (see section 1.4.5.3). These vectors offer the
advantage of not expressing any viral proteins and they can also carry approximately
36 kbp of heterologous DNA. However, they must be propagated in the presence of a
helper virus that is difficult to purify away from the vector and can lead to
contamination of the vector stock.
Currently available cell lines are not capable of complementing the growth of
vectors with all viral coding sequences deleted. Vectors produced in cell lines
therefore have lower trans gene carrying capacity and will still be capable of
expressing a range of viral proteins. Therefore, a cell line capable of supporting the
growth of a vector with deletions in multiple gene regions would be beneficial in the
development of adenovirus vectors.
The most common approach to the construction of complementing cell lines is to
transfect cells with a plasmid containing the desired viral sequences and a selectable
marker gene. Integration of the transfected DNA into the cellular chromosome allows
transfected cells to be grown in the presence of a selective drug. Expansion of
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individual clones allows cell lines constitutively expressing the viral sequences to be
isolated. An alternative approach to creating complementing cell lines was used by
Caravokyri and Leppard (1995) to construct a cell line expressing pIX. Here
expression of pIX was achieved using episomal expression plasmids containing
sequences from Epstein-Barr virus (section 3.3). One of the major advantages of this
system, compared to the more common method of integrating DNA into the host
genome, is that the plasmids are maintained at multiple copies per cell, resulting
potentially in a higher yield of expressed protein than from a single integrated
construct. Another advantage is that the transfected DNA is maintained episomally,
thus preventing mutations that might occur to the cellular genome during the
integration process and also avoids any "position effects" on protein expression, i.e.
the effect of surrounding chromatin on the expression level.
5.2. Aims.
The aim of this work was to use the expression plasmid pEPII to construct a cell
line capable of expressing adenovirus late proteins. This would be achieved by
transfecting the plasmid into 293, HeLa and A549 cells, followed by selection of
stably transfected cells using hygromycin-B, The extent of late protein expression in
any isolated cell line would then be analysed, both with and without the presence of
viral transactivating proteins. The ultimate aim of this work being to use the cell line
to complement the growth of a highly deleted vector with multiple late gene
deficiencies.
5.3. Attempts to construct stable cell lines using pEP! I pEPII.
In order to create stable cell lines a standard transfection and selection protocol
was devised. 10 /-lg of plasmid DNA was used to transfect 4 x 106 cells in a 60 mm
dish using calcium phosphate precipitation. At 48 hours post-transfection the cells
were passaged 1:3 and after a further 24 hours the growth medium was replaced with
DMEM I 10 % NCS containing one of several hygrornycin-B concentrations (50 -
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300 ug/ml). The growth medium was replaced every 3 days, maintaining hygromycin-
B selection, and cells passaged 1:3 when confluent. The results of these initial
attempts to isolate stable cell lines are summarised in table 5.1.
This initial test was carried out in 293 and HeLa cells. No cell lines isolated from
HeLa cell transfections at any hygromycin-B concentration. The inability of either of
the positive control plasmids (pCEP-IVa2 and pgERI) to create cell lines suggested
that HeLa cells were either very sensitive to hygromycin-B or that the EBNA-I
protein expressed from all the vectors was toxic to the cells. Transfection of 293 cells
resulted in stable cell lines when the control plasmids pCEP-IVa2 and pgERI were
used. pCEP-IVa2 was previously used to create a IVa2-expressing 293 cell line (S.
Brey, University of Warwick thesis, 1999) and the ability of it to create a stable cell
line here showed that the method used was viable. Plasmid pgERI (figure 3.12)
contains the EBV replicon but no adenovirus sequences. The ability of this plasmid to
create stable cell lines showed that the EBV sequences (oriP and EBNA-I) were
functioning correctly. No cell lines could be isolated using the negative control
plasmid, pBR322. This shows that it is the EBV sequences present on the other two
plasmids that are responsible for their maintenance in stable cell lines.
Despite the control plasmids functioning correctly in 293 cells, neither of the two
expression plasmids (pEPI and pEPII) could be used to create a stable cell line. As the
vector backbone had been shown to be functional, this inablity to be stably maintained
in 293 cells must be due in some way to the Ad5 sequences present in the plasmid.
Late proteins were shown to be expressed from the MLTU when the plasmid pEPIl
was transfected into 293 cells (chapter 4). One or more of these proteins may be toxic
to the cell, thus preventing any transfected cell from forming a stable cell line.
5.4. Modifications to expression plasmid pEPII.
In an attempt to allow plasmid pEPII to be maintained in 293 cells, strategies
were devised to reduce the expression of potentially toxic proteins. These involved
two deletions to remove the expression of selected late proteins, and a frameshift
mutation was introduced into the E2A DNA binding protein (DBP) reading frame.
Although DBP is not expressed from the MLTU, the E2A gene is located within the
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MLTU on the opposite strand and may still be expressed from the E2 promoter. DBP
is known to be toxic to human cells (Klessig et al., 1984) and has previously been
expressed from tightly-regulated inducible promoters to allow the construction of
stable cell lines (Brough et al., 1992; Zhou et al., 1996; Zhou and Beaudet, 2000).
Therefore, if cells are unable to tolerate constitutive expression of DBP, plasmid
pEPII will not be maintained in a stable manner and this would explain the inability to
isolate a stable cell line.
The cloning strategy required to introduce a point mutation into the DBP reading
frame was complex. Therefore, before undertaking this work, expression studies were
performed to determine if the plasmids did express DBP. 10 J..lgof either pEP! or
pEPII (chapter 3) was used to trans feet 4 x 106 293 cells in a 60 mm dish using
calcium phosphate precipitation. Cells were left for 48 hours before protein extracts
were made as described in section 2.3.5.1. For Ad5-infected cell extracts, 4 x 106 293
cells were infected at an m.o.i. of 10 pfu/cell and proteins extracted 24 hours later.
Proteins were separated by SDS-PAGE with the protein from 1 x 106 cells loaded per
lane for transfections, and from 5 x 104 cell silane for virus-infected cells. Proteins
were then transferred to nitrocellulose membranes and probed with an anti-DBP
monospecific antiserum (figure 5.0). Both plasmids pEP! and pEPII were found to
express DBP when transfected into 293 cells.
To determine if it was late protein or DBP expression that was causing the toxic
effect, the three modified plasmids were constructed and assessed for their ability to
create stable cell lines. The modifications and their effects on the number of proteins
potentially expressed are summarised in figure 5.1.
5.4.1. Construction of deleted variants of pEPIl.
Plasmid pEPII (figure 3.13) was digested with Pme! and Bamill. The resulting
26531 bp fragment was modified by converting the 5' overhang to a blunt terminus
using the Klenow filling method (section 2.3.2.3). The DNA was then circularised to
create plasmid pEP8! and positive clones identified by restriction enzyme analysis
using EcoRV (figure 5.2). Plasmids with the deletion would produce a diagnostic
3881 bp fragment plus fragments of 12377,4364,2623,2052 and 1238 bp; the parent
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Figure 5.0. Expression of DBP from plasmids pEP! and pEPll.
10 ug of each plasmid was transfected into 4 x 106 293 cells in a 60
mm dish using calcium phosphate precipitation. Cells were left for
48 hours before protein extracts were made as described in section
2.3.5.1. Protein extracts from 1 x 106 cells were analysed on a 10 %
(w/v) polyacrylamide-SDS gel followed by Western blotting with
anti-DBP antiserum. The plasmid transfected is indicated above the
relevant lane with AdS-infected cell extract used as a positive
control. Positions of molecular weight markers (M) are indicated
on the left, the arrow on the right indicates the position of DBP.
Figure 5.1. Modifications to expression plasmid pEPII.
A. Diagrammatic representation of modifications made to pEPII to create pEP~I,
pEP~II and pEP~E2A. Restriction enzyme sites used to create the deletions and their
positions in the viral genome are indicated.
B. Proteins predicted to be expressed from plasmids pEP~I and pEP~II. Plasmid
pEP~E2A is predicted to express the same range of late proteins as pEPII.
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Figure 5.2. Plasmid pEP~I.
A. Plasmid map showing unique
sites and sites of interest.
Numbering in brackets refers to the
original numbering in the Ad5
sequence (Chroboczek et al., 1992).
Abbreviations: Hygromycin,
hygromycin resistance gene; SV40
pA, simian virus 40 polyadenylation
signal; OriP, EBV latent origin of
replication; EBNA-l. Epstein-Barr
virus nuclear antigen 1; amp,
ampicillin resistance gene, Ad5,
adenovirus sequence.
B. I % agarose gel visualised by
ethidium bromide staining. Lane 1,
1 kb ladder. Lane 2, EcoRV digest
of pEP~1. The arrow indicates
diagnostic band used to determine
that plasmid contains the deletion.
plasmid pEPII would produce 4546 and 7639 bp fragments against this same
background.
Plasmid pEPII (figure 3.13) was digested with AscI. The resulting 25219 bp
fragment was then circularised to create plasmid pEP~II and positive clones identified
by restriction enzyme analysis using EcoRV (figure 5.3). The absence of the 4546,
2623 and 2052 bp bands and the presence of the predicted novel junction fragment of
7240 bp upon digestion ofpEP~II with EcoRV (figure 3.13) confirmed the deletion.
5.4.2. Introduction of a frameshift mutation into the DBP reading frame.
Plasmid pBRZ171 (figure 3.9) was digested with PmeI and BamHI and the
resulting 8308 bp fragment was cloned into BstZ17I / BamHI digested pE2(SI)SX (a
gift from Dr. Leppard; figure A.8). pE2(SI)SX contains Ad5 sequence from 21562 to
27331 bp, with a SmaI to XhoI modification at bp position 23912, resulting in a
frameshift mutation in the DBP reading frame. This ligation resulted in the generation
of plasmid pE2SX-L (figure A.9) which contains Ad5 sequence from 13255 bp to
27331 bp. This plasmid was then digested with Asci and the resulting 9620 bp
fragment was cloned into AscI digested pEPII, replacing the pEPII sequence and
introducing the mutation. The resulting plasmid, termed pEP~E2A, was identified by
restriction enzyme analysis (figure 5.4). Bands at 7639 and 2625 bp after EcoRV
digestion confirmed that the insert was present and in the correct orientation, the
alternative orientation would have produced bands of 5859 and 4403 bp. The presence
of the DBP mutation was confirmed by XhoI digestion (figure 5.4). The mutation
introduces an XhoI site at AdS bp 23912, upon digestion with XhoI any plasmid
containing the mutation will produce an extra band of 886 bp (figure 5.4, lane 4)
when compared to plasmid pEPII (figure 5.4, lane 6).
5.4.3. Expression of late proteins from modified plasmids.
The extent of late protein expression from plasmids pEP~I, pEP~II and
pEP~2A was determined by Western blot analysis and is discussed in section 4.4.
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Figure 5.3. Plasmid pEP !lII.
A. Plasmid map showing unique sites
and sites of interest. Numbering in
brackets refers to the original
numbering in the AdS sequence
(Chroboczek et al., 1992).
Abbreviations: Hygromycin,
hygromycin resistance gene; SV40 pA,
simian virus 40 polyadenylation
signal; OriP, EBV latent origin of
replication; EBNA-l. Epstein-Barr
virus nuclear antigen 1; amp,
ampicillin resistance gene, AdS,
adenovirus sequence.
B. 1 % agarose gel visualised by
ethidium bromide staining. Lane 1, 1
kb ladder. Lane 2, EcoRV digest of
pEP!lII.
Figure 5.4. Plasmid pEP AE2A.
A. Plasmid map showing unique sites and sites of interest. Numbering in brackets refers
to the original numbering in the AdS sequence (Chroboczek et al., 1992). Abbreviations:
Hygromycin, hygromycin resistance gene; SV40 pA, simian virus 40 polyadenylation
signal; OriP, EBV latent origin of replication; EBNA-l. Epstein-Barr virus nuclear
antigen 1; amp, ampicillin resistance gene, AdS, adenovirus sequence.
B. 1% agarose gels visualised by ethidium bromide staining. Lanes 1,3 and S, 1 kb
ladder. Lane 2, EcoRV digest ofpEP~E2A. Lane 4, Xhol digest ofpEP~E2A. Lane 6,
Xhal digest of pEPII. The arrows indicate diagnostic bands used to determine insert
orientation. The band showing presence of E2A mutation is indicated by a broken arrow.
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(figures 4.6 and 4.7). Briefly, pEP~I was shown to express the lA-lOOK and fibre
polypeptides; pEP~I1 expressed the hexon, fibre and IlIa polypeptides and plasmid
pEP~2A was shown to express the lA-lOOK, penton and fibre polypeptides,
Although only a small number of late proteins were detected in transfected cells,
plasmid pEP~2A should be capable of expressing the full range of late proteins.
5.5. Isolation of stable cell lines using modified expression plasmids.
Transfection of 293 cells and isolation of cell lines was carried out as described
in section 5.3. The same plasmids were used for the transfections with the addition of
the three modified plasmids; pEP~I, pEP~II and pEP~2A. Also, only 293 cells were
used due to the inability to isolate HeLa-derived cell lines when using the control
plasmids. The results of these transfections is summarised in table 5.2.
Table 5.2. Attempts to construct stable cell lines using modified expression
plasmids. 293 cells were transfected with a range of plasmids and the isolation of
stable cell lines was attempted over a range of hygromycin-B concentrations (50 -
300 ug/ml), + indicates that a stable cell line was isolated. - indicates that a stable
cell line was not isolated.
293 cells
50 uc/ml 100 ua/ml 200 us/ml 100 uz/ml
pEPI - - - -
pEPII - - - -
pEP~I - - - -
pEP~II + + + +
pEP~E2A + + + +
pgERI + + + +
pCEP-IVa2 + + + +
pBR322 - - - -
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As was previously observed, the two control plasmids, pgERI and pCEP-IVa2,
were stably maintained in 293 cells, whereas the two expression plasmids, pEPI and
pEPII were not. Of the three modified plasmids both pEP~I1 and pEP~E2A gave rise
to stable cell lines, but pEP~I did not. The only difference plasmid pEP~2A has
when compared to pEPIIII is that it has a frameshift mutation in the DBP coding
region. Therefore, the fact that pEP~2A but not pEPI/II was capable of stable
maintenance indicates that it was the expression of DBP that prevented stable cell
lines from emerging, presumably because of toxicity. The DBP reading frame covers
the region from bp 22445 to 24032; plasmid pEP~I has a deletion that covers bp
13258 to 21563 and therefore retains the DBP reading frame. The deletion in plasmid
pEP~I1 covers the region from bp 15760 to 25290 and therefore does not contain the
DBP reading frame. The presence of the DBP coding region in pEP~I and its inability
to be stably maintained further supports the suggestion that DBP is toxic to 293 cells.
A transient transfection assay was used to confirm that DBP was being expressed
from the plasmids that were incapable of being stably maintained. Transfected cell
proteins were separated by SDS-PAGE, transferred to nitrocellulose membranes and
probed for DBP expression using an anti-DBP monospecific antiserum (figure 5.5).
Both plasmid pEPII and pEP~I were found to express DBP when transfected into 293
cells, but as predicted plasmids pEP~I1 and pEP~2A did not. Thus confirming that
the expression of DBP correlates with the inability of a plasmid to be stably
maintained.
The cell line created by plasmid pEP~E2A, termed 293-EP, was chosen for
further analysis as it should be capable of expression of the full range of late proteins.
Also, the major proteins recognised by the available antisera were lA-lOOK, penton
and fibre, of which only fibre is expressed by plasmid pEP~II. This would make
analysis of expression from the pEP~II derived cell line a more difficult task.
5.6. Analysis of the 293-EP cell line.
5.6.1. Analysis of late protein expression in 293-EP cells.
Protein samples from 293-EP cells were taken 14 and 28 days post transfection
and analysed by Western blotting using antisera AbJLBI and AbR1I89. No
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Figure 5.5. Expression of DBP in transiently transfected cells.
10 ug of each plasmid was transfected into 4 x 106 293 cells in a 60 mm
dish using calcium phosphate precipitation. Cells were left for 48 hours
before protein extracts were made as described in section 2.3.5.1.
Protein extracts from 1 x 106 cells were analysed on a 10 % (w/v)
polyacrylamide-SDS gel followed by Western blotting with anti-DBP
antiserum. The plasmid transfected is indicated above the relevant lane
with AdS-infected cell extract used as a positive control. Positions of
molecular weight markers (M) are indicated on the left, the arrow on the
right indicates the position ofDBP.
expression of late proteins could be detected (data not shown), even when protein
from 2 x 106 cells was loaded on the gel. This is approximately twice the amount of
protein that was loaded to detect late protein expression after transient transfection.
293-EP cells were also analysed by immunofluorescence microscopy using AbR1I89
and anti-L4 lOOK antisera but, once again, no late protein expression could be
detected (data not shown).
Research has shown that regulation of the MLP may be affected by several viral
proteins (section 3.4). With the absence of virally encoded activators being a possible
reason for the lack of expression, experiments were designed to attempt to induce
expression from the MLP with superinfecting virus. Two 60 mm dishes, each
containing 4 x 106 293-EP cells were infected with wt Ad5 at an m.o.i, of 10 pfu/cell.
After 1 hour the growth medium was replaced with DMEM /10 % NCS for one dish
and DMEM /10 % NCS containing 10 mM hydroxyurea for the other. This procedure
was repeated with mock-infected 293-EP cells and also with Ad5-infected and mock-
infected 293 cells. Hydroxyurea (HU) is a reagent that prevents the synthesis of
dexoyribonucleotides by specifically inhibiting ribonucleoside diphosphate reductase.
Therefore, treating infected cells with HU prevents viral DNA replication and late
protein synthesis. Any late protein expression observed in these cells would be due to
the MLP IMLTU construct present on the expression plasmid being activated by early
proteins expressed by the virus. Cells were grown for 48 hours before protein extracts
were made and separated by SDS-PAGE with the protein from 1 x 106 cells loaded
per lane. Proteins were then transferred to nitrocellulose membranes and probed using
antiserum AbR1I89 (figure 5.6A).
lOOK, penton and fibre expression was detected in infected 293 cells but not in .
HU-treated / infected 293 cells. This shows that treatment of infected cells with 10
mM HU effectively blocked viral DNA replication and late protein expression.
However, no evidence of late protein expression could be detected in infected 293-EP
cells that were treated with HU, suggesting that the presence of early viral proteins
was not sufficient to activate the MLP. Analysis of the same protein extracts with
anti-DBP antibody (figure 5.6B) confirmed the expression of the early protein DBP
from the infecting virus, which would suggest that all the other early proteins were
also expressed.
The previous result also revealed that the two delayed early proteins, IVa2 and
IX, were not expressed in cells treated with HU (figure 5.6B). The IVa2 protein is a
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Figure S.6. Attempted induction of late protein expression in 293-EP cells using
wt AdS infection.
Protein extracts from 293-EP and 293 cells, analysed on a 10 % CA)or 15 % CB)Cw/v)
polyacrylamide-SOS gel followed by Western blotting with polyc1onal antiserum
AbR1I89 CA)or anti - OBP, anti - IVa2, anti - pIX antisera CB).The use of AdS
superinfection and / or 10 mM hydroxyurea treatment is indicated above the lane.
Positions of molecular weight markers are indicated on the left, with arrows on the
right indicating the position of viral proteins.
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known transcriptional activator of the MLP (Tribouley et al., 1994; Lutz and
Kedinger, 1996) and IX has been shown to activate TATA containing promoters,
including the MLP, in vitro (Lutz et al., 1997). To investigate whether the absence of
either of these proteins was responsible for the lack of MLP activity, 293-EP cells
were transfected with plasmids expressing IVa2 and IX. Transfected cell proteins
were separated by SDS-PAGE, transferred to nitrocellulose membranes and probed
using antiserum AbR1I89 (figure S.7A). No late proteins could be detected in 293-EP
cells transfected with either pCEP-IVa2, pCMV-IX or a combination of the two.
Analysis of the same protein extracts with anti-IVa2 and anti-IX antisera revealed that
both proteins were effectively expressed from their respective plasmids (figure S.7B).
To rule out the possibility that both early proteins and delayed early proteins were
required for activation of the MLP an experiment was designed to provide all viral
proteins using a wt Ad2 infection. Since the experiment would depend on being able
to distinguish between late proteins expressed by the plasmid or the virus, any
differences in the reactivity of the available antisera with Ad2 and AdS late proteins
had firstly to be determined. To achieve this, proteins from Ad2 and Ads-infected 293
cells were separated by SDS-PAGE, transferred to nitrocellulose membranes and
probed with AbJLB1, AbBFl or AbR1I89 (figure 5.8). From these results it is clear
that both AbJLB 1 and AbBFl react with epitopes present on AdS hexon but not on
Ad2 hexon. AbBFI was raised against intact wt AdS virions and had already been
shown to have reactivity against penton in transiently transfected cells (figure 4.1).
Higher levels of protein expression in infected cells compared to transfected cells also
revealed activity against hexon. In addition, the fibre polypeptide detected by
AbR1I89 is a lower molecular weight in AdS. These results provide a basis for
distinguishing between hexon and fibre polypeptides expressed from wt Ad2 and
plasmid pEPLlli2A.
To determine if expression of Ad2 proteins could activate expression from
plasmid pEPLlli2A, 293-EP cells were infected with wt Ad2 and infected-cell protein
extracts were analysed by SDS-PAGE and Western blotting with antisera AbJLBI
and AbR1I89 (figure 5.9). Analysis with antiserum AbJLB 1 did not reveal the
presence of any AdS hex on polypeptide in 293-EP cells infected with Ad2 (figure
S.9A). Also, antiserum AbR1I89 failed to detect the expression of the lower molecular
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Figure 5.7. Attempted induction of late protein expression in 293-EP cells using
pIX and IVa2 expression plasmids.
10 ug of plasmid pCEP-IVa2 (figure A7) and I or pCMV-IX (Caravokyri and
Leppard, 1995) were transfected into 4 x 106 293-EP cells in 60 mm dishes by
calcium phosphate precipitation. Cells were grown for 48 hours before protein
extracts were made as described in section 2.3.5.1. Protein extracts from 1 x 106 cells
were analysed on 10 % (A) or 15 % (B) (w/v) polyacrylamide-SDS gels followed by
Western blotting with polyc1onal antiserum AbR1I89 (A) or anti -DBP, anti - IVa2
and anti - pIX antisera (B). Plasmid(s) transfected into 293-EP cells are indicated
above the relevant lane, with wild type AdS-infected cell extract used as a positive
control. Positions of molecular weight markers (M) are indicated on the left, with
arrows on the right indicating the position of viral proteins.
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Figure 5.8. Differences in reactivity of antisera with Ad2 and Ad5 proteins.
4 x 106 293 cells in 60 mm dishes were infected with Ad2 or Ad5 at an m.o.i, of 10
pfulcell and proteins extracted 24 hours later. Protein extracts from 5 x 105 cells were
analysed on 10 % (w/v) polyacrylamide-SDS gels followed by Western blotting with
polyclonal antiserum AbJLBl (A), AbBF1 (B) or AbR1I89 (C). Positions of
molecular weight markers (M) are indicated on the left, with arrows on the right
indicating the position of viral proteins.
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Figure 5.9. Attempted induction of late protein expression in 293-EP cells using
wt Ad2 infection.
4 x 106 293-EP cells in 60 mm dishes were infected with wt Ad2 at an m.o.i. of 10
pfu/cell. 293 cells were also infected with Ad2 and AdS to provide controls. Protein
extracts were made 48 hours post-infection and protein from 1 x 106 cells was
analysed on a 10 % (w/v) polyacrylamide-SDS gel followed by Western blotting with
polyclonal antiserum AbJLB 1 (A) or AbR1I89 (B). The cell type and Ad serotype
used is indicated above the relevant lane. 293-EP (100) and 293-EP (200) indicates
cells grown in the presence of 100 or 200 ug/ml hygromycin-B. Positions of
molecular weight markers are indicated on the left, with arrows on the right indicating
the position of viral proteins.
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weight form of the Ad5 fibre polypeptide, with protein extracts from 293-EP cells
containing only the higher molecular weight Ad2 form (figure 5.9B).
5.6.2. Detection of adenovirus sequences in 293-EP cells.
The possibility was considered that rearrangement or deletion of the expression
plasmid might explain the absence of late protein expression in the 293-EP cell line.
To test this hypothesis, DNA was extracted from 293-EP cells and probed for the
presence of plasmid sequence. DNA extracts were made from 293-EP, 293-GERI and
293-IVa2 cells (S. Brey, University of Warwick thesis, 1999), using the method
described in section 2.3.6.1. 293-GERI cells are a stable cell line created using the
expression vector pgERI that does not contain any adenovirus sequence (figure 3.12).
DNA extracted from 2 x 106 cells was digested for 16 hours with 60 units of enzyme.
The enzymes used were EcoRV for the 293-EP extract and EcoRI for the 293-GERI
and 293-IVa2 extracts. In addition, control digests of the original plasmid
preparations were carried out as controls. Digested samples were separated on a 0.7 %
agarose gel and analysed by Southern blotting using nick-translated pEPAE2A as a
probe (figure 5.10). Extraction and analysis of DNA from 293-IVa2 cells failed to
show the presence of any plasmid sequence (lane 2) and is probably due to a problem
with the DNA extraction or digestion procedures. The extract from 293-GERI cells
clearly contains the plasmid pgERI as the three bands present in the control digest
(lane 6) are also present in the cellular DNA extract (lane 3). The result from 293-EP
cells is not as clear, with only a subset of bands being visible (lane 1) when compared
to the plasmid digest (lane 4). The absence of the 12377 and 7639 bp bands could be
due to rearrangement of the plasmid after transfection. This is unlikely however as the
two fragments are not adjacent to each other in the plasmid and any rearrangement
would be predicted to produce additional unexpected bands. A more plausible
explanation is that there has been a problem with inefficient transfer of DNA
fragments to the nylon membrane, a hypothesis supported by a degree of smearing in
the area of the blot expected to contain the absent fragments.
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Figure 5.10. Southern analysis of DNA sequences present in 293-EP cells.
DNA extracts from 293-EP, 293-GERI and 293-IVa2 cells were analysed on an 0.7 %
agarose gel followed by Southern blotting using nick-translated pEP ~E2A as a probe.
Plasmids used in the construction of the cell lines were also included as markers.
Fragment sizes (in bp) are indicated.
Panel A. 14 day (336 hour) exposure.
Lane 1, 293-EP DNA extract from 2 x 106 cells, EcoRV digest.
Lane 2, 293-IVa2 DNA extract from 2 x 106 cells, EcoRI digest.
Lane 3, 293-GERI DNA extract from 2 x 106 cells, EcoRI digest.
Panel B. 1 day (24 hour) exposure.
Lane 4, Plasmid pEP~E2A (50 ng), EcoRV digest.
Lane 5, Plasmid pCEP-IVa2 (50 ng), EcoRI digest.
Lane 6, Plasmid pgERI (50 ng), EcoRI digest.
Lane 7, 1 kb ladder.
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5.7. Discussion.
The initial problems encountered in creating stable cell lines with plasmids pEPI
and pEPII were due to 293 cells being unable to tolerate DBP expression, presumably
because of toxicity. This problem was resolved by introducing a frameshift mutation
into the DBP reading frame and thus abolishing its expression. However, results from
the subsequent experiments with the modified plasmid, pEPLlE2A, indicate that there
is another fundamental problem in achieving expression of adenovirus late proteins in
a stable cell line. The functionality of the EBV sequences required for episomal
maintenance of the plasmid has been proven and adenoviral sequences have been
detected in the stable cell lines created. However, the results of the Southern analysis
of plasmid sequences present in 293-EP cells are inconclusive. Although the majority
of plasmid pEPLlE2A was detected in DNA extracts from 293-EP cells, two larger
fragments were undetectable. The whole process of DNA extraction and Southern
analysis proved to be inconsistent, with the results shown in figure 5.10 being the only
successful attempt at detecting plasmid sequences in any cell line. Therefore, it is
impossible to rule out the possibility that the expression plasmid in 293-EP cells
became deleted or rearranged in some way during selection, leading to it becoming
non-functional.
The lack of any late protein expression In 293-EP cells was unexpected as
plasmid pEPLlE2A ha been shown to express late proteins effectively in a transient
transfection assay (section 4.4). It was expected that this basal level of expression,
mediated by cellular transcription factors and possibly the EIA-13S protein present in
293 cells, would continue as the plasmid was maintained as an episome. The inability
to activate the MLP by providing known viral transactivators in trans suggests that
the promoter has become inactivated in some way after transfection. This inactivation
could be due to methylation of promoter sequences eliminating binding of one or
more essential transcription factors, a process that has already been shown to regulate
expression of the Ad2 E2A gene in vitro (Langner et al., 1984; Hermann and
Doerfler, 1991). In this case, downregulation of the E2A promoter is due to the
methylation of specific 5' ceo a 3' sequences present in two AP2 sites. Methylation
of these sequences prevents the AP2 transcription factor from binding to the DNA site
and forming the transcription-activating complex. The adenovirus MLP contains one
5' CCGG 3' sequence which overlaps the UPE (upstream promoter element) which is
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the USF transcription factor binding site (underlined) 5' GGCCACGTGACCGG 3'.
Methylation of this sequence could possibly prevent USF binding to the UPE and
therefore inhibit activation of the MLP. This possibility could be tested using
methylation sensitive restriction enzymes and Southern blotting, provided greater
reliability could be achieved with detecting recovered plasmid DNAs.
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Chapter 6 : Construction of a regulated system
for adenovirus type 5 late protein expression.
Chapter 6 : Construction of a regulated system for adenovirus type 5
late protein expression.
6.1. Introduction.
Regulating recombinant protein production in mammalian cells has become an
integral part of protein functional analysis. Having the ability to control when and
how much of a particular protein is expressed makes it possible to study temporal and
concentration-dependent effects on a host system and also allows the expression of
toxic proteins.
One commonly used method to regulate transgene expression is the use of a
metallothionein promoter. The metallothioneins are a highly conserved family of
small, cysteine-rich proteins which bind heavy metals and are thought to be involved
in heavy-metal detoxification and homeostasis (Hamer, 1986). They have been found
to be inducible by heavy metals such as zinc, copper and cadmium, this induction
being due to increased transcription of the gene (Durnam and Palmiter, 1981; Karin et
al., 1984).
The sheep metallothionein la (sMT-Ia) promoter is ideal for the regulated
expression of toxic proteins as it is inducible but produces only low levels of basal
expression, unlike the mouse metallothionein I promoter. This is due to the sMT-Ia
promoter not containing a basal level expression sequence motif (Peterson and
Mercer, 1986; Peterson et al., 1988; Peterson and Mercer, 1988). Comparison of the
sMT-Ia promoter sequence with the promoters of metallothionein genes from other
species identified a number of conserved regions which may be important in the
regulation of the sMT-Ia gene by heavy metals (Peterson and Mercer, 1986). These
conserved regions are indicated in figure 6.1. Found between -21 and -27 is the
TATA box (element a). Element b, found between -40 and -54, is highly conserved
between MT genes (Stuart et aI., 1985) and has been implicated in the regulation of
the mouse MT-I gene by heavy metals (Carter et al., 1984; Stuart et al., 1984).
Sequences homologous to these mouse and human heavy metal response elements
(MREs) also appear a further five times in the sMT-Ia promoter (elements c - g). The
promoter has been shown to be induced by zinc, copper and cadmium (Peterson and
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Mercer, 1986), with addition of 100 flM ZnS04 producing a 95-fold increase of sMT-
la mRNA when compared to the basal level
6.2. Aims.
The results presented in chapter 5 indicated that there was a problem in activating
the MLP when the expression plasmid was present in a stable cell line. Potentially,
active expression was being selected against by virtue of the toxicity of one or more
protein products. The aim of the work described here was to overcome this difficulty
by developing a system for regulated expression of late proteins through the use of the
sheep metallothionein-Ia promoter.
6.3. Construction and analysis of a regulated reporter plasmid.
In order to assess the optimum conditions for induction of the metallothionein
promoter a reporter plasmid was constructed which contained the lacZ gene from E.
coli, downstream of the sheep metallothionein promoter. The enzyme (3-galactosidase
encoded by the lacZ gene catalyses the hydrolysis of various (3-galactosides. Its
activity can be monitored histochemically by the cleavage of the substrate X-gal (5-
bromo-4-chloro-3-indolyl (3-D-galactoside; Alam and Cook, 1990) which is converted
to an indigo blue derivative that is readily visible in cells.
To construct the reporter plasmid pMT -lacZ, the lacZ gene was excised from
plasmid pcDNA3.1/lacZ (Invitrogen, figure A.6) by digestion with Kpnl and Xbal.
The resulting 3121 bp fragment was subsequently cloned into Kpnl I Xbal digested
pMT-CB6+ (Cook et al., 1996; figure A.ll). An EcoRI digest, generating bands of
4864, 3096 and 868 bp, was used to identify clones containing the insert (figure 6.2).
The optimum conditions for induction of the sMT-Ia promoter were determined
by monitoring (3-galactosidase expression from pMT-IacZ in 293 cells. 2 x 106 cells in
6-well plates were transfected with 2.5 ug of pMT-IacZ using calcium phosphate
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Figure 6.2. Plasmid pMT-lacZ.
Reporter plasmid containing the lacZ
gene driven by a sheep
metallothionein- Ia promoter.
A. Plasmid map showing unique sites
and sites of interest. pMT -1a, sheep
metallothionein promoter. Amp,
ampicillin resistance gene. Neomycin,
neomycin resistance gene. SV40 pA,
simian virus 40 polyadenylation signal.
B. 1% agarose gel visualised by
ethidium bromide staining. Lane 1, 1
kb ladder. Lane 2, EcoRI digest of
pMT -lacZ. The plasmid is predicted to
yield fragments of 4864, 3096 and 868
bp.
precipitation. Cells were grown on glass coverslips to aid subsequent photography.
Cells were grown for 24 hours after which time the growth medium was replaced with
DMEM I 10 % NCS containing a range of ZnS04 concentrations (0 - 200 J..lM).Cells
were grown for a further 48 hours and then fixed, stained and photographed as
described in section 2.3.5.7. The results of this experiment are shown in figure 6.3.
There is no evidence of ~-galactosidase expression in uninduced cells or cells induced
with 50 J..lMZnS04 (panels A and B). There is some expression in cells grown in 100
J..lMZnS04 (panel C) but maximum levels of expression are achieved by inducing the
promoter with 150 - 200 J..lMZnS04 (panels D and E), although levels did not reach
those shown by the more powerful constitutive CMV promoter in pcDNA3.1I1acZ
(panel F). After repetition of the experiment, the most consistent levels of induction
were observed with 150 J..lMZnS04 and this concentration was chosen for any further
induction experiments.
6.4. Construction and analysis of an inducible MLTV expression cassette.
6.4.1. Strategy to clone the sheep metallothionein la (sMT.la) promoter
upstream of the MLTV.
The first step in the cloning strategy was to create a subclone of pBRZ17I (figure
3.9) into which the sMT -Ia promoter could be inserted. pBRZ171 was digested with
Pad and XbaI and the resulting 4844 bp fragment was cloned into Pad I XbaI
digested pBR322PXP (figure A.l2) creating plasmid pKW2S. Plasmids bearing the
correct insert were determined by restriction enzyme analysis with EcoRV (figure
6.4). This digest generated the predicted bands of 5755,2040 and 1238 bp.
The sMT-Ia promoter was removed from plasmid pMT-CB6+ (figure A.ll) by
digestion with EcoRI. The cohesive ends of the resulting 868 bp fragment were filled
using E. coli DNA polymerase and the modified fragment cloned into BstZI711 Pvull
digested and dephosphorylated pKW2S. This cloning strategy was chosen as it placed
the transcription start site and TATA box of the sMT-Ia promoter in approximately
the same position as the equivalent excised MLP sequences (figure 6.5).
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Figure 6.3. Induction of ~-galactosidase expression in 293
cells. 293 cell monolayers transfected with pMT-lacZ and
stained for ~-galactosidase expression following induction
with ZnS04 at various concentrations; A, uninduced control.
B, 50 JlM. C, 100 JlM. D, 150 JlM. E, 200 JlM. F, control
plasmid pcDNA3.1I1acZ.
Magnification x 20.
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Figure 6.4. Plasmid pKW2S. Plasmid
bearing Ad5 sequence from 5764 -
10589.
A. Plasmid map showing unique sites
and sites of interest. Numbering in
brackets refers to original numbering
in the Ad5 sequence (Chroboczek et
al., 1992). Amp, ampicillin resistance
gene. Ad5, adenovirus sequence.
B. 1% agarose gel visualised by
ethidium bromide staining. Lane 1, 1
kb ladder. Lane 2, EcoRV digest of
pKW2S.

The resulting plasmid, termed pKW2S-MT, was identified by restriction enzyme
analysis with HindIII and DralII (figure 6.6). The HindIIl digest generated the
predicted bands of 6388 and 3202 bp, confirming the presence of the insert. The
orientation of the insert was confirmed by the presence of a 633 bp band after DraIII
digestion. The insert in the alternative orientation would have produced a 902 bp
band.
The viral sequence in plasmid pKW2S-MT was extended rightward to the XbaI
site at Ad5 bp 28592 by cloning the 18007 bp Xbal fragment from pEPLlli2A (figure
5.4) into the XbaI site of pKW2S-MT, creating plasmid pMT-Xbal. Plasmids
containing the insert in the correct orientation were determined by restriction enzyme
analysis with EcoRV (figure 6.7). Diagnostic junction fragments of 7639 and 3183 bp
showed that the insert was present and in the correct orientation. Insert in the
alternative orientation would have produced bands of 9367 and 1455 bp. The XbaI
fragment from pEPLlli2A was used for this cloning step so that the expression plasmid
would contain the DBP frameshift mutation, shown previously to be required to
permit stable plasmid maintenance in 293 cells (chapter 5).
The viral sequence in plasmid pMT -Xbal was extended to the right end of the viral
genome by cloning the 7332 bp Spel I Clal fragment from pAdMLTU (figure 3.l0)
into Spel I Clal digested pMT-Xbal, creating plasmid pMT-MLTU. Plasmids bearing
the correct insert were determined by restriction enzyme analysis with EcoRV (figure
6.8). This digest generated the predicted bands of 7639, 6312, 4586, 4546, 2623,
2374,2056 and 1238 bp.
6.4.2. Construction of an episomal expression plasmid containing the sMT -Ia I
MLTU cassette.
The sMT-Ia I MLTU cassette was excised from plasmid pMT-MLTU by
digestion with Pad. The resulting 25861 bp fragment was cloned into Pad digested
and dephosphorylated pgERI (figure 3.12), creating plasmid pMT-EP. Plasmids
containing the insert in the desired orientation were determined by restriction enzyme
analysis with Xhol and EcoRV (figure 6.9). The 6236 bp diagnostic junction fragment
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Figure 6.6. Plasmid pKW2S-MT. Plasmid bearing Ad5 sequence from 6079-
10589, downstream of the sheep metallothionein-Ia promoter.
A. Plasmid map showing unique sites and sites of interest. Numbering in brackets
refers to original numbering in the Ad5 sequence (Chroboczek et al., 1992). Amp,
ampicillin resistance gene. AdS, adenovirus sequence. pMT-Ia, sheep metallothionein
promoter.
B. 1 % agarose gel visualised by ethidium bromide staining. Lane I, 1 kb ladder. Lane
2, HindUI digest ofpKW2S-MT.
1.4 % agarose gel visualised by ethidium bromide staining. Lane 3, 1 kb ladder. Lane
4, DraIII digest of pKW2S-MT. Arrow indicates diagnostic band used to determine
insert orientation.
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1 2 Figure 6.7. Plasmid pMT-XbaI.
Plasmid bearing Ad5 sequence from
6079 - 28592, downstream of the
sheep metallothionein-Ia promoter.
A. Plasmid map showing unique
sites and sites of interest.
Numbering in brackets refers to
original numbering in the AdS
sequence (Chroboczek et al., 1992).
Amp, ampicillin resistance gene.
AdS, adenovirus sequence. pMT-1a,
sheep metallothionein promoter.
B. 0.8 % agarose gel visualised by
ethidium bromide staining. Lane 1,
1 kb ladder. Lane 2, EcoRV digest
ofpMT-XbaI. Arrows indicate
diagnostic bands used to determine
insert orientation.
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Figure 6.S. Plasmid pMT -MLTV.
Plasmid bearing Ad5 sequence from 6079
- 35938, downstream of the sheep
metallothionein- la promoter.
A. Plasmid map showing unique sites and
sites of interest. Numbering in brackets
refers to original numbering in the Ad5
sequence (Chroboczek et al., 1992). Amp,
ampicillin resistance gene. AdS,
adenovirus sequence. pMT -1a, sheep
metallothionein promoter.
B. 0.8 % agarose gel visualised by
ethidium bromide staining. Lane 1, 1 kb
ladder. Lane 2, EeaRV digest ofpMT-
MLTU.
Figure 6.9. Plasmid pMT-EP. Episomal expression plasmid bearing Ad5 sequence
from 6079 - 32884, downstream ofthe sheep metallothionein-Ia promoter.
A. Plasmid map showing unique sites and sites of interest. Numbering in brackets
refers to original numbering in the AdS sequence (Chroboczek et al., 1992).
Abbreviations: Hygromycin, hygromycin resistance gene; SV40 pA, simian virus 40
polyadenylation signal; pMT-la, sheep metallothionein promoter; DriP, EBV latent
origin of replication; EBNA-1. Epstein-Barr virus nuclear antigen 1; amp, ampicillin
resistance gene.
B. 0.8 % agarose gels visualised by ethidium bromide staining. Lane 1 and lane 3, 1
kb ladder. Lane 2, XhoI digest ofpMT-EP. Lane 4, EcoRV digest ofpMT-EP. The
arrow indicates diagnostic band used to determine insert orientation. The band
showing the presence of the E2A mutation is indicated by a broken arrow.
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present after XhoI digestion showed that the insert was present and in the correct
orientation. Insertion in the alternative orientation would produce a band of 3127 bp.
This orientation was chosen as it places the sMT-Ia promoter in the same position,
relative to the vector backbone, as the MLP in plasmid pEP~E2A. The presence of an
886 bp band confirms the presence of the DBP frameshift mutation which creates an
extra XhoI site. Digestion with EcoRV produced the predicted bands of 12394, 7639,
4546,4364, 2623, 2056 and 1238 bp, confirming the presence of the insert.
6.4.3. Late protein expression from plasmid pMT.EP.
2 x 106 293 cells in 6-well plates were transfected with 2.5 J,.lgof pMT-EP using
calcium phosphate precipitation. Cells were grown for 24 hours after which time the
growth medium was replaced with DMEM / 10 % NCS containing 150 J,.lMZnS04.
Cells were grown for a further 48 hours and then fixed and probed with anti-lA-IOOK
antiserum (figure 6.10). Anti-lA-IOOK antiserum was chosen as previous control
experiments had shown this to be the most effective serum of those available for
detecting adenovirus proteins expressed from plasmid pEP~E2A in an
immunofluorescence assay. Also included were an uninduced control, a mock
transfection and a positive control transfection of plasmid pEP~2A. In this
transient transfection assay the levels of lA-lOOK expression from pMT-EP after
induction (panel A) were higher than those of the uninduced control (panel B),
although it is clear that there was some leaky expression from the sMT-Ia promoter in
the absence of the inducing agent. Levels of expression were lower than those
observed from the control plasmid pEP~E2A, whose expression is under MLP
control.
6.4.4. Construction of a stable cell line containing the sMT -Ia / MLTU construct.
10 ug of plasmid pMT-EP was used to transfect 4 x 106293 cells in a 60 mm dish
using calcium phosphate precipitation. At 48 hours post-transfection the cells were
passaged 1:3 and after a further 24 hours the growth medium was replaced with
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Figure 6.10. Induction ofL4-100K late protein expression from
plasmid pMT-EP.
Panel A. 293 cells transfected with expression plasmid pMT-EP,
induced 24 hours post-transfection by addition of 150 ~ ZnS04 to
growth medium.
Panel B. 293 cells transfected with expression plasmid pMT-EP,
uninduced control.
Panel C. Mock transfected 293 cells after addition of 150 J.lMZnS04•
Panel D. 293 cells transfected with expression plasmid pEPilE2A.
All cells were probed with anti-LI-I00K antiserum 48 hours post-
transfection and photographed using a 20 X objective .
DMEM I 10 % NCS containing 200lAg I ml hygromycin-B. The growth medium was
replaced every 3 days and cells passaged 1:3 when confluent.
After 28 days, 1 x 106 cells were seeded in 6-well plates and grown for 24 hours
before replacing the growth medium with DMEM I 10 % NCS I 150 lAMZnS04. Cells
were grown for a further 48 hours before being fixed and probed with anti-rA-lOOK
antiserum. However, no expression of L4-100K could be detected using this method.
Similarly, no late protein expression could be detected in cell extracts using Western
blotting with antiserum AbR1/89 (data not shown).
6.4.5. Verification of expression vector functionality.
The EBV replicon vector backbone sequences used throughout this study derived
from the same source as those used previously to create cell lines expressing
individual late proteins (Caravokyri and Leppard, 1995; S. Brey, University of
Warwick thesis, 1999; A. Arslanoglu, University of Warwick thesis, 1999).
Moreover, they were shown to be capable of conferring stable resistance to selection
in this study (chapter 5). However, in order to confirm that they were capable of
supporting stable expression of heterologous genes, a reporter plasmid containing a
GFP expression cassette was constructed. The green fluorescent protein (GFP)
reporter gene is derived from the bioluminescent jellyfish Aequorea victoria, and
upon exposure to blue light (excitation peaks at 395 and 470) fluoresces with green
light emission (between 509 and 540 nm) (Prasher et al., 1992; Chalfie et al., 1994).
The version of the gene used here has been modified to produce more rapid and
intense fluorescence, with a mutation at residue 65 of serine to threonine, which
results in a single excitation peak of 490 nm (Heim et al., 1995). GFP has a major
advantage over other routinely used reporter genes, in that there is no need to fix cells
or for a substrate, making analysis easier and faster.
In order to construct plasmid pEP-GFP, the expression vector sequences were
excised from plasmid pMT-EP by digestion with Pad and a GFP expression cassette
was excised from plasmid phGFP-S65T (Clontech, figure A.lO) by digestion with
MluI and BamHI. The cohesive ends of this 2263 bp fragment were converted to blunt
ends using the Klenow filling method, as were the ends of the 9539 bp fragment
produced by Pad digestion of pMT-EP. These two fragments were subsequently
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ligated together to create plasmid pEP-GFP. Restriction enzyme analysis using
EcoRV and HindIII (figure 6.11) produced a 2248 bp fragment confirming the insert
was in the desired orientation. An insert in the alternative orientation would have
produced a 1307 bp fragment. The insert orientation chosen was the one that would
put the CMV promoter of the GFP cassette in the same position relative to the vector
backbone as the sMT-Ia and major late promoters used in the other expression
plasmids described in this study.
Plasmid pEP-GFP was used to transfect 4 x 106 293 cells in 60 mm dishes using
calcium phosphate precipitation. At 48 hours post-transfection the cells were passaged
1:3 and after a further 24 hours the growth medium was replaced with DMEM 110 %
NCS containing 200 J.lgI ml hygromycin-B, The growth medium was replaced every
3 days and cells passaged 1:3 when confluent. Cells were grown on glass coverslips
and samples removed at 1, 15 and 42 days post transfection and assayed for
expression of GFP using the method described in section 2.3.5.4. (figure 6.12).
Expression of GFP can be seen at all times assayed post transfection. The number of
fluorescent cells increases between 1 and 15 days post-transfection, as selection
increases their proportion within the population. There is little reduction in
fluorescence intensity over the time-course of the experiment although there is
considerable heterogeneity in expression level, particularly at 42 days post-
transfection, when it might be expected that all cells would harbour and express the
plasmid. Overall, these results show that the EBV expression vector sequences are
capable of allowing stable maintenance and prolonged expression of heterologous
genes in 293 cells.
6.5. Discussion.
The sMT-Ia promoter was used successfully to regulate the expression of both a
lacZ reporter gene and the adenovirus MLTU. However, this regulation of expression
was only possible in a transient transfection assay. When plasmid pMT-EP was used
to create a stable cell line no expression of late proteins could be detected, with or
without the presence of ZnS04 in the growth medium to induce the promoter. These
results mirror those obtained with plasmid pEP~E2A, in that it would also only
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Figure 6.11. Plasmid pEP-GFP.
Episomal expression plasmid
containing a OFP expression cassette.
A. Plasmid map showing unique
sites. Abbreviations: CMV,
cytomegalovirus immediate-early
promoter; OFP, green fluorescent
protein, SV40 intron/poly A, simian
virus 40 intron and polyadenylation
sequences; Hygromycin, hygromycin
resistance gene; GriP, EBV latent
origin of replication; EBNA-l.
Epstein-Barr virus nuclear antigen 1;
amp, ampicillin resistance gene.
B. 1% agarose gel visualised by
ethidium bromide staining. Lane 1, 1
kb ladder. Lane 2, EcoRV and
HindIII digest of pEP-OFP. Arrow
indicates diagnostic band used to
determine insert orientation.
Figure 6.12. Persistence of expression from an episomal plasmid in 293 cells.
293 cells were transfected with episomal reporter plasmid pEP-GFP. Cells were put
under positive selection 3 days post transfection and passaged 1:3, when confluent.
Cells were assayed for GFP expression 1 day (panel A), 15 days (panel B) and 42
days (panel C) post-transfection, Panel D shows 293 cells transfected with phGFP-
S65T, 1 day post-transfection and is used as a positive control for GFP fluorescence.
Panel E shows 293 cells transfected with plasmid pgERI.
Magnification x 20.

express late proteins in transient transfections. The results of the experiment with the
episomal expression vector carrying the GFP cassette show that the inability to create
a functional stable cell line is not due to the EBV replicon. The EBV sequences used
to create plasmid pEP-GFP were taken straight from plasmid pMT-EP, and were then
used successfully to create a stable GFP-expressing cell line. Taken together, the
results from this chapter and chapter 5 strongly support the suggestion that it is
changes to the adenovirus sequences subsequent to transfection that are in some way
responsible for the inability of the plasmid to express late proteins in a stable cell line.
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Chapter 7 : Discussion.
Chapter 7 : General Discussion.
7.1. Introduction.
Of the numerous vectors investigated for use in gene therapy, those based on
human adenoviruses have proved efficient for delivery of genes both in vitro and in
vivo. Adenovirus- vectors have many advantages over other viral vectors for use in
gene therapy. They have a wide tropism and can infect both dividing and non-dividing
cells. They have a good safety profile, are easy to manipulate in vitro and can be
grown to high titres. Despite these advantages, low transgene-carrying capacity and
the lack of long-term persistence of gene expression, due to immune mediated
clearance of the vector, remain problems to be solved.
The aim of the work presented here was to achieve improvements over
currently existing vectors for gene therapy, through the construction of cell lines
capable of supporting the growth of viruses with late gene deletions. Deletion of late
gene regions would increase transgene carrying capacity and reduce the expression of
potentially immunogenic viral proteins, hopefully leading to increased transgene
expression. The majority of the work presented here focused on overcoming problems
associated with expressing late proteins in eukaryotic cells as discussed below.
7.2. Problems associated with the expression of AdS late proteins.
The Ad5 MLTU was successfully cloned and late proteins expressed from the
construct in a transient transfection system. The initial attempts to isolate stable cell
lines were unsucccessful due to the expression of the toxic E2A-DNA binding
protein. Subsequent removal of DBP allowed the expression plasmid to be stably
maintained in 293 cells. However, no late protein expression from the MLTU could
be detected in these cell lines. Attempts to activate expression from the major late
promoter by providing viral transactivating factors in trans also proved to be
ineffective.
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The ability of the expression plasmids used to express late proteins in a
transient transfection but not in a stable cell line was the common outcome of the
work described in both Chapters 5 and 6. There are several possibilities that may
account for these observations. Perhaps the most obvious reason is that the plasmids
became modified in some way during selection of the cell lines, most likely as a
response to selective pressure resulting from late protein expression from the plasmid
that occured immediately after transfection. Detectable levels of late protein
expression after transient transfection were not expected in the absence of the viral
transactivating IVa2 protein but considerable expression was observed. The probable
explanation for this is that after transfection, basal transcription from the MLP occurs.
As any transfected cell will receive multiple copies of the plasmid, this initial late
protein expression is at a high enough level to be detected by Western blot. However,
this basal level of expression may be toxic to the cell and is suppressed shortly after
transfection. This down-regulation of late protein expression could be due to either
reduction in plasmid copy number, defects in post-transcriptional RNA processing or
promoter methylation, as discussed below.
7.2.1. Reduction in plasmid copy number.
During the initial transfection procedure each cell will receive multiple copies of
the expression plasmid. Multiple plasmids, all expressing low levels of late protein
would be expected to produce a detectable level of expression. However, during
selection of cell lines, plasmid copy number could decrease to a level where resistance
to hygromycin-B is maintained but expression of late proteins is at a minimum,
possibly due to toxicity effects of expressed proteins. In light of previous results, this
hypothesis is unlikely. Previously, three cell lines have been created using the EBV
replicon-containing plasmids that express the IX, Ll 52/55K and IVa2 proteins
(Caravokyri and Leppard, 1995; A. Arslanoglu, S. Brey, University of Warwick, PhD
theses, 1999). All three cell lines were capable of expressing levels of protein
equivalent to a wt infection, with no apparent reduction in the levels of expression
over a prolonged period. Also, the levels of expression seen in transient transfection
assays were similar to those seen in the stable cell lines. However, the proteins
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expressed are not known to have any toxic effects on eukaryotic cells and expression
would not be expected to be selected against.
The possibility that plasmid copy number decreases could be investigated by
quantifying the number of copies per cell after transfection, then monitoring the cell
population over time for any decrease. Quantification of Southern blots probed for
plasmid sequences could be used to determine if copy number decreases over time.
Alternatively, quantitative PCR (QPCR) could be used to determine the absolute
number of plasmid copies per cell.
7.2.2. Promoter methylation.
The concept that sequence-specific promoter methylations and long-term gene
inactivations might be causally related has been experimentally substantiated by
investigations using a number of promoters (reviewed by Doerfler, 1983). In general,
results have shown that the introduction of 5-methylcytosine residues into specific 5'-
CO-3' (CpO) dinucleotides within a promoter inactivates the promoter. The
modification of one or a few CpO sequences is sufficient to shut down a promoter,
possibly by inhibiting DNA-protein interactions. For several transcription factors.
evidence has been adduced that the methylation of their target sequences blocks their
ability to bind specifically to these sequences (Kovesdi et al., 1987; Hermann and
Doerfler, 1991). This loss of interaction is likely to account for the transcriptional
inhibition of methylated promoter sequences. In addition to this loss of factor binding.
methylation may also promote the binding of repressor proteins. Recent studies have
identified two proteins, MeCP1 and MeCP2, that bind specifically to methyl-CpO and
repress methylated promoter activity in vitro as well as in vivo (Lewis et al., 1992).
Methylation of CpO sequences present in the MLP promoter could account for
the apparent shut-down of late protein expression in the stable cell lines. The MLP
contains 8 CpO sequences, one of these is located in the USF transcription factor
binding site, and another is adjacent to the DEF-B binding site. Methylation of these
sequences could prevent the two transcription factors from binding to their specific
sequences, thus preventing activation of the MLP. This would also explain why
providing the IVa2 protein in trans within the cell lines did not result in activation of
the promoter. Previous studies have shown that the transcription factor DEF-B is a
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homodimer of the IVa2 protein (Tribouley et al., 1994) and is responsible for
maximal activation of the MLP at late times of infection (Jansen-Durr et al., 1988;
1989). Binding of the USF protein is also required for activation of the MLP, and one
could hypothesise that the lack of binding of these two factors would lead to complete
inactivation of the MLP, as appears to be the case in the cell lines constructed in these
studies.
Restriction enzymes that are sensitive to CpG methylation could be used to
determine if the MLP becomes methylated during the selection of stable cell lines.
Restriction enzymes AeiI, Hhai, Nell and PmlI are sensitive to methylation and all
have recognition sequences that are present in the MLP. Comparison of restriction
digests of plasmid extracted from stable cell lines with those of unmethylated plasmid
preparations would show if the MLP is methylated in the cell line.
In addition to methylation, chromatin-related transcriptional inactivation by
histone deacetylases has been shown to down-regulate gene expression (Chen et al.,
1997; Pikaart et al. 1998). In the cell lines created, the EBNA-l protein and DriP
sequence interact to anchor the plasmid episome to the nuclear matrix (Krysan and
Calos, 1993; Middleton and Sugden, 1992,1994) and this may make the plasmid
sensitive to gene silencing by histone deacetylation, as would occur for any integrated
transgene. It has been shown that silenced transgenes can be reactivated using histone
deacetylase inhibitors such as butyrate or trichostatin A (Chen et al., 1997; Pikaart et
al. 1998). Therefore, adding one such inhibitor to the cell growth medium may allow
re-activation of the promoter and expression of the MLTU.
7.2.3. Defects in RNA processing and translation.
There is a possibility that the problem lies not with transcription of the MLTU
but with post-transcriptional processing or translation. These events are regulated at
multiple levels during viral infection and involve the interaction of several viral
proteins (section 1.3.5.4). The lack of these proteins in the cell line, even if provided
by helper virus, may lead to a block in late protein expression.
The regulated RNA splicing of the MLTU is a very complicated process, with
changes in splice site usage occurring as the infection proceeds from early to late
phases. An example of this is the formation of Ll mRNAs, which moves from
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generation of only the 52/55K mRNA at early times, to both the 52/55K and Illa
mRNAs at late times. This activation of IlIa splicing, late after infection, has been
shown to be accompanied by a virus induced dephosphorylation of the cellular family
of SR splicing factors (Kanopka et al., 1998). This modification reduces the RNA
binding capacity of SR proteins and as a consequence relieves the repression of lIla 3'
splice site usage, resulting in a shift toward an increase in lIla mRNA production.
Recent studies have also shown that overexpression of the SR protein ASF/SF2
prevents the early to late shift in late gene expression (Molin and Akusjarvi, 2000). In
addition to regulating the switch from proximal to distal splice site usage, ASF/SF2
overexpression may directly interfere with transcription from the major late promoter.
Many RNA processing factors, including ASF/SF2, have been shown to interact with
the C-terminal domain tail of RNA polymerase II (revieved by Bentley, 1999). Such
an interaction may have, or induce, adverse effects on transcription initiation and/or
elongation at the major late promoter.
The function of these SR factors in regulating gene expression could provide a
possible explanation for the lack of observed late protein expression in the stable cell
lines. During transient transfection the concentration of ASF/SF2 would be lower
relative to the plasmid copy number, than it would be if the plasmid copy number was
reduced during stable cell line selection. Thus, during transient transfection, ASF/SF2
might be unable to repress the use of distal 3' splice sites and the full pattern of late
mRNAs would be produced, leading to the observed expression of a wide range of
late proteins. However, if plasmid copy number is low, the relatively higher
concentration of ASF/SF2 would block the temporal shift in pre-mRNA splicing. If
this is the situation in the stable cell lines, they might be expected to express the Ll
52/55K protein. This protein was undetectable by Western blotting but expression
could be so low, because of the effects on promoter activity already discussed, as to
be undetectable. Of course, if ASF/SF2 acts to directly repress transcription then no
expression of late proteins would be expected, as was the case in the results presented
here.
If time had allowed, experiments would have been designed and carried out to
determine if the primary RNA transcript was being correctly spliced. This could have
been achieved by using Northern blot analysis to detect late mRNAs in total cellular
RNA extracts. Short oligonucleotide probes, specific for the 5' ends of the late
mRNAs, could be used to determine if any transcription from the MLP was occuring.
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If the probes were to detect the mRNA species of the predicted length, then it could
be assumed that transcription and splicing were occuring normally. If the mRNA
species were larger than predicted then there must be a problem involving incorrect
processing of the MLTU primary transcript. A total lack of late mRNAs would point
back to a problem with transcription initiation, possibly caused by methylation or
histone deacetylation as discussed in section 7.2.2.
If the stable cell lines were shown to be actively transcribing the MLTU,
experiments could be designed to determine if the level of late protein expression was
so low as to be undetectable by biochemical assays, but was enough to complement
late gene deficiencies. This could be achieved by assessing the ability of the cell lines
to complement the growth of appropriate temperature-sensitive (ts) mutants at the
non-permissive temperature. The biochemical assays used may not be sensitive
enough to detect low levels of late protein in the cells but this low level of expression
may be enough to complement growth. Therefore, the use of a biological assay may
be more appropriate as the intended use of the cell lines is to complement the growth
of vectors with late gene deficiencies.
7.3. Down-regulation of the sMT-Ia promoter.
The results from the work carried out using the sMT-Ia/MLTU construct
(Chapter 6) mirrored the problems encountered with the original MLPIMLTU
construct. This plasmid was also capable of expression in a transient assay but not
when present in a stable cell line. The sMT-Ia promoter could be induced successfully
24 hours after transfection, but not after selection and isolation of transfected cells.
This promoter has been widely used to express heterologous genes in eukaryotic cells
and its apparent non-functionality here was unexpected. The sMT-Ia promoter does
contain several CpO dinucleotides, some of which are present in the metal response
element (MRE) binding sequences. Methylation of these sequences could lead to
down regulation of the promoter for the reasons discussed above (section 7.2.2).
The inability of the SMT-Ia promoter to drive the expression of late proteins
suggests that it is some intrinsic property of the MLTU that is preventing the isolation
of late protein-expressing cell lines. Due to time limit restrictions, further evaluation
of the sMT -Ia promoter was not possible. The use of a control plasmid containing the
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EBV sequences and a reporter gene driven by the sMT-Ia promoter could have
determined whether the promoter was capable of regulating gene expression during
long-term maintenance of the plasmid in a 293-derived cell line.
7.4. Strategies to allow stable expression of late proteins.
The initial lack of expression in the 293-EP stable cell line was assumed to be
due to inactivation of the MLP, perhaps due to selective pressure to reduce toxic
protein expression. For this reason the MLP was replaced by the sMT-Ia promoter in
an attempt to achieve tightly regulated expression, thus preventing potentially toxic
basal levels of late protein expression. This approach was also unsuccessful with
possible reasons discussed above (section 7.3). In addition to these problems, late
protein expression from the sMT-IalMLTU construct was detected shortly after
transfection in the absence of the inducing agent (section 6.4.3). This again could
have led to promoter down-regulation to prevent the expression of toxic proteins. Any
future attempts to express the MLTU in 293 cells should use a more tightly regulated
promoter, such as the tetracycline-regulated promoter, in order to prevent this
potentially deleterious basal expression. Such a system could be implemented by
placing the MLTU under the control of a Tet-responsive (Gossem et al. 1995), bi-
directional promoter (TRBDP), which should enable tight control of gene expression
and prevent any down-regulation of gene expression due to toxic protein expression.
The construct will also express the GFP reporter gene, enabling regulated expression
of both this and the MLTU in a stable cell line. The presence of the GFP gene will
allow easier monitoring of the transcriptional activity of the construct.
Such a cell line is currently being developed (D.Farley, personal communication)
and will be created by selecting for integration of the TRBDP I MLTU I GFP cassette
(co-transfected with a plasmid containing a selectable marker gene) into HeLa cells
using antibiotic resistance. Clones of cells will be isolated and grown in the presence
of tetracycline (or doxycycline) which will repress transcription from the TRBDP, a
so-called "Tet-off' system (Gossen and Bujard, 1992). In this system, tetracycline
inactivates the transcriptional-transactivator 'reverse tTA' (provided in trans by the
cell) such that the promoter is inactive and no expression of the MLTU or GFP should
occur. If tetracycline is removed from the growth medium the promoter is activated
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and transcription of the MLTU and GFP should now occur. Clones can be quickly
screened using a GFP assay that wilI indicate successful integration of the expression
cassette into the cellular genome at locations that allow functionality of the promoter.
GFP-positive clones would therefore indicate potential expression of late proteins
from the MLTU, which could then be characterised using the appropriate assays.
In addition to using alternative promoters, another way to express late proteins in
stable cell lines could be to split the MLTU and express the late genes as two separate
units from two expression plasmids. Through the use of two selectable markers a
double-stable cell line could be created expressing the fun range of late genes. Earlier
manipulation of the MLTU to replace the MLP (Chapter 6) suggests that carefully
considered changes can be made which stilI allow the MLTU to expressed correctly.
Therefore, it is possible that the MLP or an inducible promoter could be cloned
upstream of any late gene and used to drive its expression as long as the tripartite
leader was also included to enable efficient translation of the viral mRNA.
If the lack of late protein expression is due to the activity of SR factors, then
strategies could be devised to reduce their activity and allow correct transcription and
processing of the MLTU. The activity of SR proteins is reduced by dephosphorylation
mediated by protein phosphatase 2A (PP2A, Kanopka et al., 1998). The adenovirus
E4-orf4 protein has been shown to bind to PP2A and down-regulate the transcription
of the cellular gene junB (Kleinberger and Shenk, 1993). In addition to this the work
of Kanopka et al., (1998) also suggest that E4-0rf4 is an important factor in
controlling the temporal shift in adenovirus alternative RNA splicing. If this is the
case then constitutive expression of E4-0rf4 may allow the expression of late proteins
in a stable cell line.
7.5. Alternative uses for AdS expression plasmids.
In addition to their use in the construction of cell lines to complement
adenovirus vectors, the expression plasmids constructed here also have other potential
uses in the study of late protein expression. In transient transfection, the pJasmids
apparently express proteins from across the length of the MLTU. During infection,
this pattern changes with time due to regulated RNA processing as discussed above.
The plasmid could be used to introduce mutations into MLTU splice sites in order to
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study the effects on splicing patterns and the effect on expression of upstream and
downstream reading frames.
A late protein-expressing cell line could also be used to study the late proteins
that have poorly understood functions, such as the U-33K and U-lOOK proteins.
There is absolutely no functional information about U-33K, while the function of the
U-lOOK protein has so far only been studied by using temperature sensitive (ts)
mutants, which work has implicated it in viral particle assembly (Oosterom-Dragon
and Ginsberg, 1981) and translational control (Adam and Dreyfuss, 1987; Hayes et
al., 1990). U-I00K may also be involved in directly inhibiting cellular protein
synthesis and in enhancing expression of viral late mRNAs (reviewed by Schneider,
2000). The ability to create further deletions and mutations in the U-lOOK protein
should lead to further understanding of its functions.
7.6. Concluding remarks.
Human adenoviruses have been extensively studied and characterised since
their initial isolation in the 1950's (Hilleman and Werner, 1954; Rowe et al., 1953).
Despite this extensive research there are still many aspects of the viral replication
cycle that are poorly understood, particularly aspects of virus-cell interactions and the
host immune response to infection. In the three years during which the research in this
thesis was carried out, over 4,000 references to adenovirus were published. Most of
these were concerned with the results of investigations using adenoviruses as vectors
and relatively few dealt with the basic virology and immunology of virus infection.
These shortcomings in the understanding of adenovirus biology have become more
apparent with the increasing use of adenovirus vectors in gene therapy protocols. It is
now accepted that the initial enthusiasm for utilising adenovirus vectors in clinical
gene therapy trials was rather prematurely optimistic and perhaps over-hyped. Serious
problems associated with immune responses to the vector have led to the promised
potential of adenovirus vectors being largely unrealised.
The work presented in this thesis aimed to improve adenovirus vector
technology by allowing further engineering of the genome to reduce late protein
expression. Due to an inability to isolate a stable cell line that would express late
proteins, these initial aims were not achieved. This was partly due to a poor
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understanding of how the MLTU is expressed when taken out of the context of a
natural viral infection. Further understanding of late gene expression may allow the
isolation of vectors containing large deletions that would express fewer viral proteins
and should therefore provoke a less vigorous immune response in vivo, leading to
increased persistence. Given that no one has, as yet, been able to show very long-term
persistence of expression from genes transduced by adenovirus vectors, this remains a
valid approach for further research into vector construction.
Adenovirus vectors in current use have proved to be largely ineffective, but a
better understanding of the total spectrum of virus-cell and virus-host interactions
should lead to the design of vectors providing more efficient delivery along with
minimal deleterious host reactions. As a result of continued research, the problems
associated with current adenovirus vectors may well be overcome and the desired
clinical goals achieved.
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Figure A.I. Plasmid pFGdXI.
pBR322-based plasmid bearing AdS sequences from 21562-35938, with a deletion in the
E3 region between bp 28592 and 30470 . Map shows unique sites and sites of interest.
Numbering in brackets refers to the original numbering in the AdS sequence (Chroboczek
et al., 1992). amp, ampicillin resistance gene.
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Figure A.2. Plasmid pBR322SpeI.
pBR322 with Pvull at bp 2064 converted to SpeJ. Restriction map shows unique sites.
amp, ampicillin resistance gene; tet, tetracycline resistance gene.
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Figure A.3. Plasmid pBR322.
Restriction map shows unique sites. amp, ampicillin resistance gene; tet, tetracycline
resistance gene.
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Figure A.4. Plasmid pMEP4 (Invitrogen).
Map showing unique sites and sites of interest. Abbreviations: pTK, thymidine kinase
promoter; Hygromycin, hygromycin-B resistance gene. TKpA, thymidine kinase
polyadenylation signal; SV40 pA, simian virus 40 polyadenylation signal; phMTIIa,
human metallothionein IIa promoter; OriP, EBV latent origin of replication; EBNA-l.
Epstein-Barr virus nuclear antigen 1; amp/ori, ampicillin resistance gene/bacterial origin
of replication.
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Figure A.S. Plasmid pEPI.
Plasmid map showing unique sites and sites of interest. Numbering in brackets refers
to original numbering in the Ad5 sequence (Chroboczek et al., 1992). Abbreviations:
Hygromycin, hygromycin-B resistance gene; SV40 pA, simian virus 40
polyadenylation signal; DriP, EBV latent origin of replication; EBNA-l. Epstein-
Barr virus nuclear antigen 1; amp, ampicillin resistance gene; AdS, adenovirus
sequence.
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Figure A.6. Plasmid pcDNA3.lIlacZ.
Plasmid containing lacZ reporter gene. Map showing unique sites. Abbreviations:
amp, ampicillin resistance gene; neo, neomycin resistance gene; CMV promoter,
cytomegalovirus immediate early promoter.
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Figure A.7. Plasmid pCEP-IVa2. Episomal expression plasmid containing the IVa2
cDNA from AdS. Abbreviations: Hygromycin, hygromycin resistance gene; SV40
pA, simian virus 40 polyadenylation signal; pCMV, human cytomegalovirus
immediate early promoter; OriP, EBV latent origin of replication; EBNA-l. Epstein-
Barr virus nuclear antigen 1; amp, ampicillin resistance gene.
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Figure A.8. Plasmid pE2(SI)SX.
pBR322-based plasmid bearing Ad5 sequence from 21562-27331. Contains SmaI to XhoI
modification at bp pos. 23912. Map shows unique sites and sites of interest. Numbering
in brackets refers to the original numbering in the Ad5 sequence (Chroboczek et al.,
1992). amp, ampicillin resistance gene; tet, tetracycline resistance gene.
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Figure A.9. Plasmid pE2SX-L.
pBR322-based plasmid bearing Ad5 sequence from 13255-27331. Contains Smal to Xhol
modification at bp pos. 23912. Map shows unique sites and sites of interest. Numbering
in brackets refers to the original numbering in the Ad5 sequence (Chroboczek et al.,
1992). amp, ampicillin resistance gene.
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Figure A.lO. Plasmid phGFP-S65T.
Green fluorescent protein expression plasmid. Restriction map shows unique sites.
Abbreviations: CMV, cytomegalovirus immediate-early promoter; GFP, green
fluorescent protein; SV40 intronJpolyA, simian virus 40 intron and polyadenylation
sequences; supF, ampicillin and tetracycline resistance gene.
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Figure A.H. Plasmid pMT -CB6+. Expression vector containing the sheep
metallothionein-Ia promoter. Amp, ampicillin resistance gene; neomycin, neomycin
resistance gene; pMT-Ia, sheep metallothionein promoter.
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Figure A.12. Plasmid pBR322PXP. pBR322 with Pvull at 2064 converted to XbaI,
NdeI at 2295 converted to Pad and EcoRI at 4359 converted to PmeI. Restriction
map shows unique sites. amp, ampicillin resistance gene; tet, tetracycline resistance
gene.
